CHEBI ONTOLOGY - ANNOTATIONS |
|
The Chemical Entities of Biological Interest (ChEBI) ontology is downloaded weekly from EMBL-EBI at http://www.ebi.ac.uk/chebi/. The data is made available under the Creative Commons License (CC BY 3.0, http://creativecommons.org/licenses/by/3.0/). For more information see: Degtyarenko et al. (2008) ChEBI: a database and ontology for chemical entities of biological interest. Nucleic Acids Res. 36, D344–D350.
|
Term: | organic halide salt |
|
Accession: | CHEBI:51069
|
browse the term
|
Synonyms: | related_synonym: | organic halide salts |
|
|
|
G |
DRD1 |
dopamine receptor D1 |
multiple interactions affects localization |
EXP |
A 77636 binds to and results in increased activity of DRD1 protein; SCH 23390 inhibits the reaction [A 77636 affects the localization of DRD1 protein]; SCH 23390 inhibits the reaction [A 77636 results in increased activity of DRD1 protein] |
CTD |
PMID:15985612 |
|
NCBI chr 5:175,440,036...175,444,182
Ensembl chr 5:175,440,036...175,444,182
|
|
|
G |
AKT1 |
AKT serine/threonine kinase 1 |
multiple interactions |
ISO |
Duloxetine Hydrochloride inhibits the reaction [Indomethacin results in decreased phosphorylation of AKT1 protein] |
CTD |
PMID:38701902 |
|
NCBI chr14:104,769,349...104,795,748
Ensembl chr14:104,769,349...104,795,759
|
|
G |
AR |
androgen receptor |
multiple interactions |
EXP |
Duloxetine Hydrochloride binds to and results in decreased activity of AR protein |
CTD |
PMID:25752796 |
|
NCBI chr X:67,544,021...67,730,619
Ensembl chr X:67,544,021...67,730,619
|
|
G |
CD48 |
CD48 molecule |
multiple interactions |
ISO |
Duloxetine Hydrochloride inhibits the reaction [Indomethacin results in increased expression of CD48 protein] |
CTD |
PMID:38701902 |
|
NCBI chr 1:160,678,746...160,711,822
Ensembl chr 1:160,678,746...160,711,831
|
|
G |
CYP17A1 |
cytochrome P450 family 17 subfamily A member 1 |
decreases activity multiple interactions |
EXP |
Duloxetine Hydrochloride results in decreased activity of CYP17A1 protein Duloxetine Hydrochloride inhibits the reaction [[CYP17A1 protein results in increased hydroxylation of Pregnenolone] which results in increased chemical synthesis of 17-alpha-Hydroxypregnenolone]; Duloxetine Hydrochloride inhibits the reaction [[CYP17A1 protein results in increased hydroxylation of Progesterone] which results in increased chemical synthesis of 17-alpha-Hydroxyprogesterone]; Duloxetine Hydrochloride inhibits the reaction [[CYP17A1 protein results in increased metabolism of 17-alpha-Hydroxypregnenolone] which results in increased chemical synthesis of Dehydroepiandrosterone]; Duloxetine Hydrochloride inhibits the reaction [[CYP17A1 protein results in increased metabolism of 17-alpha-Hydroxyprogesterone] which results in increased chemical synthesis of Androstenedione]; Duloxetine Hydrochloride inhibits the reaction [CYP17A1 protein results in increased hydroxylation of Pregnenolone]; Duloxetine Hydrochloride inhibits the reaction [CYP17A1 protein results in increased hydroxylation of Progesterone]; Duloxetine Hydrochloride inhibits the reaction [CYP17A1 protein results in increased metabolism of 17-alpha-Hydroxypregnenolone]; Duloxetine Hydrochloride inhibits the reaction [CYP17A1 protein results in increased metabolism of 17-alpha-Hydroxyprogesterone] |
CTD |
PMID:29100959 |
|
NCBI chr10:102,830,531...102,837,413
Ensembl chr10:102,830,531...102,837,472
|
|
G |
CYP1A1 |
cytochrome P450 family 1 subfamily A member 1 |
decreases activity |
EXP |
Duloxetine Hydrochloride results in decreased activity of CYP1A1 protein |
CTD |
PMID:33814510 |
|
NCBI chr15:74,719,542...74,725,528
Ensembl chr15:74,719,542...74,725,536
|
|
G |
CYP1A2 |
cytochrome P450 family 1 subfamily A member 2 |
multiple interactions |
ISO |
[furafylline results in decreased activity of CYP1A2 protein] which results in decreased glutathionylation of Duloxetine Hydrochloride; CYP1A2 protein results in increased activity of and results in increased glutathionylation of Duloxetine Hydrochloride |
CTD |
PMID:20669986 |
|
NCBI chr15:74,748,845...74,756,607
Ensembl chr15:74,748,845...74,756,607
|
|
G |
CYP1B1 |
cytochrome P450 family 1 subfamily B member 1 |
decreases activity |
EXP |
Duloxetine Hydrochloride results in decreased activity of CYP1B1 protein |
CTD |
PMID:33814510 |
|
NCBI chr 2:38,067,509...38,076,151
Ensembl chr 2:38,066,973...38,109,902
|
|
G |
CYP2D6 |
cytochrome P450 family 2 subfamily D member 6 (gene/pseudogene) |
multiple interactions |
ISO |
[Quinidine results in decreased activity of CYP2D6 protein] which results in decreased glutathionylation of Duloxetine Hydrochloride; CYP2D6 protein results in increased activity of and results in increased glutathionylation of Duloxetine Hydrochloride |
CTD |
PMID:20669986 |
|
NCBI chr22:42,126,499...42,130,810
Ensembl chr22:42,126,499...42,130,865
|
|
G |
HMOX1 |
heme oxygenase 1 |
increases expression |
EXP |
Duloxetine Hydrochloride results in increased expression of HMOX1 mRNA |
CTD |
PMID:29134401 |
|
NCBI chr22:35,381,096...35,394,207
Ensembl chr22:35,380,361...35,394,214
|
|
G |
IL1A |
interleukin 1 alpha |
multiple interactions |
ISO |
Duloxetine Hydrochloride inhibits the reaction [Indomethacin results in increased expression of IL1A protein] |
CTD |
PMID:38701902 |
|
NCBI chr 2:112,773,925...112,784,493
Ensembl chr 2:112,773,925...112,784,493
|
|
G |
KCNH2 |
potassium voltage-gated channel subfamily H member 2 |
decreases activity |
EXP |
Duloxetine Hydrochloride results in decreased activity of KCNH2 protein |
CTD |
PMID:28551711 |
|
NCBI chr 7:150,944,961...150,978,321
Ensembl chr 7:150,944,961...150,978,321
|
|
G |
KCNJ3 |
potassium inwardly rectifying channel subfamily J member 3 |
multiple interactions |
ISO |
Duloxetine Hydrochloride results in decreased activity of [KCNJ3 mRNA co-treated with KCNJ5 mRNA]; Duloxetine Hydrochloride results in decreased activity of [KCNJ3 mRNA co-treated with KCNJ6 mRNA] |
CTD |
PMID:22164246 |
|
NCBI chr 2:154,698,695...154,858,354
Ensembl chr 2:154,697,855...154,858,354
|
|
G |
KCNJ5 |
potassium inwardly rectifying channel subfamily J member 5 |
multiple interactions |
ISO |
Duloxetine Hydrochloride results in decreased activity of [KCNJ3 mRNA co-treated with KCNJ5 mRNA] |
CTD |
PMID:22164246 |
|
NCBI chr11:128,891,356...128,921,163
Ensembl chr11:128,891,356...128,921,163
|
|
G |
KCNJ6 |
potassium inwardly rectifying channel subfamily J member 6 |
multiple interactions |
ISO |
Duloxetine Hydrochloride results in decreased activity of [KCNJ3 mRNA co-treated with KCNJ6 mRNA] |
CTD |
PMID:22164246 |
|
NCBI chr21:37,607,373...37,916,457
Ensembl chr21:37,607,373...38,121,345
|
|
G |
NFE2L2 |
NFE2 like bZIP transcription factor 2 |
affects localization |
EXP |
Duloxetine Hydrochloride affects the localization of NFE2L2 protein |
CTD |
PMID:29134401 |
|
NCBI chr 2:177,230,303...177,264,727
Ensembl chr 2:177,218,667...177,392,756
|
|
G |
PRL |
prolactin |
increases expression |
EXP |
Duloxetine Hydrochloride results in increased expression of PRL protein |
CTD |
PMID:17606668 |
|
NCBI chr 6:22,287,246...22,302,835
Ensembl chr 6:22,287,244...22,302,826
|
|
G |
VEGFA |
vascular endothelial growth factor A |
multiple interactions |
ISO |
Duloxetine Hydrochloride inhibits the reaction [Indomethacin results in decreased expression of VEGFA protein] |
CTD |
PMID:38701902 |
|
NCBI chr 6:43,770,211...43,786,487
Ensembl chr 6:43,770,184...43,786,487
|
|
|
G |
CHRNA2 |
cholinergic receptor nicotinic alpha 2 subunit |
multiple interactions |
EXP ISO |
Dimethylphenylpiperazinium Iodide results in increased activity of [CHRNB4 protein binds to CHRNA2 protein] 1,1-dimethyl-4-phenylpiperazinium iodide affects binding competes with [Epibatidine binds to Chrna2 protein] |
CTD RGD |
PMID:9454827 PMID:15016836 |
RGD:2303194 |
NCBI chr 8:27,459,756...27,479,261
Ensembl chr 8:27,459,756...27,479,883
|
|
G |
CHRNA3 |
cholinergic receptor nicotinic alpha 3 subunit |
multiple interactions |
EXP ISO |
Dimethylphenylpiperazinium Iodide results in increased activity of [CHRNB4 protein binds to CHRNA3 protein] 1,1-dimethyl-4-phenylpiperazinium iodide affects binding [Epibatidine binds to Chrna3 protein] |
CTD RGD |
PMID:9454827 PMID:15016836 |
RGD:2303194 |
NCBI chr15:78,593,052...78,620,996
Ensembl chr15:78,593,052...78,621,295
|
|
G |
CHRNA4 |
cholinergic receptor nicotinic alpha 4 subunit |
multiple interactions |
EXP ISO |
Dimethylphenylpiperazinium Iodide inhibits the reaction [epibatidine binds to [CHRNA4 protein binds to CHRNB2 protein]]; Dimethylphenylpiperazinium Iodide results in increased activity of [CHRNA4 protein binds to CHRNB2 protein]; Dimethylphenylpiperazinium Iodide results in increased activity of [CHRNB4 protein binds to CHRNA4 protein] 1,1-dimethyl-4-phenylpiperazinium iodide affects binding to Chrna4 protein; 1,1-dimethyl-4-phenylpiperazinium iodide competes with [Epibatidine binds to Chrna4 protein] |
CTD RGD |
PMID:9454827 PMID:14645658 PMID:15016836 |
RGD:2303194 |
NCBI chr20:63,343,223...63,361,349
Ensembl chr20:63,343,223...63,378,401
|
|
G |
CHRNA7 |
cholinergic receptor nicotinic alpha 7 subunit |
multiple interactions increases response to substance increases activity |
EXP |
Dimethylphenylpiperazinium Iodide inhibits the reaction [Bungarotoxins binds to CHRNA7 protein] CHRNA7 protein mutant form results in increased susceptibility to Dimethylphenylpiperazinium Iodide Dimethylphenylpiperazinium Iodide results in increased activity of CHRNA7 protein |
CTD |
PMID:10082212 PMID:10216184 |
|
NCBI chr15:32,030,483...32,173,018
Ensembl chr15:31,923,438...32,173,018
|
|
G |
CHRNB2 |
cholinergic receptor nicotinic beta 2 subunit |
multiple interactions |
EXP ISO |
Dimethylphenylpiperazinium Iodide inhibits the reaction [epibatidine binds to [CHRNA4 protein binds to CHRNB2 protein]]; Dimethylphenylpiperazinium Iodide results in increased activity of [CHRNA4 protein binds to CHRNB2 protein] 1,1-dimethyl-4-phenylpiperazinium iodide affects binding to Chrnb2 protein; 1,1-dimethyl-4-phenylpiperazinium iodide competes with [Epibatidine binds to Chrnb2 protein] |
CTD RGD |
PMID:14645658 PMID:15016836 |
RGD:2303194 |
NCBI chr 1:154,567,778...154,580,013
Ensembl chr 1:154,567,778...154,580,013
|
|
G |
CHRNB4 |
cholinergic receptor nicotinic beta 4 subunit |
multiple interactions |
EXP |
Dimethylphenylpiperazinium Iodide results in increased activity of [CHRNB4 protein binds to CHRNA2 protein]; Dimethylphenylpiperazinium Iodide results in increased activity of [CHRNB4 protein binds to CHRNA3 protein]; Dimethylphenylpiperazinium Iodide results in increased activity of [CHRNB4 protein binds to CHRNA4 protein] |
CTD |
PMID:9454827 |
|
NCBI chr15:78,624,111...78,661,641
Ensembl chr15:78,624,111...78,727,754
|
|
G |
TNF |
tumor necrosis factor |
increases activity |
ISO |
TNF results in increased activity of Dimethylphenylpiperazinium Iodide |
CTD |
PMID:15086448 |
|
NCBI chr 6:31,575,565...31,578,336
Ensembl chr 6:31,575,565...31,578,336
|
|
|
G |
ABCB1 |
ATP binding cassette subfamily B member 1 |
decreases activity |
EXP |
thiazolyl blue results in decreased activity of ABCB1 protein |
CTD |
PMID:15451006 |
|
NCBI chr 7:87,503,017...87,713,295
Ensembl chr 7:87,503,017...87,713,323
|
|
G |
ACO2 |
aconitase 2 |
multiple interactions |
ISO |
[Calcium results in increased activity of ACO2 protein] which results in increased reduction of thiazolyl blue; [Potassium deficiency results in decreased activity of ACO2 protein] which results in decreased reduction of thiazolyl blue |
CTD |
PMID:12548706 |
|
NCBI chr22:41,469,117...41,528,974
Ensembl chr22:41,447,830...41,529,273
|
|
G |
CASP3 |
caspase 3 |
increases activity |
EXP |
thiazolyl blue results in increased activity of CASP3 protein |
CTD |
PMID:22401948 |
|
NCBI chr 4:184,627,696...184,649,447
Ensembl chr 4:184,627,696...184,650,062
|
|
G |
CASP8 |
caspase 8 |
increases activity |
EXP |
thiazolyl blue results in increased activity of CASP8 protein |
CTD |
PMID:22401948 |
|
NCBI chr 2:201,233,463...201,287,711
Ensembl chr 2:201,233,443...201,361,836
|
|
G |
NQO2 |
N-ribosyldihydronicotinamide:quinone dehydrogenase 2 |
increases reduction multiple interactions |
EXP |
NQO2 protein results in increased reduction of thiazolyl blue resveratrol inhibits the reaction [NQO2 protein results in increased reduction of thiazolyl blue]; Tacrine inhibits the reaction [NQO2 protein results in increased reduction of thiazolyl blue] |
CTD |
PMID:29281794 |
|
NCBI chr 6:2,999,894...3,019,755
Ensembl chr 6:2,987,987...3,019,755
|
|
|
G |
GPC1 |
glypican 1 |
decreases degradation |
ISO |
3-beta-(2-(diethylamino)ethoxy)androst-5-en-17-one results in decreased degradation of GPC1 protein |
CTD |
PMID:21642435 |
|
NCBI chr 2:240,435,663...240,468,076
Ensembl chr 2:240,435,663...240,468,076
|
|
G |
IL1B |
interleukin 1 beta |
multiple interactions |
ISO |
3-beta-(2-(diethylamino)ethoxy)androst-5-en-17-one inhibits the reaction [[Lipopolysaccharides results in increased susceptibility to Silicon Dioxide] which results in increased secretion of IL1B protein] |
CTD |
PMID:36860548 |
|
NCBI chr 2:112,829,751...112,836,779
Ensembl chr 2:112,829,751...112,836,816
|
|
|
G |
HTR1A |
5-hydroxytryptamine receptor 1A |
multiple interactions |
ISO |
[1-((4-fluorobenzoylamino)ethyl)-4-(7-methoxy-1-naphthyl)piperazine hydrochloride binds to and results in increased activity of HTR1A protein] which results in decreased susceptibility to 1-(3-chlorophenyl)piperazine; [1-((4-fluorobenzoylamino)ethyl)-4-(7-methoxy-1-naphthyl)piperazine hydrochloride binds to and results in increased activity of HTR1A protein] which results in decreased susceptibility to Apomorphine; [1-((4-fluorobenzoylamino)ethyl)-4-(7-methoxy-1-naphthyl)piperazine hydrochloride binds to and results in increased activity of HTR1A protein] which results in decreased susceptibility to Physostigmine; tertatolol inhibits the reaction [[1-((4-fluorobenzoylamino)ethyl)-4-(7-methoxy-1-naphthyl)piperazine hydrochloride binds to and results in increased activity of HTR1A protein] which results in decreased susceptibility to Apomorphine]; tertatolol inhibits the reaction [[1-((4-fluorobenzoylamino)ethyl)-4-(7-methoxy-1-naphthyl)piperazine hydrochloride binds to and results in increased activity of HTR1A protein] which results in decreased susceptibility to Physostigmine] |
CTD |
PMID:8539317 |
|
NCBI chr 5:63,957,874...63,962,445
Ensembl chr 5:63,957,874...63,962,507
|
|
|
G |
BAX |
BCL2 associated X, apoptosis regulator |
increases response to substance |
EXP |
BAX protein results in increased susceptibility to Acridine Orange |
CTD |
PMID:16177561 |
|
NCBI chr19:48,954,875...48,961,798
Ensembl chr19:48,954,815...48,961,798
|
|
G |
GSTP1 |
glutathione S-transferase pi 1 |
multiple interactions |
EXP |
[Acridine Orange binds to Platinum Compounds] which results in increased expression of GSTP1 mRNA; [Acridine Orange binds to Platinum] which results in increased expression of GSTP1 mRNA |
CTD |
PMID:16814760 |
|
NCBI chr11:67,583,812...67,586,653
Ensembl chr11:67,583,742...67,586,656
|
|
G |
TP53 |
tumor protein p53 |
multiple interactions |
EXP |
Acridine Orange results in increased stability of and results in increased activity of TP53 protein |
CTD |
PMID:16177561 |
|
NCBI chr17:7,668,421...7,687,490
Ensembl chr17:7,661,779...7,687,546
|
|
|
G |
ACHE |
acetylcholinesterase (Yt blood group) |
decreases activity |
EXP |
Ambenonium Chloride results in decreased activity of ACHE protein |
CTD |
PMID:33844597 |
|
NCBI chr 7:100,889,994...100,896,994
Ensembl chr 7:100,889,994...100,896,974
|
|
G |
APP |
amyloid beta precursor protein |
affects cleavage |
ISO |
Ambenonium Chloride affects the cleavage of APP protein |
CTD |
PMID:11099780 |
|
NCBI chr21:25,880,550...26,171,128
Ensembl chr21:25,880,535...26,171,128
|
|
|
G |
SLC19A3 |
solute carrier family 19 member 3 |
multiple interactions |
EXP |
Amprolium inhibits the reaction [SLC19A3 protein results in increased uptake of Metformin]; Amprolium inhibits the reaction [SLC19A3 protein results in increased uptake of Thiamine] |
CTD |
PMID:26528626 |
|
NCBI chr 2:227,683,763...227,718,028
Ensembl chr 2:227,683,763...227,718,028
|
|
|
G |
CYP2D6 |
cytochrome P450 family 2 subfamily D member 6 (gene/pseudogene) |
increases hydroxylation increases metabolic processing multiple interactions |
EXP |
CYP2D6 protein results in increased hydroxylation of Atomoxetine Hydrochloride CYP2D6 protein results in increased metabolism of Atomoxetine Hydrochloride Quinidine inhibits the reaction [CYP2D6 protein results in increased metabolism of Atomoxetine Hydrochloride] |
CTD |
PMID:17470523 PMID:34431675 |
|
NCBI chr22:42,126,499...42,130,810
Ensembl chr22:42,126,499...42,130,865
|
|
|
G |
ALDH1A1 |
aldehyde dehydrogenase 1 family member A1 |
increases expression multiple interactions |
EXP |
Benzophenoneidum results in increased expression of ALDH1A1 protein ALDH1A1 protein promotes the reaction [Benzophenoneidum results in increased lipidation of and results in increased cleavage of MAP1LC3B protein] |
CTD |
PMID:28722353 |
|
NCBI chr 9:72,900,671...72,953,053
Ensembl chr 9:72,900,671...73,080,442
|
|
G |
ANO6 |
anoctamin 6 |
increases expression |
EXP |
Benzophenoneidum results in increased expression of ANO6 protein |
CTD |
PMID:28722353 |
|
NCBI chr12:45,216,095...45,440,404
Ensembl chr12:45,215,987...45,482,280
|
|
G |
ARAF |
A-Raf proto-oncogene, serine/threonine kinase |
increases expression |
EXP |
Benzophenoneidum results in increased expression of ARAF protein |
CTD |
PMID:28722353 |
|
NCBI chr X:47,561,205...47,571,908
Ensembl chr X:47,561,205...47,571,908
|
|
G |
ATP6AP2 |
ATPase H+ transporting accessory protein 2 |
increases expression |
EXP |
Benzophenoneidum results in increased expression of ATP6AP2 protein |
CTD |
PMID:28722353 |
|
NCBI chr X:40,580,970...40,606,848
Ensembl chr X:40,579,372...40,606,848
|
|
G |
CCDC22 |
coiled-coil domain containing 22 |
increases expression |
EXP |
Benzophenoneidum results in increased expression of CCDC22 protein |
CTD |
PMID:28722353 |
|
NCBI chr X:49,235,470...49,250,520
Ensembl chr X:49,235,470...49,250,520
|
|
G |
CCDC39 |
coiled-coil domain 39 molecular ruler complex subunit |
increases expression |
EXP |
Benzophenoneidum results in increased expression of CCDC39 protein |
CTD |
PMID:28722353 |
|
NCBI chr 3:180,614,008...180,679,489
Ensembl chr 3:180,602,858...180,684,942
|
|
G |
CD44 |
CD44 molecule (IN blood group) |
increases expression |
EXP |
Benzophenoneidum results in increased expression of CD44 protein |
CTD |
PMID:28722353 |
|
NCBI chr11:35,139,171...35,232,402
Ensembl chr11:35,138,882...35,232,402
|
|
G |
CHTF18 |
chromosome transmission fidelity factor 18 |
increases expression |
EXP |
Benzophenoneidum results in increased expression of CHTF18 protein |
CTD |
PMID:28722353 |
|
NCBI chr16:788,620...798,074
Ensembl chr16:788,046...800,737
|
|
G |
COMMD1 |
copper metabolism domain containing 1 |
increases expression |
EXP |
Benzophenoneidum results in increased expression of COMMD1 protein |
CTD |
PMID:28722353 |
|
NCBI chr 2:61,888,391...62,136,058
Ensembl chr 2:61,888,724...62,147,247
|
|
G |
COPS7B |
COP9 signalosome subunit 7B |
increases expression |
EXP |
Benzophenoneidum results in increased expression of COPS7B protein |
CTD |
PMID:28722353 |
|
NCBI chr 2:231,781,671...231,809,253
Ensembl chr 2:231,781,671...231,809,254
|
|
G |
CUL3 |
cullin 3 |
increases expression |
EXP |
Benzophenoneidum results in increased expression of CUL3 protein |
CTD |
PMID:28722353 |
|
NCBI chr 2:224,470,150...224,585,363
Ensembl chr 2:224,470,150...224,585,397
|
|
G |
DYNLT1 |
dynein light chain Tctex-type 1 |
increases expression |
EXP |
Benzophenoneidum results in increased expression of DYNLT1 protein |
CTD |
PMID:28722353 |
|
NCBI chr 6:158,636,474...158,644,743
Ensembl chr 6:158,636,474...158,644,743
|
|
G |
EIF4G3 |
eukaryotic translation initiation factor 4 gamma 3 |
increases expression |
EXP |
Benzophenoneidum results in increased expression of EIF4G3 protein |
CTD |
PMID:28722353 |
|
NCBI chr 1:20,806,292...21,176,897
Ensembl chr 1:20,806,292...21,177,285
|
|
G |
FASTKD2 |
FAST kinase domains 2 |
increases expression |
EXP |
Benzophenoneidum results in increased expression of FASTKD2 protein |
CTD |
PMID:28722353 |
|
NCBI chr 2:206,765,606...206,796,189
Ensembl chr 2:206,765,357...206,796,189
|
|
G |
H2AX |
H2A.X variant histone |
increases phosphorylation |
ISO |
Benzophenoneidum results in increased phosphorylation of H2AX protein |
CTD |
PMID:37527026 |
|
NCBI chr11:119,093,874...119,095,465
Ensembl chr11:119,093,874...119,095,465
|
|
G |
HOOK3 |
hook microtubule tethering protein 3 |
increases expression |
EXP |
Benzophenoneidum results in increased expression of HOOK3 protein |
CTD |
PMID:28722353 |
|
NCBI chr 8:42,896,978...43,030,535
Ensembl chr 8:42,896,946...43,030,535
|
|
G |
HSD17B7 |
hydroxysteroid 17-beta dehydrogenase 7 |
increases expression |
EXP |
Benzophenoneidum results in increased expression of HSD17B7 protein |
CTD |
PMID:28722353 |
|
NCBI chr 1:162,790,702...162,812,823
Ensembl chr 1:162,790,702...162,812,823
|
|
G |
HTT |
huntingtin |
increases expression |
EXP |
Benzophenoneidum results in increased expression of HTT protein |
CTD |
PMID:28722353 |
|
NCBI chr 4:3,074,681...3,243,960
Ensembl chr 4:3,041,363...3,243,957
|
|
G |
IQGAP3 |
IQ motif containing GTPase activating protein 3 |
increases expression |
EXP |
Benzophenoneidum results in increased expression of IQGAP3 protein |
CTD |
PMID:28722353 |
|
NCBI chr 1:156,525,405...156,572,565
Ensembl chr 1:156,525,405...156,572,604
|
|
G |
KIFAP3 |
kinesin associated protein 3 |
increases expression |
EXP |
Benzophenoneidum results in increased expression of KIFAP3 protein |
CTD |
PMID:28722353 |
|
NCBI chr 1:169,921,329...170,085,184
Ensembl chr 1:169,921,326...170,085,208
|
|
G |
MAP1LC3B |
microtubule associated protein 1 light chain 3 beta |
multiple interactions |
EXP |
ALDH1A1 protein promotes the reaction [Benzophenoneidum results in increased lipidation of and results in increased cleavage of MAP1LC3B protein]; Benzophenoneidum results in increased lipidation of and results in increased cleavage of MAP1LC3B protein |
CTD |
PMID:28722353 |
|
NCBI chr16:87,392,336...87,404,774
Ensembl chr16:87,383,953...87,404,779
|
|
G |
MAP2K4 |
mitogen-activated protein kinase kinase 4 |
increases expression |
EXP |
Benzophenoneidum results in increased expression of MAP2K4 protein |
CTD |
PMID:28722353 |
|
NCBI chr17:12,020,877...12,143,828
Ensembl chr17:12,020,829...12,143,830
|
|
G |
MBD3 |
methyl-CpG binding domain protein 3 |
increases expression |
EXP |
Benzophenoneidum results in increased expression of MBD3 protein |
CTD |
PMID:28722353 |
|
NCBI chr19:1,573,596...1,592,865
Ensembl chr19:1,573,596...1,592,865
|
|
G |
MKI67 |
marker of proliferation Ki-67 |
increases expression |
ISO |
Benzophenoneidum results in increased expression of MKI67 protein |
CTD |
PMID:37527026 |
|
NCBI chr10:128,096,659...128,126,423
Ensembl chr10:128,096,659...128,126,423
|
|
G |
NOA1 |
nitric oxide associated 1 |
increases expression |
EXP |
Benzophenoneidum results in increased expression of NOA1 protein |
CTD |
PMID:28722353 |
|
NCBI chr 4:56,963,350...56,977,606
Ensembl chr 4:56,963,350...56,977,606
|
|
G |
NUP62 |
nucleoporin 62 |
increases expression |
EXP |
Benzophenoneidum results in increased expression of NUP62 protein |
CTD |
PMID:28722353 |
|
NCBI chr19:49,906,825...49,929,504
Ensembl chr19:49,906,825...49,929,764
|
|
G |
PLCG1 |
phospholipase C gamma 1 |
increases expression |
EXP |
Benzophenoneidum results in increased expression of PLCG1 protein |
CTD |
PMID:28722353 |
|
NCBI chr20:41,137,543...41,177,626
Ensembl chr20:41,136,960...41,196,801
|
|
G |
PPP4R1 |
protein phosphatase 4 regulatory subunit 1 |
increases expression |
EXP |
Benzophenoneidum results in increased expression of PPP4R1 protein |
CTD |
PMID:28722353 |
|
NCBI chr18:9,546,794...9,617,199
Ensembl chr18:9,546,791...9,615,240
|
|
G |
PRIM2 |
DNA primase subunit 2 |
increases expression |
EXP |
Benzophenoneidum results in increased expression of PRIM2 protein |
CTD |
PMID:28722353 |
|
NCBI chr 6:57,221,540...57,646,850
Ensembl chr 6:57,314,805...57,646,850
|
|
G |
PROM1 |
prominin 1 |
increases expression |
EXP |
Benzophenoneidum results in increased expression of PROM1 protein |
CTD |
PMID:28722353 |
|
NCBI chr 4:15,968,228...16,084,023
Ensembl chr 4:15,963,076...16,084,378
|
|
G |
PRORP |
protein only RNase P catalytic subunit |
increases expression |
EXP |
Benzophenoneidum results in increased expression of PRORP protein |
CTD |
PMID:28722353 |
|
NCBI chr14:35,121,839...35,277,622
Ensembl chr14:35,121,846...35,277,622
|
|
G |
SHMT1 |
serine hydroxymethyltransferase 1 |
increases expression |
EXP |
Benzophenoneidum results in increased expression of SHMT1 protein |
CTD |
PMID:28722353 |
|
NCBI chr17:18,327,873...18,363,550
Ensembl chr17:18,327,873...18,363,550
|
|
G |
SRSF11 |
serine and arginine rich splicing factor 11 |
increases expression |
EXP |
Benzophenoneidum results in increased expression of SRSF11 protein |
CTD |
PMID:28722353 |
|
NCBI chr 1:70,205,696...70,253,052
Ensembl chr 1:70,205,682...70,253,052
|
|
G |
TBC1D15 |
TBC1 domain family member 15 |
increases expression |
EXP |
Benzophenoneidum results in increased expression of TBC1D15 protein |
CTD |
PMID:28722353 |
|
NCBI chr12:71,839,759...71,924,313
Ensembl chr12:71,839,707...71,927,248
|
|
G |
TFAM |
transcription factor A, mitochondrial |
increases expression |
EXP |
Benzophenoneidum results in increased expression of TFAM protein |
CTD |
PMID:28722353 |
|
NCBI chr10:58,385,410...58,399,220
Ensembl chr10:58,385,345...58,399,220
|
|
G |
USP24 |
ubiquitin specific peptidase 24 |
increases expression |
EXP |
Benzophenoneidum results in increased expression of USP24 protein |
CTD |
PMID:28722353 |
|
NCBI chr 1:55,066,359...55,215,364
Ensembl chr 1:55,066,359...55,215,378
|
|
G |
WASHC5 |
WASH complex subunit 5 |
increases expression |
EXP |
Benzophenoneidum results in increased expression of WASHC5 protein |
CTD |
PMID:28722353 |
|
NCBI chr 8:125,024,260...125,091,792
Ensembl chr 8:125,024,260...125,091,819
|
|
|
G |
GPT |
glutamic--pyruvic transaminase |
increases activity |
ISO |
Azure A results in increased activity of GPT protein |
CTD |
PMID:33775737 |
|
NCBI chr 8:144,503,068...144,507,172
Ensembl chr 8:144,502,973...144,507,174
|
|
|
G |
APP |
amyloid beta precursor protein |
multiple interactions |
EXP |
[Azure B affects the cleavage of APP protein] which results in decreased secretion of APP protein modified form; Azure B results in decreased expression of and affects the cleavage of APP protein |
CTD |
PMID:30500345 |
|
NCBI chr21:25,880,550...26,171,128
Ensembl chr21:25,880,535...26,171,128
|
|
G |
BACE1 |
beta-secretase 1 |
decreases activity |
EXP |
Azure B results in decreased activity of BACE1 protein |
CTD |
PMID:30500345 |
|
NCBI chr11:117,285,698...117,316,256
Ensembl chr11:117,285,232...117,316,259
|
|
|
G |
AACS |
acetoacetyl-CoA synthetase |
increases expression |
ISO |
Benzalkonium Compounds results in increased expression of AACS mRNA |
CTD |
PMID:31199489 |
|
NCBI chr12:125,065,435...125,143,316
Ensembl chr12:125,065,434...125,143,333
|
|
G |
ABCA1 |
ATP binding cassette subfamily A member 1 |
decreases expression |
EXP |
Benzalkonium Compounds results in decreased expression of ABCA1 mRNA |
CTD |
PMID:26919959 |
|
NCBI chr 9:104,781,006...104,928,155
Ensembl chr 9:104,781,006...104,928,155
|
|
G |
ABCA12 |
ATP binding cassette subfamily A member 12 |
increases expression |
EXP |
Benzalkonium Compounds results in increased expression of ABCA12 mRNA |
CTD |
PMID:25377654 |
|
NCBI chr 2:214,931,542...215,138,626
Ensembl chr 2:214,931,542...215,138,626
|
|
G |
ABCA6 |
ATP binding cassette subfamily A member 6 |
decreases expression |
EXP |
Benzalkonium Compounds results in decreased expression of ABCA6 mRNA |
CTD |
PMID:20713136 |
|
NCBI chr17:69,078,702...69,141,895
Ensembl chr17:69,078,702...69,141,895
|
|
G |
ACOD1 |
aconitate decarboxylase 1 |
increases expression |
ISO |
Benzalkonium Compounds results in increased expression of ACOD1 mRNA |
CTD |
PMID:30171875 |
|
NCBI chr13:76,948,511...76,958,638
Ensembl chr13:76,948,511...76,958,638
|
|
G |
ACP6 |
acid phosphatase 6, lysophosphatidic |
increases expression |
ISO |
Benzalkonium Compounds results in increased expression of ACP6 mRNA |
CTD |
PMID:31199489 |
|
NCBI chr 1:147,629,658...147,670,524
Ensembl chr 1:147,629,652...147,670,524
|
|
G |
ACSL4 |
acyl-CoA synthetase long chain family member 4 |
increases expression |
ISO |
Benzalkonium Compounds results in increased expression of ACSL4 mRNA |
CTD |
PMID:31199489 |
|
NCBI chr X:109,641,335...109,733,257
Ensembl chr X:109,624,244...109,733,403
|
|
G |
ADA |
adenosine deaminase |
increases expression |
ISO |
Benzalkonium Compounds results in increased expression of ADA mRNA |
CTD |
PMID:30171875 |
|
NCBI chr20:44,619,522...44,651,699
Ensembl chr20:44,584,896...44,652,252
|
|
G |
ADH1C |
alcohol dehydrogenase 1C (class I), gamma polypeptide |
decreases expression |
ISO |
Benzalkonium Compounds results in decreased expression of ADH1 mRNA |
CTD |
PMID:31199489 |
|
NCBI chr 4:99,336,497...99,352,746
Ensembl chr 4:99,336,497...99,352,746
|
|
G |
ADORA1 |
adenosine A1 receptor |
decreases expression |
ISO |
Benzalkonium Compounds results in decreased expression of ADORA1 mRNA |
CTD |
PMID:30171875 |
|
NCBI chr 1:203,127,726...203,167,405
Ensembl chr 1:203,090,654...203,167,405
|
|
G |
ADRA2A |
adrenoceptor alpha 2A |
multiple interactions |
ISO |
[IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of ADRA2A mRNA |
CTD |
PMID:30171875 |
|
NCBI chr10:111,077,029...111,080,907
Ensembl chr10:111,077,029...111,080,907
|
|
G |
AGTR2 |
angiotensin II receptor type 2 |
multiple interactions |
ISO |
[IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of AGTR2 mRNA |
CTD |
PMID:30171875 |
|
NCBI chr X:116,170,744...116,174,974
Ensembl chr X:116,170,744...116,174,974
|
|
G |
AKR1B10 |
aldo-keto reductase family 1 member B10 |
increases expression |
EXP |
Benzalkonium Compounds results in increased expression of AKR1B10 mRNA |
CTD |
PMID:30806763 |
|
NCBI chr 7:134,527,567...134,541,412
Ensembl chr 7:134,527,567...134,541,412
|
|
G |
ALB |
albumin |
decreases expression |
ISO |
Benzalkonium Compounds results in decreased expression of ALB mRNA |
CTD |
PMID:31199489 |
|
NCBI chr 4:73,404,287...73,421,482
Ensembl chr 4:73,397,114...73,421,482
|
|
G |
AMIGO2 |
adhesion molecule with Ig like domain 2 |
increases expression |
EXP |
Benzalkonium Compounds results in increased expression of AMIGO2 mRNA |
CTD |
PMID:37149095 |
|
NCBI chr12:47,075,707...47,079,959
Ensembl chr12:47,075,707...47,079,959
|
|
G |
APOA1 |
apolipoprotein A1 |
decreases expression |
ISO |
Benzalkonium Compounds results in decreased expression of APOA1 mRNA |
CTD |
PMID:31199489 |
|
NCBI chr11:116,835,751...116,837,622
Ensembl chr11:116,835,751...116,837,622
|
|
G |
APOA2 |
apolipoprotein A2 |
decreases expression |
ISO |
Benzalkonium Compounds results in decreased expression of APOA2 mRNA |
CTD |
PMID:31199489 |
|
NCBI chr 1:161,222,292...161,223,628
Ensembl chr 1:161,222,290...161,223,631
|
|
G |
APOC1 |
apolipoprotein C1 |
decreases expression |
ISO |
Benzalkonium Compounds results in decreased expression of APOC1 mRNA |
CTD |
PMID:31199489 |
|
NCBI chr19:44,914,325...44,919,346
Ensembl chr19:44,914,247...44,919,349
|
|
G |
AQP3 |
aquaporin 3 (Gill blood group) |
increases expression |
ISO |
Benzalkonium Compounds results in increased expression of AQP3 mRNA |
CTD |
PMID:30171875 |
|
NCBI chr 9:33,441,160...33,447,593
Ensembl chr 9:33,441,156...33,447,596
|
|
G |
AREG |
amphiregulin |
increases expression |
ISO |
Benzalkonium Compounds results in increased expression of AREG mRNA |
CTD |
PMID:30171875 |
|
NCBI chr 4:74,445,136...74,455,005
Ensembl chr 4:74,445,136...74,455,005
|
|
G |
ARG2 |
arginase 2 |
increases expression |
ISO |
Benzalkonium Compounds results in increased expression of ARG2 mRNA |
CTD |
PMID:30171875 |
|
NCBI chr14:67,619,920...67,651,708
Ensembl chr14:67,619,920...67,651,708
|
|
G |
ART3 |
ADP-ribosyltransferase 3 (inactive) |
decreases expression |
ISO |
Benzalkonium Compounds results in decreased expression of ART3 mRNA |
CTD |
PMID:31199489 |
|
NCBI chr 4:76,011,190...76,112,786
Ensembl chr 4:76,011,184...76,114,048
|
|
G |
ATF4 |
activating transcription factor 4 |
decreases expression |
EXP |
Benzalkonium Compounds results in decreased expression of ATF4 mRNA |
CTD |
PMID:28236482 |
|
NCBI chr22:39,520,559...39,522,686
Ensembl chr22:39,519,695...39,522,686
|
|
G |
ATP5F1E |
ATP synthase F1 subunit epsilon |
decreases expression |
ISO |
Benzalkonium Compounds results in decreased expression of ATP5F1E mRNA |
CTD |
PMID:31199489 |
|
NCBI chr20:59,025,475...59,032,335
Ensembl chr20:59,025,475...59,032,345
|
|
G |
ATP5MG |
ATP synthase membrane subunit g |
decreases expression |
ISO |
Benzalkonium Compounds results in decreased expression of ATP5MG mRNA |
CTD |
PMID:31199489 |
|
NCBI chr11:118,401,606...118,409,847
Ensembl chr11:118,401,346...118,433,278
|
|
G |
B3GALT4 |
beta-1,3-galactosyltransferase 4 |
affects response to substance |
EXP |
B3GALT4 SNP affects the susceptibility to Benzalkonium Compounds |
CTD |
PMID:27258892 |
|
NCBI chr 6:33,277,123...33,278,825
Ensembl chr 6:33,277,123...33,284,832
|
|
G |
BAMBI |
BMP and activin membrane bound inhibitor |
increases expression |
EXP |
Benzalkonium Compounds results in increased expression of BAMBI mRNA |
CTD |
PMID:20146380 |
|
NCBI chr10:28,677,521...28,682,932
Ensembl chr10:28,677,510...28,682,932
|
|
G |
BCL3 |
BCL3 transcription coactivator |
increases expression |
ISO |
Benzalkonium Compounds results in increased expression of BCL3 mRNA |
CTD |
PMID:30171875 |
|
NCBI chr19:44,747,705...44,760,044
Ensembl chr19:44,747,705...44,760,044
|
|
G |
BTC |
betacellulin |
decreases expression |
ISO |
Benzalkonium Compounds results in decreased expression of BTC mRNA |
CTD |
PMID:30171875 |
|
NCBI chr 4:74,744,759...74,794,523
Ensembl chr 4:74,744,759...74,794,523
|
|
G |
C3 |
complement C3 |
multiple interactions |
ISO |
[IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of C3 mRNA |
CTD |
PMID:30171875 |
|
NCBI chr19:6,677,704...6,720,650
Ensembl chr19:6,677,704...6,730,562
|
|
G |
CASP3 |
caspase 3 |
multiple interactions increases cleavage |
EXP |
benzoylcarbonyl-aspartyl-glutamyl-valyl-aspartyl-fluoromethyl ketone inhibits the reaction [Benzalkonium Compounds analog results in increased cleavage of CASP3 protein] |
CTD |
PMID:31982400 |
|
NCBI chr 4:184,627,696...184,649,447
Ensembl chr 4:184,627,696...184,650,062
|
|
G |
CASP8 |
caspase 8 |
decreases expression |
EXP |
Benzalkonium Compounds results in decreased expression of CASP8 mRNA |
CTD |
PMID:28236482 |
|
NCBI chr 2:201,233,463...201,287,711
Ensembl chr 2:201,233,443...201,361,836
|
|
G |
CCL11 |
C-C motif chemokine ligand 11 |
increases expression |
ISO |
Benzalkonium Compounds results in increased expression of CCL11 protein |
CTD |
PMID:30517752 |
|
NCBI chr17:34,285,742...34,288,334
Ensembl chr17:34,285,742...34,288,334
|
|
G |
CCL2 |
C-C motif chemokine ligand 2 |
increases expression increases secretion |
ISO EXP |
Benzalkonium Compounds results in increased expression of CCL2 mRNA; Benzalkonium Compounds results in increased expression of CCL2 protein Benzalkonium Compounds results in increased secretion of CCL2 protein |
CTD |
PMID:30171875 PMID:30517752 PMID:31707104 |
|
NCBI chr17:34,255,285...34,257,203
Ensembl chr17:34,255,274...34,257,208
|
|
G |
CCL20 |
C-C motif chemokine ligand 20 |
increases expression |
EXP |
Benzalkonium Compounds results in increased expression of CCL20 mRNA |
CTD |
PMID:30806763 |
|
NCBI chr 2:227,813,842...227,817,556
Ensembl chr 2:227,805,739...227,817,564
|
|
G |
CCL24 |
C-C motif chemokine ligand 24 |
decreases expression |
ISO |
Benzalkonium Compounds results in decreased expression of CCL24 mRNA |
CTD |
PMID:30171875 |
|
NCBI chr 7:75,810,825...75,823,372
Ensembl chr 7:75,810,825...75,823,356
|
|
G |
CCL3 |
C-C motif chemokine ligand 3 |
increases expression multiple interactions |
ISO |
Benzalkonium Compounds results in increased expression of CCL3 protein [IL6RA gene mutant form results in increased susceptibility to Benzalkonium Compounds] which results in increased expression of CCL3 protein |
CTD |
PMID:30517752 PMID:31158415 |
|
NCBI chr17:36,088,256...36,090,143
Ensembl chr17:36,088,256...36,090,169
|
|
G |
CCL4 |
C-C motif chemokine ligand 4 |
decreases expression multiple interactions increases expression |
EXP ISO |
Benzalkonium Compounds results in decreased expression of CCL4 mRNA; Benzalkonium Compounds results in decreased expression of CCL4 protein [IL6RA gene mutant form results in increased susceptibility to Benzalkonium Compounds] which results in increased expression of CCL4 protein Benzalkonium Compounds results in increased expression of CCL4 protein |
CTD |
PMID:18353026 PMID:20713136 PMID:30517752 PMID:31158415 |
|
NCBI chr17:36,103,827...36,105,614
Ensembl chr17:36,103,827...36,105,621
|
|
G |
CCL5 |
C-C motif chemokine ligand 5 |
increases expression |
ISO |
Benzalkonium Compounds results in increased expression of CCL5 protein |
CTD |
PMID:30517752 |
|
NCBI chr17:35,871,491...35,880,360
Ensembl chr17:35,871,491...35,880,793
|
|
G |
CCL7 |
C-C motif chemokine ligand 7 |
increases expression |
ISO |
Benzalkonium Compounds results in increased expression of CCL7 mRNA; Benzalkonium Compounds results in increased expression of CCL7 protein |
CTD |
PMID:30171875 PMID:30517752 |
|
NCBI chr17:34,270,221...34,272,242
Ensembl chr17:34,270,221...34,272,242
|
|
G |
CCN2 |
cellular communication network factor 2 |
decreases expression |
EXP |
Benzalkonium Compounds results in decreased expression of CCN2 mRNA |
CTD |
PMID:25377654 |
|
NCBI chr 6:131,948,176...131,951,372
Ensembl chr 6:131,948,176...131,951,372
|
|
G |
CCN3 |
cellular communication network factor 3 |
increases expression |
ISO |
Benzalkonium Compounds results in increased expression of CCN3 mRNA |
CTD |
PMID:30171875 |
|
NCBI chr 8:119,416,446...119,424,434
Ensembl chr 8:119,416,446...119,424,434
|
|
G |
CCR4 |
C-C motif chemokine receptor 4 |
decreases expression |
ISO |
Benzalkonium Compounds results in decreased expression of CCR4 mRNA |
CTD |
PMID:30171875 |
|
NCBI chr 3:32,951,644...32,956,349
Ensembl chr 3:32,951,644...32,957,120
|
|
G |
CCR5 |
C-C motif chemokine receptor 5 |
increases expression |
ISO |
Benzalkonium Compounds results in increased expression of CCR5 mRNA |
CTD |
PMID:30171875 |
|
NCBI chr 3:46,370,142...46,376,206
Ensembl chr 3:46,370,946...46,376,206
|
|
G |
CD177 |
CD177 molecule |
multiple interactions |
ISO |
[IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of CD177 mRNA |
CTD |
PMID:30171875 |
|
NCBI chr19:43,353,686...43,366,081
Ensembl chr19:43,353,686...43,363,172
|
|
G |
CD274 |
CD274 molecule |
multiple interactions |
ISO |
[IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of CD274 mRNA |
CTD |
PMID:30171875 |
|
NCBI chr 9:5,450,542...5,470,554
Ensembl chr 9:5,450,503...5,470,566
|
|
G |
CDC6 |
cell division cycle 6 |
multiple interactions decreases expression |
EXP |
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one promotes the reaction [Benzalkonium Compounds results in decreased expression of CDC6 protein] Benzalkonium Compounds results in decreased expression of CDC6 mRNA; Benzalkonium Compounds results in decreased expression of CDC6 protein |
CTD |
PMID:36725023 |
|
NCBI chr17:40,287,879...40,304,657
Ensembl chr17:40,287,879...40,304,657
|
|
G |
CFAP61 |
cilia and flagella associated protein 61 |
increases expression |
ISO |
Benzalkonium Compounds results in increased expression of CFAP61 mRNA |
CTD |
PMID:31199489 |
|
NCBI chr20:20,052,532...20,360,698
Ensembl chr20:20,052,514...20,360,703
|
|
G |
CFD |
complement factor D |
decreases expression |
ISO |
Benzalkonium Compounds results in decreased expression of CFD mRNA |
CTD |
PMID:30171875 |
|
NCBI chr19:859,664...863,641
Ensembl chr19:859,453...867,884
|
|
G |
CHI3L1 |
chitinase 3 like 1 |
increases expression |
ISO |
Benzalkonium Compounds results in increased expression of CHI3L1 mRNA |
CTD |
PMID:30171875 |
|
NCBI chr 1:203,178,931...203,186,704
Ensembl chr 1:203,178,931...203,186,704
|
|
G |
CHRNB4 |
cholinergic receptor nicotinic beta 4 subunit |
decreases expression |
ISO |
Benzalkonium Compounds results in decreased expression of CHRNB4 mRNA |
CTD |
PMID:30171875 |
|
NCBI chr15:78,624,111...78,661,641
Ensembl chr15:78,624,111...78,727,754
|
|
G |
CIMAP1D |
CIMAP1 family member D |
decreases expression |
ISO |
Benzalkonium Compounds results in decreased expression of CIMAP1D mRNA |
CTD |
PMID:30171875 |
|
NCBI chr19:463,361...491,624
Ensembl chr19:463,346...474,983
|
|
G |
CLCF1 |
cardiotrophin like cytokine factor 1 |
increases expression |
ISO |
Benzalkonium Compounds results in increased expression of CLCF1 mRNA |
CTD |
PMID:30171875 |
|
NCBI chr11:67,364,168...67,374,177
Ensembl chr11:67,364,168...67,374,177
|
|
G |
CNFN |
cornifelin |
increases expression |
EXP |
Benzalkonium Compounds results in increased expression of CNFN mRNA; Benzalkonium Compounds results in increased expression of CNFN protein |
CTD |
PMID:25377654 |
|
NCBI chr19:42,387,019...42,390,297
Ensembl chr19:42,387,019...42,390,297
|
|
G |
CSF1 |
colony stimulating factor 1 |
increases expression |
ISO |
Benzalkonium Compounds results in increased expression of CSF1 protein |
CTD |
PMID:30517752 |
|
NCBI chr 1:109,910,506...109,930,992
Ensembl chr 1:109,910,242...109,930,992
|
|
G |
CSF2 |
colony stimulating factor 2 |
increases expression |
ISO |
Benzalkonium Compounds results in increased expression of CSF2 protein |
CTD |
PMID:30517752 |
|
NCBI chr 5:132,073,789...132,076,170
Ensembl chr 5:132,073,789...132,076,170
|
|
G |
CSF3 |
colony stimulating factor 3 |
increases expression |
ISO |
Benzalkonium Compounds results in increased expression of CSF3 protein |
CTD |
PMID:30517752 |
|
NCBI chr17:40,015,440...40,017,813
Ensembl chr17:40,015,361...40,017,813
|
|
G |
CTPS1 |
CTP synthase 1 |
multiple interactions |
ISO |
[IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of CTPS1 mRNA |
CTD |
PMID:30171875 |
|
NCBI chr 1:40,979,696...41,012,565
Ensembl chr 1:40,979,300...41,012,565
|
|
G |
CXCL1 |
C-X-C motif chemokine ligand 1 |
increases expression multiple interactions |
ISO |
Benzalkonium Compounds results in increased expression of CXCL1 protein; Benzalkonium Compounds results in increased expression of CXCL3 mRNA [IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of CXCL3 mRNA |
CTD |
PMID:30171875 PMID:30517752 |
|
NCBI chr 4:73,869,393...73,871,308
Ensembl chr 4:73,869,393...73,871,308
|
|
G |
CXCL10 |
C-X-C motif chemokine ligand 10 |
increases expression multiple interactions |
ISO |
Benzalkonium Compounds results in increased expression of CXCL10 mRNA; Benzalkonium Compounds results in increased expression of CXCL10 protein [IL6RA gene mutant form results in increased susceptibility to Benzalkonium Compounds] which results in increased expression of CXCL10 protein |
CTD |
PMID:23445166 PMID:30517752 PMID:31158415 |
|
NCBI chr 4:76,021,118...76,023,497
Ensembl chr 4:76,021,118...76,023,497
|
|
G |
CXCL2 |
C-X-C motif chemokine ligand 2 |
increases expression multiple interactions |
ISO |
Benzalkonium Compounds results in increased expression of CXCL2 mRNA; Benzalkonium Compounds results in increased expression of CXCL2 protein [IL6RA gene mutant form results in increased susceptibility to Benzalkonium Compounds] which results in increased expression of CXCL2 protein |
CTD |
PMID:30171875 PMID:30517752 PMID:31158415 |
|
NCBI chr 4:74,097,040...74,099,195
Ensembl chr 4:74,097,040...74,099,196
|
|
G |
CXCL6 |
C-X-C motif chemokine ligand 6 |
increases expression multiple interactions |
ISO |
Benzalkonium Compounds results in increased expression of CXCL5 mRNA; Benzalkonium Compounds results in increased expression of CXCL5 protein [IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of CXCL5 mRNA |
CTD |
PMID:30171875 PMID:30517752 |
|
NCBI chr 4:73,836,678...73,838,760
Ensembl chr 4:73,836,640...73,849,064
|
|
G |
CXCL8 |
C-X-C motif chemokine ligand 8 |
decreases expression increases expression increases secretion decreases secretion |
EXP |
Benzalkonium Compounds results in decreased expression of CXCL8 mRNA; Benzalkonium Compounds results in decreased expression of CXCL8 protein Benzalkonium Compounds results in increased expression of CXCL8 mRNA Benzalkonium Compounds results in increased secretion of CXCL8 protein Benzalkonium Compounds results in decreased secretion of CXCL8 protein |
CTD |
PMID:8006454 PMID:12781210 PMID:16099135 PMID:17763283 PMID:19729060 PMID:20146380 PMID:21920952 PMID:25290854 PMID:27965148 PMID:28214551 PMID:28236482 PMID:30806763 More...
|
|
NCBI chr 4:73,740,569...73,743,716
Ensembl chr 4:73,740,519...73,743,716
|
|
G |
CXCR1 |
C-X-C motif chemokine receptor 1 |
increases expression |
EXP |
Benzalkonium Compounds results in increased expression of CXCR1 mRNA |
CTD |
PMID:30806763 |
|
NCBI chr 2:218,162,841...218,166,962
Ensembl chr 2:218,162,841...218,166,962
|
|
G |
CXCR4 |
C-X-C motif chemokine receptor 4 |
increases expression |
EXP |
Benzalkonium Compounds results in increased expression of CXCR4 mRNA |
CTD |
PMID:20713136 |
|
NCBI chr 2:136,114,349...136,118,149
Ensembl chr 2:136,114,349...136,119,177
|
|
G |
CYP1A1 |
cytochrome P450 family 1 subfamily A member 1 |
decreases expression increases expression |
EXP |
Benzalkonium Compounds results in decreased expression of CYP1A1 mRNA Benzalkonium Compounds results in increased expression of CYP1A1 mRNA |
CTD |
PMID:20713136 PMID:30806763 |
|
NCBI chr15:74,719,542...74,725,528
Ensembl chr15:74,719,542...74,725,536
|
|
G |
CYP27A1 |
cytochrome P450 family 27 subfamily A member 1 |
decreases expression |
EXP |
Benzalkonium Compounds results in decreased expression of CYP27A1 mRNA |
CTD |
PMID:20713136 |
|
NCBI chr 2:218,782,147...218,815,293
Ensembl chr 2:218,781,749...218,815,293
|
|
G |
CYP51A1 |
cytochrome P450 family 51 subfamily A member 1 |
increases expression |
ISO |
Benzalkonium Compounds results in increased expression of CYP51 mRNA |
CTD |
PMID:31199489 |
|
NCBI chr 7:92,112,153...92,134,803
Ensembl chr 7:92,084,987...92,134,803
|
|
G |
DDIT3 |
DNA damage inducible transcript 3 |
increases expression |
EXP |
Benzalkonium Compounds results in increased expression of DDIT3 mRNA |
CTD |
PMID:37149095 |
|
NCBI chr12:57,516,588...57,520,517
Ensembl chr12:57,516,588...57,521,737
|
|
G |
DHCR24 |
24-dehydrocholesterol reductase |
increases expression |
ISO |
Benzalkonium Compounds results in increased expression of DHCR24 mRNA |
CTD |
PMID:31199489 |
|
NCBI chr 1:54,849,627...54,887,195
Ensembl chr 1:54,849,627...54,887,195
|
|
G |
DHCR7 |
7-dehydrocholesterol reductase |
decreases activity increases expression |
EXP ISO |
Benzalkonium Compounds results in decreased activity of DHCR7 protein Benzalkonium Compounds results in increased expression of DHCR7 mRNA |
CTD |
PMID:26919959 |
|
NCBI chr11:71,427,287...71,449,043
Ensembl chr11:71,428,193...71,452,868
|
|
G |
DIO1 |
iodothyronine deiodinase 1 |
decreases activity |
EXP |
Benzalkonium Compounds results in decreased activity of DIO1 protein |
CTD |
PMID:30561685 |
|
NCBI chr 1:53,894,187...53,911,086
Ensembl chr 1:53,891,239...53,911,086
|
|
G |
DIO2 |
iodothyronine deiodinase 2 |
decreases activity |
EXP |
Benzalkonium Compounds results in decreased activity of DIO2 protein |
CTD |
PMID:30561685 |
|
NCBI chr14:80,197,526...80,231,057
Ensembl chr14:80,197,526...80,387,757
|
|
G |
DIO3 |
iodothyronine deiodinase 3 |
decreases activity |
EXP |
Benzalkonium Compounds results in decreased activity of DIO3 protein |
CTD |
PMID:30561685 |
|
NCBI chr14:101,561,495...101,563,452
Ensembl chr14:101,560,139...101,563,452
|
|
G |
DLK1 |
delta like non-canonical Notch ligand 1 |
decreases expression |
ISO |
Benzalkonium Compounds results in decreased expression of DLK1 mRNA |
CTD |
PMID:31199489 |
|
NCBI chr14:100,726,892...100,738,224
Ensembl chr14:100,725,705...100,738,224
|
|
G |
DUSP1 |
dual specificity phosphatase 1 |
increases expression |
EXP |
Benzalkonium Compounds results in increased expression of DUSP1 mRNA |
CTD |
PMID:30806763 |
|
NCBI chr 5:172,768,096...172,771,195
Ensembl chr 5:172,768,096...172,771,195
|
|
G |
DUSP10 |
dual specificity phosphatase 10 |
increases expression |
EXP |
Benzalkonium Compounds results in increased expression of DUSP10 mRNA |
CTD |
PMID:37149095 |
|
NCBI chr 1:221,701,424...221,742,089
Ensembl chr 1:221,701,424...221,742,089
|
|
G |
EBP |
EBP cholestenol delta-isomerase |
increases expression |
EXP |
Benzalkonium Compounds results in increased expression of EBP mRNA |
CTD |
PMID:26919959 |
|
NCBI chr X:48,521,808...48,528,716
Ensembl chr X:48,521,799...48,528,716
|
|
G |
EGF |
epidermal growth factor |
decreases expression |
ISO |
Benzalkonium Compounds results in decreased expression of EGF mRNA |
CTD |
PMID:30171875 |
|
NCBI chr 4:109,912,883...110,013,766
Ensembl chr 4:109,912,883...110,013,766
|
|
G |
EGR1 |
early growth response 1 |
increases expression |
EXP |
Benzalkonium Compounds results in increased expression of EGR1 mRNA |
CTD |
PMID:25377654 |
|
NCBI chr 5:138,465,479...138,469,303
Ensembl chr 5:138,465,479...138,469,303
|
|
G |
ELF3 |
E74 like ETS transcription factor 3 |
increases expression |
ISO |
Benzalkonium Compounds results in increased expression of ELF3 mRNA |
CTD |
PMID:30171875 |
|
NCBI chr 1:202,010,587...202,017,183
Ensembl chr 1:202,007,945...202,017,183
|
|
G |
ELOVL1 |
ELOVL fatty acid elongase 1 |
increases expression |
EXP |
Benzalkonium Compounds results in increased expression of ELOVL1 mRNA |
CTD |
PMID:29155129 |
|
NCBI chr 1:43,363,401...43,368,011
Ensembl chr 1:43,363,398...43,368,074
|
|
G |
ELOVL6 |
ELOVL fatty acid elongase 6 |
increases expression |
ISO |
Benzalkonium Compounds results in increased expression of ELOVL6 mRNA |
CTD |
PMID:31199489 |
|
NCBI chr 4:110,045,846...110,199,202
Ensembl chr 4:110,045,846...110,199,199
|
|
G |
ENDOU |
endonuclease, poly(U) specific |
increases expression |
ISO |
Benzalkonium Compounds results in increased expression of ENDOU mRNA |
CTD |
PMID:30171875 |
|
NCBI chr12:47,709,734...47,725,490
Ensembl chr12:47,709,734...47,725,567
|
|
G |
ENO1 |
enolase 1 |
decreases expression |
ISO |
Benzalkonium Compounds results in decreased expression of ENO1 mRNA |
CTD |
PMID:31199489 |
|
NCBI chr 1:8,861,000...8,878,686
Ensembl chr 1:8,861,000...8,879,190
|
|
G |
ETNK1 |
ethanolamine kinase 1 |
increases expression |
ISO |
Benzalkonium Compounds results in increased expression of ETNK1 mRNA |
CTD |
PMID:31199489 |
|
NCBI chr12:22,625,171...22,690,665
Ensembl chr12:22,625,075...22,690,665
|
|
G |
EXO1 |
exonuclease 1 |
increases expression |
ISO |
Benzalkonium Compounds results in increased expression of EXO1 mRNA |
CTD |
PMID:30171875 |
|
NCBI chr 1:241,847,986...241,889,939
Ensembl chr 1:241,847,967...241,895,148
|
|
G |
EZR |
ezrin |
increases expression |
EXP |
Benzalkonium Compounds results in increased expression of EZR mRNA; Benzalkonium Compounds results in increased expression of EZR protein |
CTD |
PMID:29893927 |
|
NCBI chr 6:158,765,748...158,819,368
Ensembl chr 6:158,765,741...158,819,368
|
|
G |
FAM83A |
family with sequence similarity 83 member A |
increases expression |
ISO |
Benzalkonium Compounds results in increased expression of FAM83A mRNA |
CTD |
PMID:30171875 |
|
NCBI chr 8:123,179,047...123,210,079
Ensembl chr 8:123,178,960...123,210,079
|
|
G |
FGF2 |
fibroblast growth factor 2 |
affects response to substance |
EXP |
FGF2 SNP affects the susceptibility to Benzalkonium Compounds |
CTD |
PMID:27206134 |
|
NCBI chr 4:122,826,682...122,898,236
Ensembl chr 4:122,826,682...122,898,236
|
|
G |
FGR |
FGR proto-oncogene, Src family tyrosine kinase |
increases expression |
ISO |
Benzalkonium Compounds results in increased expression of FGR mRNA |
CTD |
PMID:30171875 |
|
NCBI chr 1:27,612,064...27,635,185
Ensembl chr 1:27,612,064...27,635,185
|
|
G |
FLG |
filaggrin |
increases expression |
ISO |
Benzalkonium Compounds results in increased expression of FLG mRNA |
CTD |
PMID:30171875 |
|
NCBI chr 1:152,302,165...152,325,239
Ensembl chr 1:152,302,165...152,325,239
|
|
G |
FOXC1 |
forkhead box C1 |
multiple interactions |
ISO |
[IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of FOXC1 mRNA |
CTD |
PMID:30171875 |
|
NCBI chr 6:1,609,915...1,613,897
Ensembl chr 6:1,609,915...1,613,897
|
|
G |
FOXN1 |
forkhead box N1 |
multiple interactions |
ISO |
[IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of FOXN1 mRNA |
CTD |
PMID:30171875 |
|
NCBI chr17:28,506,348...28,538,900
Ensembl chr17:28,506,243...28,538,900
|
|
G |
FOXP3 |
forkhead box P3 |
multiple interactions |
ISO |
[IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of FOXP3 mRNA |
CTD |
PMID:30171875 |
|
NCBI chr X:49,250,438...49,264,710
Ensembl chr X:49,250,438...49,264,800
|
|
G |
GATA3 |
GATA binding protein 3 |
multiple interactions |
ISO |
[IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of GATA3 mRNA |
CTD |
PMID:30171875 |
|
NCBI chr10:8,045,333...8,075,198
Ensembl chr10:8,045,378...8,075,198
|
|
G |
GCLC |
glutamate-cysteine ligase catalytic subunit |
increases expression |
EXP |
Benzalkonium Compounds results in increased expression of GCLC mRNA |
CTD |
PMID:30806763 |
|
NCBI chr 6:53,497,341...53,545,101
Ensembl chr 6:53,497,341...53,616,970
|
|
G |
GCLM |
glutamate-cysteine ligase modifier subunit |
increases expression |
EXP |
Benzalkonium Compounds results in increased expression of GCLM mRNA |
CTD |
PMID:30806763 |
|
NCBI chr 1:93,885,199...93,909,430
Ensembl chr 1:93,885,199...93,909,456
|
|
G |
GPX2 |
glutathione peroxidase 2 |
increases expression |
ISO |
Benzalkonium Compounds results in increased expression of GPX2 mRNA |
CTD |
PMID:30171875 |
|
NCBI chr14:64,939,158...64,942,745
Ensembl chr14:64,939,152...64,942,746
|
|
G |
HBEGF |
heparin binding EGF like growth factor |
increases expression |
ISO |
Benzalkonium Compounds results in increased expression of HBEGF mRNA |
CTD |
PMID:30171875 |
|
NCBI chr 5:140,332,843...140,346,603
Ensembl chr 5:140,332,843...140,346,603
|
|
G |
HCK |
HCK proto-oncogene, Src family tyrosine kinase |
multiple interactions |
ISO |
[IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of HCK mRNA |
CTD |
PMID:30171875 |
|
NCBI chr20:32,052,242...32,101,856
Ensembl chr20:32,052,197...32,101,856
|
|
G |
HERPUD1 |
homocysteine inducible ER protein with ubiquitin like domain 1 |
increases expression |
EXP |
Benzalkonium Compounds results in increased expression of HERPUD1 mRNA |
CTD |
PMID:37149095 |
|
NCBI chr16:56,932,142...56,944,864
Ensembl chr16:56,932,142...56,944,864
|
|
G |
HGF |
hepatocyte growth factor |
multiple interactions |
ISO |
[IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of HGF mRNA |
CTD |
PMID:30171875 |
|
NCBI chr 7:81,699,010...81,770,047
Ensembl chr 7:81,699,010...81,770,438
|
|
G |
HIF1A |
hypoxia inducible factor 1 subunit alpha |
increases expression |
ISO |
Benzalkonium Compounds results in increased expression of HIF1A mRNA |
CTD |
PMID:30171875 |
|
NCBI chr14:61,695,513...61,748,258
Ensembl chr14:61,695,513...61,748,259
|
|
G |
HIF1A-AS3 |
HIF1A antisense RNA 3 |
decreases expression |
EXP |
Benzalkonium Compounds results in decreased expression of HIF1A-AS3 |
CTD |
PMID:37149095 |
|
NCBI chr14:61,715,558...61,751,097
Ensembl chr14:61,678,402...61,751,163
|
|
G |
HLA-DOA |
major histocompatibility complex, class II, DO alpha |
affects response to substance |
EXP |
HLA-DOA SNP affects the susceptibility to Benzalkonium Compounds |
CTD |
PMID:27258892 |
|
NCBI chr 6:33,004,182...33,009,591
Ensembl chr 6:33,004,182...33,009,591
|
|
G |
HLA-DOB |
major histocompatibility complex, class II, DO beta |
affects response to substance |
EXP |
HLA-DOB SNP affects the susceptibility to Benzalkonium Compounds |
CTD |
PMID:27258892 |
|
NCBI chr 6:32,812,763...32,817,002
Ensembl chr 6:32,812,763...32,820,466
|
|
G |
HLA-DPA1 |
major histocompatibility complex, class II, DP alpha 1 |
affects response to substance |
EXP |
HLA-DPA1 SNP affects the susceptibility to Benzalkonium Compounds |
CTD |
PMID:27258892 |
|
NCBI chr 6:33,064,569...33,080,748
Ensembl chr 6:33,064,569...33,080,775
|
|
G |
HLA-DPB1 |
major histocompatibility complex, class II, DP beta 1 |
affects response to substance |
EXP |
HLA-DPB1 SNP affects the susceptibility to Benzalkonium Compounds |
CTD |
PMID:27258892 |
|
NCBI chr 6:33,075,990...33,089,696
Ensembl chr 6:33,075,936...33,089,696
|
|
G |
HLA-DQB2 |
major histocompatibility complex, class II, DQ beta 2 |
affects response to substance |
EXP |
HLA-DQB2 SNP affects the susceptibility to Benzalkonium Compounds |
CTD |
PMID:27258892 |
|
NCBI chr 6:32,756,098...32,763,532
Ensembl chr 6:32,756,098...32,763,532
|
|
G |
HMGCR |
3-hydroxy-3-methylglutaryl-CoA reductase |
increases expression |
EXP ISO |
Benzalkonium Compounds results in increased expression of HMGCR mRNA |
CTD |
PMID:26919959 PMID:31199489 |
|
NCBI chr 5:75,336,529...75,362,116
Ensembl chr 5:75,336,329...75,364,001
|
|
G |
HMGCS2 |
3-hydroxy-3-methylglutaryl-CoA synthase 2 |
increases expression |
ISO |
Benzalkonium Compounds results in increased expression of HMGCS2 mRNA |
CTD |
PMID:31199489 |
|
NCBI chr 1:119,747,996...119,768,932
Ensembl chr 1:119,748,002...119,768,905
|
|
G |
HMOX1 |
heme oxygenase 1 |
increases expression |
EXP |
Benzalkonium Compounds results in increased expression of HMOX1 mRNA |
CTD |
PMID:37149095 |
|
NCBI chr22:35,381,096...35,394,207
Ensembl chr22:35,380,361...35,394,214
|
|
G |
HOXA7 |
homeobox A7 |
decreases expression |
ISO |
Benzalkonium Compounds results in decreased expression of HOXA7 mRNA |
CTD |
PMID:30171875 |
|
NCBI chr 7:27,153,716...27,156,675
Ensembl chr 7:27,153,716...27,157,936
|
|
G |
HSD17B7 |
hydroxysteroid 17-beta dehydrogenase 7 |
increases expression |
ISO |
Benzalkonium Compounds results in increased expression of HSD17B7 mRNA |
CTD |
PMID:31199489 |
|
NCBI chr 1:162,790,702...162,812,823
Ensembl chr 1:162,790,702...162,812,823
|
|
G |
HSPA5 |
heat shock protein family A (Hsp70) member 5 |
decreases expression |
EXP |
Benzalkonium Compounds results in decreased expression of HSPA5 mRNA |
CTD |
PMID:28236482 |
|
NCBI chr 9:125,234,853...125,241,343
Ensembl chr 9:125,234,853...125,241,382
|
|
G |
ICAM1 |
intercellular adhesion molecule 1 |
increases expression |
EXP |
Benzalkonium Compounds results in increased expression of ICAM1 mRNA; Benzalkonium Compounds results in increased expression of ICAM1 protein |
CTD |
PMID:21742781 PMID:30806763 |
|
NCBI chr19:10,271,120...10,286,615
Ensembl chr19:10,271,093...10,286,615
|
|
G |
ID1 |
inhibitor of DNA binding 1 |
increases expression |
EXP |
Benzalkonium Compounds results in increased expression of ID1 mRNA |
CTD |
PMID:37149095 |
|
NCBI chr20:31,605,289...31,606,510
Ensembl chr20:31,573,014...31,606,515
|
|
G |
IDI1 |
isopentenyl-diphosphate delta isomerase 1 |
increases expression |
ISO |
Benzalkonium Compounds results in increased expression of IDI1 mRNA |
CTD |
PMID:31199489 |
|
NCBI chr10:1,039,152...1,056,704
Ensembl chr10:1,039,152...1,049,119
|
|
G |
IFNG |
interferon gamma |
increases expression |
ISO |
Benzalkonium Compounds results in increased expression of IFNG protein |
CTD |
PMID:30517752 |
|
NCBI chr12:68,154,768...68,159,740
Ensembl chr12:68,154,768...68,159,740
|
|
G |
IGHA2 |
immunoglobulin heavy constant alpha 2 (A2m marker) |
multiple interactions |
ISO |
[IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of IGHA mRNA |
CTD |
PMID:30171875 |
|
NCBI chr14:105,586,937...105,588,394
Ensembl chr14:105,583,731...105,588,395
|
|
G |
IGHG3 |
immunoglobulin heavy constant gamma 3 (G3m marker) |
increases expression |
ISO |
Benzalkonium Compounds results in increased expression of IGHG3 mRNA |
CTD |
PMID:30171875 |
|
NCBI chr14:105,765,914...105,771,405
Ensembl chr14:105,764,503...105,771,405
|
|
G |
IGKV1D-27 |
immunoglobulin kappa variable 1D-27 (pseudogene) |
decreases expression |
EXP |
Benzalkonium Compounds results in decreased expression of IGKV1D-27 mRNA |
CTD |
PMID:25377654 |
|
NCBI chr 2:89,968,869...89,969,344
Ensembl chr 2:89,968,867...89,969,335
|
|
G |
IGLL1 |
immunoglobulin lambda like polypeptide 1 |
decreases expression |
ISO |
Benzalkonium Compounds results in decreased expression of IGHD mRNA |
CTD |
PMID:30171875 |
|
NCBI chr22:23,573,125...23,580,290
Ensembl chr22:23,573,125...23,580,302
|
|
G |
IL10 |
interleukin 10 |
multiple interactions increases expression |
EXP ISO |
Benzalkonium Compounds results in increased expression of and results in decreased secretion of IL10 protein [IL6RA gene mutant form results in increased susceptibility to Benzalkonium Compounds] which results in decreased expression of IL10 protein Benzalkonium Compounds results in increased expression of IL10 protein |
CTD |
PMID:29953848 PMID:30517752 PMID:31158415 |
|
NCBI chr 1:206,767,602...206,772,494
Ensembl chr 1:206,767,602...206,774,541
|
|
G |
IL13RA2 |
interleukin 13 receptor subunit alpha 2 |
increases expression |
ISO |
Benzalkonium Compounds results in increased expression of IL13RA2 mRNA |
CTD |
PMID:30171875 |
|
NCBI chr X:115,003,982...115,017,616
Ensembl chr X:115,003,975...115,019,977
|
|
G |
IL15 |
interleukin 15 |
increases expression |
ISO |
Benzalkonium Compounds results in increased expression of IL15 protein |
CTD |
PMID:30517752 |
|
NCBI chr 4:141,636,583...141,733,987
Ensembl chr 4:141,636,583...141,733,987
|
|
G |
IL17F |
interleukin 17F |
increases expression |
ISO |
Benzalkonium Compounds results in increased expression of IL17F mRNA |
CTD |
PMID:23445166 |
|
NCBI chr 6:52,236,681...52,245,689
Ensembl chr 6:52,236,681...52,245,689
|
|
G |
IL18 |
interleukin 18 |
increases expression |
ISO EXP |
Benzalkonium Compounds results in increased expression of IL18 protein Benzalkonium Compounds results in increased expression of IL18 mRNA |
CTD |
PMID:30517752 PMID:30806763 |
|
NCBI chr11:112,143,260...112,164,094
Ensembl chr11:112,143,251...112,164,096
|
|
G |
IL1A |
interleukin 1 alpha |
increases secretion multiple interactions increases expression |
EXP ISO |
Benzalkonium Compounds results in increased secretion of IL1A protein [IL6RA gene mutant form results in increased susceptibility to Benzalkonium Compounds] which results in increased expression of IL1A protein Benzalkonium Compounds results in increased expression of IL1A protein Benzalkonium Compounds results in increased expression of IL1A mRNA; Benzalkonium Compounds results in increased expression of IL1A protein |
CTD |
PMID:8006454 PMID:12781210 PMID:25290854 PMID:30240708 PMID:30517752 PMID:31158415 More...
|
|
NCBI chr 2:112,773,925...112,784,493
Ensembl chr 2:112,773,925...112,784,493
|
|
G |
IL1B |
interleukin 1 beta |
increases expression multiple interactions |
EXP ISO |
Benzalkonium Compounds results in increased expression of IL1B protein [IL6RA gene mutant form results in increased susceptibility to Benzalkonium Compounds] which results in increased expression of IL1B protein |
CTD |
PMID:29953848 PMID:30517752 PMID:31158415 |
|
NCBI chr 2:112,829,751...112,836,779
Ensembl chr 2:112,829,751...112,836,816
|
|
G |
IL1F10 |
interleukin 1 family member 10 |
multiple interactions |
ISO |
[IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of IL1F10 mRNA |
CTD |
PMID:30171875 |
|
NCBI chr 2:113,067,970...113,075,843
Ensembl chr 2:113,067,970...113,075,843
|
|
G |
IL22 |
interleukin 22 |
multiple interactions increases expression |
ISO |
[IL6RA gene mutant form results in increased susceptibility to Benzalkonium Compounds] which results in increased expression of IL22 protein Benzalkonium Compounds results in increased expression of IL22 protein |
CTD |
PMID:30517752 PMID:31158415 |
|
NCBI chr12:68,248,242...68,253,604
Ensembl chr12:68,248,242...68,253,604
|
|
G |
IL23A |
interleukin 23 subunit alpha |
increases expression |
ISO |
Benzalkonium Compounds results in increased expression of IL23A mRNA |
CTD |
PMID:30171875 |
|
NCBI chr12:56,338,884...56,340,410
Ensembl chr12:56,334,174...56,340,410
|
|
G |
IL24 |
interleukin 24 |
increases expression |
EXP |
Benzalkonium Compounds results in increased expression of IL24 mRNA |
CTD |
PMID:37149095 |
|
NCBI chr 1:206,897,443...206,904,139
Ensembl chr 1:206,897,443...206,904,139
|
|
G |
IL27 |
interleukin 27 |
increases expression |
ISO |
Benzalkonium Compounds results in increased expression of IL27 protein |
CTD |
PMID:30517752 |
|
NCBI chr16:28,499,362...28,506,834
Ensembl chr16:28,499,362...28,512,051
|
|
G |
IL3 |
interleukin 3 |
increases expression |
ISO |
Benzalkonium Compounds results in increased expression of IL3 protein |
CTD |
PMID:30517752 |
|
NCBI chr 5:132,060,655...132,063,204
Ensembl chr 5:132,060,655...132,063,204
|
|
G |
IL31 |
interleukin 31 |
increases expression |
ISO |
Benzalkonium Compounds results in increased expression of IL31 protein |
CTD |
PMID:30517752 |
|
NCBI chr12:122,172,029...122,174,221
Ensembl chr12:122,172,029...122,174,221
|
|
G |
IL31RA |
interleukin 31 receptor A |
decreases expression |
ISO |
Benzalkonium Compounds results in decreased expression of IL31RA mRNA |
CTD |
PMID:30171875 |
|
NCBI chr 5:55,839,789...55,922,850
Ensembl chr 5:55,851,357...55,922,854
|
|
G |
IL34 |
interleukin 34 |
decreases expression |
ISO |
Benzalkonium Compounds results in decreased expression of IL34 mRNA |
CTD |
PMID:30171875 |
|
NCBI chr16:70,579,899...70,660,682
Ensembl chr16:70,579,895...70,660,682
|
|
G |
IL36A |
interleukin 36 alpha |
increases expression |
ISO |
Benzalkonium Compounds results in increased expression of IL36A mRNA |
CTD |
PMID:30171875 |
|
NCBI chr 2:113,005,459...113,011,072
Ensembl chr 2:113,005,459...113,008,044
|
|
G |
IL36B |
interleukin 36 beta |
increases expression |
ISO |
Benzalkonium Compounds results in increased expression of IL36B mRNA |
CTD |
PMID:30171875 |
|
NCBI chr 2:113,022,089...113,052,867
Ensembl chr 2:113,022,089...113,052,867
|
|
G |
IL36G |
interleukin 36 gamma |
increases expression |
ISO |
Benzalkonium Compounds results in increased expression of IL36G mRNA |
CTD |
PMID:30171875 |
|
NCBI chr 2:112,978,006...112,985,658
Ensembl chr 2:112,973,203...112,985,658
|
|
G |
IL4 |
interleukin 4 |
increases expression multiple interactions |
ISO |
Benzalkonium Compounds results in increased expression of IL4 protein [IL6RA gene mutant form results in increased susceptibility to Benzalkonium Compounds] which results in decreased expression of IL4 protein |
CTD |
PMID:30517752 PMID:31158415 |
|
NCBI chr 5:132,673,989...132,682,678
Ensembl chr 5:132,673,986...132,682,678
|
|
G |
IL5 |
interleukin 5 |
increases expression |
ISO |
Benzalkonium Compounds results in increased expression of IL5 protein |
CTD |
PMID:30517752 |
|
NCBI chr 5:132,541,445...132,556,815
Ensembl chr 5:132,541,445...132,556,838
|
|
G |
IL6 |
interleukin 6 |
increases secretion affects response to substance multiple interactions increases expression |
EXP ISO |
Benzalkonium Compounds results in increased secretion of IL6 protein IL6 protein affects the susceptibility to Benzalkonium Compounds [IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of ADRA2A mRNA; [IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of AGTR2 mRNA; [IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of C1S2 mRNA; [IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of C3 mRNA; [IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of CD177 mRNA; [IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of CD274 mRNA; [IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of CTPS1 mRNA; [IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of CXCL3 mRNA; [IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of CXCL5 mRNA; [IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of FOXC1 mRNA; [IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of FOXN1 mRNA; [IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of FOXP3 mRNA; [IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of GATA3 mRNA; [IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of GSDMA3 mRNA; [IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of HCK mRNA; [IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of HGF mRNA; [IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of IGHA mRNA; [IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of IL1F10 mRNA; [IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of KRT2 mRNA; [IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of KRTAP14 mRNA; [IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of KRTAP16-3 mRNA; [IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of KRTAP19-2 mRNA; [IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of KRTAP19-5 mRNA; [IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of KRTAP19-9B mRNA; [IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of KRTAP6-1 mRNA; [IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of KRTAP6-2 mRNA; [IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of LTB mRNA; [IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of MMP25 mRNA; [IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of MMP9 mRNA; [IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of MRGPRA2B mRNA; [IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of MSX2 mRNA; [IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of MYLK3 mRNA; [IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of NRG2 mRNA; [IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of PDCD1 mRNA; [IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of PROKR2 mRNA; [IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of PTX3 mRNA; [IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of REG1 mRNA; [IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of REG3G mRNA; [IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of RYR1 mRNA; [IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of SAA3 mRNA; [IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of SERPINB13 mRNA; [IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of SIGLECE mRNA; [IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of SOX21 mRNA; [IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of SRMS mRNA; [IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of ST14 mRNA; [IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of TFAP2B mRNA; [IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of TNFRSF13C mRNA; [IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of TNFRSF26 mRNA; [IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of TNFSF8 mRNA; [IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of TSLP mRNA; [IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of VTCN1 mRNA; [IL6RA gene mutant form results in increased susceptibility to Benzalkonium Compounds] which results in increased expression of IL6 protein Benzalkonium Compounds results in increased expression of IL6 mRNA; Benzalkonium Compounds results in increased expression of IL6 protein Benzalkonium Compounds results in increased expression of and results in increased secretion of IL6 protein |
CTD |
PMID:17763283 PMID:28214551 PMID:29953848 PMID:30171875 PMID:30517752 PMID:31158415 PMID:31707104 More...
|
|
NCBI chr 7:22,727,200...22,731,998
Ensembl chr 7:22,725,884...22,732,002
|
|
G |
IL6R |
interleukin 6 receptor |
multiple interactions increases response to substance |
ISO |
[IL6RA gene mutant form results in increased susceptibility to Benzalkonium Compounds] which results in decreased expression of IL10 protein; [IL6RA gene mutant form results in increased susceptibility to Benzalkonium Compounds] which results in decreased expression of IL4 protein; [IL6RA gene mutant form results in increased susceptibility to Benzalkonium Compounds] which results in increased expression of CCL3 protein; [IL6RA gene mutant form results in increased susceptibility to Benzalkonium Compounds] which results in increased expression of CCL4 protein; [IL6RA gene mutant form results in increased susceptibility to Benzalkonium Compounds] which results in increased expression of CXCL10 protein; [IL6RA gene mutant form results in increased susceptibility to Benzalkonium Compounds] which results in increased expression of CXCL2 protein; [IL6RA gene mutant form results in increased susceptibility to Benzalkonium Compounds] which results in increased expression of IL1A protein; [IL6RA gene mutant form results in increased susceptibility to Benzalkonium Compounds] which results in increased expression of IL1B protein; [IL6RA gene mutant form results in increased susceptibility to Benzalkonium Compounds] which results in increased expression of IL22 protein; [IL6RA gene mutant form results in increased susceptibility to Benzalkonium Compounds] which results in increased expression of IL6 protein |
CTD |
PMID:31158415 |
|
NCBI chr 1:154,405,343...154,469,450
Ensembl chr 1:154,405,193...154,469,450
|
|
G |
IL7R |
interleukin 7 receptor |
increases expression |
EXP |
Benzalkonium Compounds results in increased expression of IL7R mRNA |
CTD |
PMID:20713136 |
|
NCBI chr 5:35,856,891...35,879,603
Ensembl chr 5:35,852,695...35,879,603
|
|
G |
INHBA |
inhibin subunit beta A |
increases expression |
ISO |
Benzalkonium Compounds results in increased expression of INHBA mRNA |
CTD |
PMID:30171875 |
|
NCBI chr 7:41,685,114...41,705,406
Ensembl chr 7:41,667,168...41,705,834
|
|
G |
INSIG1 |
insulin induced gene 1 |
increases expression |
ISO |
Benzalkonium Compounds results in increased expression of INSIG1 mRNA |
CTD |
PMID:31199489 |
|
NCBI chr 7:155,297,878...155,310,235
Ensembl chr 7:155,297,776...155,310,235
|
|
G |
ISL1 |
ISL LIM homeobox 1 |
decreases expression |
ISO |
Benzalkonium Compounds results in decreased expression of ISL1 mRNA |
CTD |
PMID:30171875 |
|
NCBI chr 5:51,383,448...51,394,730
Ensembl chr 5:51,383,448...51,394,730
|
|
G |
IYD |
iodotyrosine deiodinase |
multiple interactions |
EXP |
Benzalkonium Compounds inhibits the reaction [IYD protein results in increased metabolism of Monoiodotyrosine] |
CTD |
PMID:33352258 |
|
NCBI chr 6:150,369,012...150,405,969
Ensembl chr 6:150,368,892...150,405,969
|
|
G |
KCNH2 |
potassium voltage-gated channel subfamily H member 2 |
decreases activity |
EXP |
Benzalkonium Compounds results in decreased activity of KCNH2 protein |
CTD |
PMID:24052561 |
|
NCBI chr 7:150,944,961...150,978,321
Ensembl chr 7:150,944,961...150,978,321
|
|
G |
KDM7A |
lysine demethylase 7A |
increases expression |
EXP |
Benzalkonium Compounds results in increased expression of KDM7A mRNA |
CTD |
PMID:37149095 |
|
NCBI chr 7:140,084,746...140,176,983
Ensembl chr 7:140,084,746...140,176,983
|
|
G |
KDM8 |
lysine demethylase 8 |
decreases expression |
ISO |
Benzalkonium Compounds results in decreased expression of KDM8 mRNA |
CTD |
PMID:31199489 |
|
NCBI chr16:27,203,526...27,221,768
Ensembl chr16:27,203,508...27,221,768
|
|
G |
KIR3DL2 |
killer cell immunoglobulin like receptor, three Ig domains and long cytoplasmic tail 2 |
decreases expression |
EXP |
Benzalkonium Compounds results in decreased expression of KIR3DL2 mRNA |
CTD |
PMID:25377654 |
|
NCBI chr19:54,850,443...54,867,207
Ensembl chr19:54,850,443...54,867,209
|
|
G |
KLF2 |
KLF transcription factor 2 |
increases expression |
EXP |
Benzalkonium Compounds results in increased expression of KLF2 mRNA |
CTD |
PMID:37149095 |
|
NCBI chr19:16,324,826...16,328,685
Ensembl chr19:16,324,826...16,328,685
|
|
G |
KLK8 |
kallikrein related peptidase 8 |
increases expression |
ISO |
Benzalkonium Compounds results in increased expression of KLK8 mRNA |
CTD |
PMID:30171875 |
|
NCBI chr19:50,996,008...51,001,604
Ensembl chr19:50,996,007...51,002,711
|
|
G |
KRT2 |
keratin 2 |
multiple interactions |
ISO |
[IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of KRT2 mRNA |
CTD |
PMID:30171875 |
|
NCBI chr12:52,644,558...52,652,211
Ensembl chr12:52,644,558...52,652,211
|
|
G |
KRT6B |
keratin 6B |
increases expression |
ISO |
Benzalkonium Compounds results in increased expression of KRT6B mRNA |
CTD |
PMID:30171875 |
|
NCBI chr12:52,446,651...52,452,146
Ensembl chr12:52,446,651...52,452,146
|
|
G |
KRTAP19-5 |
keratin associated protein 19-5 |
multiple interactions |
ISO |
[IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of KRTAP19-5 mRNA |
CTD |
PMID:30171875 |
|
NCBI chr21:30,501,657...30,502,141
Ensembl chr21:30,501,657...30,502,141
|
|
G |
KRTAP19-6 |
keratin associated protein 19-6 |
multiple interactions |
ISO |
[IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of KRTAP16-3 mRNA |
CTD |
PMID:30171875 |
|
NCBI chr21:30,541,535...30,541,864
Ensembl chr21:30,541,535...30,541,864
|
|
G |
KRTAP23-1 |
keratin associated protein 23-1 |
multiple interactions |
ISO |
[IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of KRTAP14 mRNA |
CTD |
PMID:30171875 |
|
NCBI chr21:30,348,399...30,348,606
Ensembl chr21:30,348,399...30,348,606
|
|
G |
KRTAP6-1 |
keratin associated protein 6-1 |
multiple interactions |
ISO |
[IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of KRTAP6-1 mRNA |
CTD |
PMID:30171875 |
|
NCBI chr21:30,613,431...30,613,930
Ensembl chr21:30,613,431...30,613,930
|
|
G |
KRTAP6-3 |
keratin associated protein 6-3 |
multiple interactions |
ISO |
[IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of KRTAP6-2 mRNA |
CTD |
PMID:30171875 |
|
NCBI chr21:30,592,440...30,593,055
Ensembl chr21:30,592,440...30,593,075
|
|
G |
LCE3B |
late cornified envelope 3B |
increases expression |
ISO |
Benzalkonium Compounds results in increased expression of LCE3C mRNA |
CTD |
PMID:30171875 |
|
NCBI chr 1:152,613,811...152,614,098
Ensembl chr 1:152,613,811...152,614,098
|
|
G |
LCE5A |
late cornified envelope 5A |
decreases expression |
ISO |
Benzalkonium Compounds results in decreased expression of LCE1M mRNA |
CTD |
PMID:30171875 |
|
NCBI chr 1:152,510,803...152,512,177
Ensembl chr 1:152,510,803...152,512,177
|
|
G |
LDHA |
lactate dehydrogenase A |
decreases expression |
ISO |
Benzalkonium Compounds results in decreased expression of LDHA mRNA |
CTD |
PMID:31199489 |
|
NCBI chr11:18,394,563...18,408,425
Ensembl chr11:18,394,560...18,408,425
|
|
G |
LDLR |
low density lipoprotein receptor |
increases expression |
ISO |
Benzalkonium Compounds results in increased expression of LDLR mRNA |
CTD |
PMID:31199489 |
|
NCBI chr19:11,089,463...11,133,820
Ensembl chr19:11,089,418...11,133,820
|
|
G |
LIF |
LIF interleukin 6 family cytokine |
increases expression |
ISO |
Benzalkonium Compounds results in increased expression of LIF protein |
CTD |
PMID:30517752 |
|
NCBI chr22:30,240,453...30,246,759
Ensembl chr22:30,240,453...30,246,759
|
|
G |
LOXL1 |
lysyl oxidase like 1 |
decreases expression |
ISO |
Benzalkonium Compounds results in decreased expression of LOXL1 mRNA |
CTD |
PMID:31199489 |
|
NCBI chr15:73,926,462...73,952,136
Ensembl chr15:73,925,989...73,952,137
|
|
G |
LST1 |
leukocyte specific transcript 1 |
increases expression |
ISO |
Benzalkonium Compounds results in increased expression of LST1 mRNA |
CTD |
PMID:30171875 |
|
NCBI chr 6:31,586,277...31,588,909
Ensembl chr 6:31,586,124...31,588,909
|
|
G |
LTB |
lymphotoxin beta |
multiple interactions |
ISO |
[IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of LTB mRNA |
CTD |
PMID:30171875 |
|
NCBI chr 6:31,580,558...31,582,425
Ensembl chr 6:31,580,525...31,582,522
|
|
G |
MAPK14 |
mitogen-activated protein kinase 14 |
increases phosphorylation |
EXP |
Benzalkonium Compounds results in increased phosphorylation of MAPK14 protein |
CTD |
PMID:15737199 |
|
NCBI chr 6:36,027,808...36,124,214
Ensembl chr 6:36,027,752...36,122,511
|
|
G |
MESP2 |
mesoderm posterior bHLH transcription factor 2 |
decreases expression |
ISO |
Benzalkonium Compounds results in decreased expression of MESP2 mRNA |
CTD |
PMID:30171875 |
|
NCBI chr15:89,776,332...89,778,754
Ensembl chr15:89,760,591...89,778,754
|
|
G |
MIF |
macrophage migration inhibitory factor |
increases secretion |
EXP |
Benzalkonium Compounds results in increased secretion of MIF protein |
CTD |
PMID:31707104 |
|
NCBI chr22:23,894,383...23,895,223
Ensembl chr22:23,894,383...23,895,227
|
|
G |
MIR1296 |
microRNA 1296 |
increases expression |
EXP |
Benzalkonium Compounds results in increased expression of MIR1296 mRNA |
CTD |
PMID:25377654 |
|
NCBI chr10:63,372,957...63,373,048
Ensembl chr10:63,372,957...63,373,048
|
|
G |
MIR4279 |
microRNA 4279 |
increases expression |
EXP |
Benzalkonium Compounds results in increased expression of MIR4279 |
CTD |
PMID:37149095 |
|
NCBI chr 5:31,936,102...31,936,159
Ensembl chr 5:31,936,102...31,936,159
|
|
G |
MIR548AC |
microRNA 548ac |
increases expression |
EXP |
Benzalkonium Compounds results in increased expression of MIR548AC mRNA |
CTD |
PMID:25377654 |
|
NCBI chr 1:116,560,024...116,560,111
Ensembl chr 1:116,560,024...116,560,111
|
|
G |
MIR548C |
microRNA 548c |
increases expression |
EXP |
Benzalkonium Compounds results in increased expression of MIR548C |
CTD |
PMID:37149095 |
|
NCBI chr12:64,622,509...64,622,605
Ensembl chr12:64,622,509...64,622,605
|
|
G |
MIR635 |
microRNA 635 |
increases expression |
EXP |
Benzalkonium Compounds results in increased expression of MIR635 |
CTD |
PMID:37149095 |
|
NCBI chr17:68,424,451...68,424,548
Ensembl chr17:68,424,451...68,424,548
|
|
G |
MIR891A |
microRNA 891a |
decreases expression |
EXP |
Benzalkonium Compounds results in decreased expression of MIR891A |
CTD |
PMID:37149095 |
|
NCBI chr X:146,027,794...146,027,872
Ensembl chr X:146,027,794...146,027,872
|
|
G |
MMP10 |
matrix metallopeptidase 10 |
increases expression |
EXP |
Benzalkonium Compounds results in increased expression of MMP10 mRNA |
CTD |
PMID:30806763 |
|
NCBI chr11:102,770,502...102,780,628
Ensembl chr11:102,770,502...102,780,628
|
|
G |
MMP12 |
matrix metallopeptidase 12 |
increases expression |
ISO |
Benzalkonium Compounds results in increased expression of MMP12 mRNA |
CTD |
PMID:30171875 |
|
NCBI chr11:102,862,736...102,874,982
Ensembl chr11:102,862,736...102,874,982
|
|
G |
MMP2 |
matrix metallopeptidase 2 |
increases activity |
ISO |
Benzalkonium Compounds results in increased activity of MMP2 protein |
CTD |
PMID:21058936 |
|
NCBI chr16:55,478,830...55,506,691
Ensembl chr16:55,389,700...55,506,691
|
|
G |
MMP25 |
matrix metallopeptidase 25 |
multiple interactions |
ISO |
[IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of MMP25 mRNA |
CTD |
PMID:30171875 |
|
NCBI chr16:3,046,561...3,060,726
Ensembl chr16:3,046,062...3,060,729
|
|
G |
MMP9 |
matrix metallopeptidase 9 |
multiple interactions increases activity |
ISO |
[IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of MMP9 mRNA Benzalkonium Compounds results in increased activity of MMP9 protein |
CTD |
PMID:21058936 PMID:30171875 |
|
NCBI chr20:46,008,908...46,016,561
Ensembl chr20:46,008,908...46,016,561
|
|
G |
MSMO1 |
methylsterol monooxygenase 1 |
increases expression |
ISO |
Benzalkonium Compounds results in increased expression of MSMO1 mRNA |
CTD |
PMID:31199489 |
|
NCBI chr 4:165,327,669...165,343,164
Ensembl chr 4:165,327,667...165,343,164
|
|
G |
MSX2 |
msh homeobox 2 |
multiple interactions |
ISO |
[IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of MSX2 mRNA |
CTD |
PMID:30171875 |
|
NCBI chr 5:174,724,582...174,730,896
Ensembl chr 5:174,724,582...174,730,896
|
|
G |
MT2A |
metallothionein 2A |
decreases expression |
ISO |
Benzalkonium Compounds results in decreased expression of MT2 mRNA |
CTD |
PMID:31199489 |
|
NCBI chr16:56,608,584...56,609,497
Ensembl chr16:56,608,584...56,609,497
|
|
G |
MTHFD2 |
methylenetetrahydrofolate dehydrogenase (NADP+ dependent) 2, methenyltetrahydrofolate cyclohydrolase |
decreases expression |
ISO |
Benzalkonium Compounds results in decreased expression of MTHFD2 mRNA |
CTD |
PMID:31199489 |
|
NCBI chr 2:74,198,615...74,217,565
Ensembl chr 2:74,186,172...74,217,565
|
|
G |
MYLK3 |
myosin light chain kinase 3 |
multiple interactions |
ISO |
[IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of MYLK3 mRNA |
CTD |
PMID:30171875 |
|
NCBI chr16:46,702,282...46,763,246
Ensembl chr16:46,702,282...46,790,407
|
|
G |
NDUFA4 |
NDUFA4 mitochondrial complex associated |
decreases expression |
ISO |
Benzalkonium Compounds results in decreased expression of NDUFA4 mRNA |
CTD |
PMID:31199489 |
|
NCBI chr 7:10,931,943...10,940,153
Ensembl chr 7:10,931,943...10,940,153
|
|
G |
NR4A2 |
nuclear receptor subfamily 4 group A member 2 |
increases expression |
EXP |
Benzalkonium Compounds results in increased expression of NR4A2 mRNA |
CTD |
PMID:25377654 |
|
NCBI chr 2:156,324,437...156,332,721
Ensembl chr 2:156,324,437...156,342,348
|
|
G |
NRG2 |
neuregulin 2 |
multiple interactions |
ISO |
[IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of NRG2 mRNA |
CTD |
PMID:30171875 |
|
NCBI chr 5:139,846,781...140,043,299
Ensembl chr 5:139,846,779...140,043,299
|
|
G |
NTRK3 |
neurotrophic receptor tyrosine kinase 3 |
affects response to substance |
EXP |
NTRK3 SNP affects the susceptibility to Benzalkonium Compounds |
CTD |
PMID:27206134 |
|
NCBI chr15:87,859,751...88,256,739
Ensembl chr15:87,859,751...88,256,791
|
|
G |
OCLN |
occludin |
decreases expression |
ISO |
Benzalkonium Compounds results in decreased expression of OCLN protein |
CTD |
PMID:29514330 |
|
NCBI chr 5:69,492,547...69,558,104
Ensembl chr 5:69,492,292...69,558,104
|
|
G |
ODC1 |
ornithine decarboxylase 1 |
decreases expression |
ISO |
Benzalkonium Compounds results in decreased expression of ODC1 mRNA |
CTD |
PMID:31199489 |
|
NCBI chr 2:10,439,968...10,448,327
Ensembl chr 2:10,439,968...10,448,327
|
|
G |
OLR1 |
oxidized low density lipoprotein receptor 1 |
increases expression |
ISO |
Benzalkonium Compounds results in increased expression of OLR1 mRNA |
CTD |
PMID:30171875 |
|
NCBI chr12:10,158,301...10,176,266
Ensembl chr12:10,158,301...10,172,138
|
|
G |
ORM1 |
orosomucoid 1 |
decreases expression |
ISO |
Benzalkonium Compounds results in decreased expression of ORM1 mRNA |
CTD |
PMID:30171875 |
|
NCBI chr 9:114,323,098...114,326,479
Ensembl chr 9:114,323,098...114,326,479
|
|
G |
PARP1 |
poly(ADP-ribose) polymerase 1 |
increases cleavage multiple interactions |
EXP |
Benzalkonium Compounds analog results in increased cleavage of PARP1 protein benzoylcarbonyl-aspartyl-glutamyl-valyl-aspartyl-fluoromethyl ketone inhibits the reaction [Benzalkonium Compounds analog results in increased cleavage of PARP1 protein] |
CTD |
PMID:31982400 |
|
NCBI chr 1:226,360,691...226,408,093
Ensembl chr 1:226,360,210...226,408,154
|
|
G |
PBK |
PDZ binding kinase |
increases expression |
ISO |
Benzalkonium Compounds results in increased expression of PBK mRNA |
CTD |
PMID:30171875 |
|
NCBI chr 8:27,809,624...27,837,817
Ensembl chr 8:27,809,624...27,838,082
|
|
G |
PCSK9 |
proprotein convertase subtilisin/kexin type 9 |
decreases expression |
ISO |
Benzalkonium Compounds results in decreased expression of PCSK9 mRNA |
CTD |
PMID:31199489 |
|
NCBI chr 1:55,039,548...55,064,852
Ensembl chr 1:55,039,445...55,064,852
|
|
G |
PDCD1 |
programmed cell death 1 |
multiple interactions |
ISO |
[IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of PDCD1 mRNA |
CTD |
PMID:30171875 |
|
NCBI chr 2:241,849,884...241,858,894
Ensembl chr 2:241,849,884...241,858,894
|
|
G |
PFDN6 |
prefoldin subunit 6 |
affects response to substance |
EXP |
PFDN6 SNP affects the susceptibility to Benzalkonium Compounds |
CTD |
PMID:27258892 |
|
NCBI chr 6:33,289,197...33,290,934
Ensembl chr 6:33,289,302...33,298,401
|
|
G |
PGLYRP3 |
peptidoglycan recognition protein 3 |
increases expression |
ISO |
Benzalkonium Compounds results in increased expression of PGLYRP3 mRNA |
CTD |
PMID:30171875 |
|
NCBI chr 1:153,297,116...153,312,952
Ensembl chr 1:153,297,116...153,312,952
|
|
G |
PGP |
phosphoglycolate phosphatase |
increases expression |
ISO |
Benzalkonium Compounds results in increased expression of PGP mRNA |
CTD |
PMID:31199489 |
|
NCBI chr16:2,211,593...2,214,840
Ensembl chr16:2,211,593...2,214,840
|
|
G |
PLA2G5 |
phospholipase A2 group V |
decreases expression |
ISO |
Benzalkonium Compounds results in decreased expression of PLA2G5 mRNA |
CTD |
PMID:30171875 |
|
NCBI chr 1:20,028,408...20,091,911
Ensembl chr 1:20,028,179...20,091,911
|
|
G |
PLCXD3 |
phosphatidylinositol specific phospholipase C X domain containing 3 |
increases expression |
ISO |
Benzalkonium Compounds results in increased expression of PLCXD3 mRNA |
CTD |
PMID:31199489 |
|
NCBI chr 5:41,306,952...41,510,601
Ensembl chr 5:41,306,952...41,510,601
|
|
G |
PLK2 |
polo like kinase 2 |
decreases expression |
EXP |
Benzalkonium Compounds results in decreased expression of PLK2 mRNA |
CTD |
PMID:37149095 |
|
NCBI chr 5:58,453,982...58,460,086
Ensembl chr 5:58,453,982...58,460,139
|
|
G |
PNPLA2 |
patatin like phospholipase domain containing 2 |
decreases expression |
ISO |
Benzalkonium Compounds results in decreased expression of PNPLA2 mRNA |
CTD |
PMID:31199489 |
|
NCBI chr11:818,914...825,573
Ensembl chr11:818,914...825,573
|
|
G |
POLR1D |
RNA polymerase I and III subunit D |
decreases expression |
ISO |
Benzalkonium Compounds results in decreased expression of POLR1D mRNA |
CTD |
PMID:31199489 |
|
NCBI chr13:27,620,743...27,667,411
Ensembl chr13:27,620,742...27,744,237
|
|
G |
PPARA |
peroxisome proliferator activated receptor alpha |
decreases expression |
ISO |
Benzalkonium Compounds results in decreased expression of PPARA mRNA |
CTD |
PMID:31199489 |
|
NCBI chr22:46,150,526...46,243,756
Ensembl chr22:46,150,521...46,243,755
|
|
G |
PRKAA2 |
protein kinase AMP-activated catalytic subunit alpha 2 |
increases expression |
ISO |
Benzalkonium Compounds results in increased expression of PRKAA2 mRNA |
CTD |
PMID:31199489 |
|
NCBI chr 1:56,645,314...56,715,335
Ensembl chr 1:56,645,314...56,715,335
|
|
G |
PRKAG2 |
protein kinase AMP-activated non-catalytic subunit gamma 2 |
increases expression |
ISO |
Benzalkonium Compounds results in increased expression of PRKAG2 mRNA |
CTD |
PMID:31199489 |
|
NCBI chr 7:151,556,127...151,877,115
Ensembl chr 7:151,556,124...151,877,214
|
|
G |
PROKR2 |
prokineticin receptor 2 |
multiple interactions |
ISO |
[IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of PROKR2 mRNA |
CTD |
PMID:30171875 |
|
NCBI chr20:5,299,218...5,316,954
Ensembl chr20:5,299,218...5,316,954
|
|
G |
PTGS2 |
prostaglandin-endoperoxide synthase 2 |
increases expression |
EXP |
Benzalkonium Compounds results in increased expression of PTGS2 mRNA |
CTD |
PMID:30806763 |
|
NCBI chr 1:186,671,791...186,680,423
Ensembl chr 1:186,671,791...186,680,922
|
|
G |
PTX3 |
pentraxin 3 |
multiple interactions |
ISO |
[IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of PTX3 mRNA |
CTD |
PMID:30171875 |
|
NCBI chr 3:157,436,850...157,443,633
Ensembl chr 3:157,436,850...157,443,633
|
|
G |
REG1A |
regenerating family member 1 alpha |
multiple interactions |
ISO |
[IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of REG1 mRNA |
CTD |
PMID:30171875 |
|
NCBI chr 2:79,120,488...79,123,409
Ensembl chr 2:79,120,362...79,123,409
|
|
G |
REG3G |
regenerating family member 3 gamma |
multiple interactions |
ISO |
[IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of REG3G mRNA |
CTD |
PMID:30171875 |
|
NCBI chr 2:79,025,702...79,028,501
Ensembl chr 2:79,025,686...79,028,505
|
|
G |
RGL2 |
ral guanine nucleotide dissociation stimulator like 2 |
affects response to substance |
EXP |
RGL2 SNP affects the susceptibility to Benzalkonium Compounds |
CTD |
PMID:27258892 |
|
NCBI chr 6:33,291,654...33,301,612
Ensembl chr 6:33,291,654...33,298,942
|
|
G |
RNU2-63P |
RNA, U2 small nuclear 63, pseudogene |
decreases expression |
EXP |
Benzalkonium Compounds results in decreased expression of RNU2-63P |
CTD |
PMID:37149095 |
|
NCBI chr 2:88,016,354...88,016,547
Ensembl chr 2:88,016,354...88,016,547
|
|
G |
RNU6-454P |
RNA, U6 small nuclear 454, pseudogene |
decreases expression |
EXP |
Benzalkonium Compounds results in decreased expression of RNU6-454P |
CTD |
PMID:37149095 |
|
NCBI chr 3:15,339,749...15,339,850
Ensembl chr 3:15,339,749...15,339,855
|
|
G |
RNU6-643P |
RNA, U6 small nuclear 643, pseudogene |
decreases expression |
EXP |
Benzalkonium Compounds results in decreased expression of RNU6-643P |
CTD |
PMID:37149095 |
|
NCBI chr 6:41,302,466...41,302,572
Ensembl chr 6:41,302,466...41,302,572
|
|
G |
RPS18 |
ribosomal protein S18 |
affects response to substance |
EXP |
RPS18 SNP affects the susceptibility to Benzalkonium Compounds |
CTD |
PMID:27258892 |
|
NCBI chr 6:33,272,075...33,276,511
Ensembl chr 6:33,272,075...33,276,511
|
|
G |
RYR1 |
ryanodine receptor 1 |
multiple interactions |
ISO |
[IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of RYR1 mRNA |
CTD |
PMID:30171875 |
|
NCBI chr19:38,433,691...38,587,564
Ensembl chr19:38,433,691...38,595,273
|
|
G |
SAA3P |
serum amyloid A3, pseudogene |
multiple interactions |
ISO |
[IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of SAA3 mRNA |
CTD |
PMID:30171875 |
|
NCBI chr11:18,112,472...18,116,132
Ensembl chr11:18,112,472...18,116,132 Ensembl chr11:18,112,472...18,116,132
|
|
G |
SCD |
stearoyl-CoA desaturase |
increases expression |
EXP |
Benzalkonium Compounds results in increased expression of SCD mRNA |
CTD |
PMID:29155129 |
|
NCBI chr10:100,347,233...100,364,826
Ensembl chr10:100,347,233...100,364,826
|
|
G |
SDIM1 |
stress responsive DNAJB4 interacting membrane protein 1 |
increases expression |
EXP |
Benzalkonium Compounds results in increased expression of SDIM1 mRNA |
CTD |
PMID:37149095 |
|
|
|
G |
SERPINB13 |
serpin family B member 13 |
multiple interactions |
ISO |
[IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of SERPINB13 mRNA |
CTD |
PMID:30171875 |
|
NCBI chr18:63,587,343...63,599,192
Ensembl chr18:63,586,989...63,604,639
|
|
G |
SERPINE1 |
serpin family E member 1 |
increases expression |
ISO |
Benzalkonium Compounds results in increased expression of SERPINE1 mRNA |
CTD |
PMID:30171875 |
|
NCBI chr 7:101,127,104...101,139,247
Ensembl chr 7:101,127,104...101,139,247
|
|
G |
SESN2 |
sestrin 2 |
decreases expression |
ISO |
Benzalkonium Compounds results in decreased expression of SESN2 mRNA |
CTD |
PMID:31199489 |
|
NCBI chr 1:28,259,518...28,282,491
Ensembl chr 1:28,259,518...28,282,491
|
|
G |
SFN |
stratifin |
increases expression |
ISO |
Benzalkonium Compounds results in increased expression of SFN mRNA |
CTD |
PMID:30171875 |
|
NCBI chr 1:26,863,149...26,864,456
Ensembl chr 1:26,863,149...26,864,456
|
|
G |
SFRP4 |
secreted frizzled related protein 4 |
decreases expression |
ISO |
Benzalkonium Compounds results in decreased expression of SFRP4 mRNA |
CTD |
PMID:30171875 |
|
NCBI chr 7:37,905,932...37,916,817
Ensembl chr 7:37,905,932...38,025,695
|
|
G |
SIGLEC9 |
sialic acid binding Ig like lectin 9 |
multiple interactions |
ISO |
[IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of SIGLECE mRNA |
CTD |
PMID:30171875 |
|
NCBI chr19:51,119,778...51,136,263
Ensembl chr19:51,124,906...51,136,651
|
|
G |
SLC16A1 |
solute carrier family 16 member 1 |
increases expression |
ISO |
Benzalkonium Compounds results in increased expression of SLC16A1 mRNA |
CTD |
PMID:31199489 |
|
NCBI chr 1:112,911,847...112,956,196
Ensembl chr 1:112,911,847...112,957,593
|
|
G |
SLC7A11 |
solute carrier family 7 member 11 |
increases expression |
EXP |
Benzalkonium Compounds results in increased expression of SLC7A11 mRNA |
CTD |
PMID:30806763 PMID:37149095 |
|
NCBI chr 4:138,164,097...138,312,671
Ensembl chr 4:138,164,097...138,242,349
|
|
G |
SNORA38 |
small nucleolar RNA, H/ACA box 38 |
decreases expression |
EXP |
Benzalkonium Compounds results in decreased expression of SNORA38 |
CTD |
PMID:37149095 |
|
NCBI chr 6:31,623,079...31,623,210
Ensembl chr 6:31,623,079...31,623,210
|
|
G |
SNORA71D |
small nucleolar RNA, H/ACA box 71D |
decreases expression |
EXP |
Benzalkonium Compounds results in decreased expression of SNORA71D mRNA |
CTD |
PMID:25377654 |
|
NCBI chr20:38,433,862...38,433,999
Ensembl chr20:38,433,865...38,433,998
|
|
G |
SNORD115-45 |
small nucleolar RNA, C/D box 115-45 |
increases expression |
EXP |
Benzalkonium Compounds results in increased expression of SNORD115-45 |
CTD |
PMID:37149095 |
|
NCBI chr15:25,264,527...25,264,579
Ensembl chr15:25,264,510...25,264,590
|
|
G |
SOX21 |
SRY-box transcription factor 21 |
multiple interactions |
ISO |
[IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of SOX21 mRNA |
CTD |
PMID:30171875 |
|
NCBI chr13:94,709,622...94,712,545
Ensembl chr13:94,709,622...94,712,545
|
|
G |
SPRR1A |
small proline rich protein 1A |
increases expression |
ISO |
Benzalkonium Compounds results in increased expression of SPRR1A mRNA |
CTD |
PMID:30171875 |
|
NCBI chr 1:152,984,081...152,985,814
Ensembl chr 1:152,984,081...152,985,814
|
|
G |
SPRR1B |
small proline rich protein 1B |
increases expression |
ISO |
Benzalkonium Compounds results in increased expression of SPRR1B mRNA |
CTD |
PMID:30171875 |
|
NCBI chr 1:153,031,203...153,032,900
Ensembl chr 1:153,031,203...153,032,900
|
|
G |
SPRR2A |
small proline rich protein 2A |
increases expression |
ISO |
Benzalkonium Compounds results in increased expression of SPRR2H mRNA |
CTD |
PMID:30171875 |
|
NCBI chr 1:153,056,120...153,057,512
Ensembl chr 1:153,056,120...153,057,512
|
|
G |
SPRR2B |
small proline rich protein 2B |
increases expression |
ISO |
Benzalkonium Compounds results in increased expression of SPRR2B mRNA |
CTD |
PMID:30171875 |
|
NCBI chr 1:153,070,226...153,087,799
Ensembl chr 1:153,070,226...153,071,611
|
|
G |
SPRR2F |
small proline rich protein 2F |
increases expression |
ISO |
Benzalkonium Compounds results in increased expression of SPRR2F mRNA |
CTD |
PMID:30171875 |
|
NCBI chr 1:153,112,121...153,119,468
Ensembl chr 1:153,112,121...153,113,516
|
|
G |
SQLE |
squalene epoxidase |
increases expression |
ISO |
Benzalkonium Compounds results in increased expression of SQLE mRNA |
CTD |
PMID:31199489 |
|
NCBI chr 8:124,998,505...125,022,283
Ensembl chr 8:124,998,497...125,022,283
|
|
G |
SREBF2 |
sterol regulatory element binding transcription factor 2 |
increases expression |
EXP |
Benzalkonium Compounds results in increased expression of SREBF2 mRNA |
CTD |
PMID:26919959 |
|
NCBI chr22:41,833,105...41,907,305
Ensembl chr22:41,833,105...41,907,306
|
|
G |
SRMS |
src-related kinase lacking C-terminal regulatory tyrosine and N-terminal myristylation sites |
multiple interactions |
ISO |
[IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of SRMS mRNA |
CTD |
PMID:30171875 |
|
NCBI chr20:63,538,489...63,547,749
Ensembl chr20:63,538,489...63,547,749
|
|
G |
ST14 |
ST14 transmembrane serine protease matriptase |
multiple interactions |
ISO |
[IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of ST14 mRNA |
CTD |
PMID:30171875 |
|
NCBI chr11:130,159,782...130,210,362
Ensembl chr11:130,159,782...130,210,362
|
|
G |
TAPBP |
TAP binding protein |
affects response to substance |
EXP |
TAPBP SNP affects the susceptibility to Benzalkonium Compounds |
CTD |
PMID:27258892 |
|
NCBI chr 6:33,299,694...33,314,078
Ensembl chr 6:33,299,694...33,314,284
|
|
G |
TFAP2B |
transcription factor AP-2 beta |
multiple interactions |
ISO |
[IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of TFAP2B mRNA |
CTD |
PMID:30171875 |
|
NCBI chr 6:50,818,355...50,847,619
Ensembl chr 6:50,818,723...50,847,619
|
|
G |
TGFB1 |
transforming growth factor beta 1 |
increases expression |
ISO |
Benzalkonium Compounds results in increased expression of TGFB1 protein |
CTD |
PMID:30517752 |
|
NCBI chr19:41,330,323...41,353,922
Ensembl chr19:41,301,587...41,353,922
|
|
G |
TGM3 |
transglutaminase 3 |
increases expression |
ISO |
Benzalkonium Compounds results in increased expression of TGM3 mRNA |
CTD |
PMID:30171875 |
|
NCBI chr20:2,296,001...2,341,079
Ensembl chr20:2,296,001...2,341,079
|
|
G |
TGM7 |
transglutaminase 7 |
decreases expression |
ISO |
Benzalkonium Compounds results in decreased expression of TGM7 mRNA |
CTD |
PMID:30171875 |
|
NCBI chr15:43,276,271...43,302,255
Ensembl chr15:43,276,271...43,302,255
|
|
G |
THBS1 |
thrombospondin 1 |
increases expression |
ISO |
Benzalkonium Compounds results in increased expression of THBS1 mRNA |
CTD |
PMID:30171875 |
|
NCBI chr15:39,581,079...39,599,466
Ensembl chr15:39,581,079...39,599,466
|
|
G |
TLR1 |
toll like receptor 1 |
increases expression |
ISO |
Benzalkonium Compounds results in increased expression of TLR1 mRNA |
CTD |
PMID:30171875 |
|
NCBI chr 4:38,787,569...38,805,644
Ensembl chr 4:38,787,555...38,856,817
|
|
G |
TLR4 |
toll like receptor 4 |
increases activity |
ISO |
Benzalkonium Compounds results in increased activity of TLR4 protein |
CTD |
PMID:29514330 |
|
NCBI chr 9:117,704,403...117,724,735
Ensembl chr 9:117,704,175...117,724,735
|
|
G |
TMPRSS11B |
transmembrane serine protease 11B |
increases expression |
ISO |
Benzalkonium Compounds results in increased expression of TMPRSS11B mRNA |
CTD |
PMID:30171875 |
|
NCBI chr 4:68,226,653...68,245,694
Ensembl chr 4:68,226,653...68,245,694
|
|
G |
TNF |
tumor necrosis factor |
decreases secretion increases expression |
EXP ISO |
Benzalkonium Compounds results in decreased secretion of TNF protein Benzalkonium Compounds results in increased expression of TNF mRNA; Benzalkonium Compounds results in increased expression of TNF protein |
CTD |
PMID:29953848 PMID:30171875 PMID:30517752 |
|
NCBI chr 6:31,575,565...31,578,336
Ensembl chr 6:31,575,565...31,578,336
|
|
G |
TNFAIP6 |
TNF alpha induced protein 6 |
increases expression |
ISO |
Benzalkonium Compounds results in increased expression of TNFAIP6 mRNA |
CTD |
PMID:30171875 |
|
NCBI chr 2:151,357,592...151,381,340
Ensembl chr 2:151,357,592...151,380,046
|
|
G |
TNFRSF13C |
TNF receptor superfamily member 13C |
multiple interactions |
ISO |
[IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of TNFRSF13C mRNA |
CTD |
PMID:30171875 |
|
NCBI chr22:41,922,032...41,926,806
Ensembl chr22:41,922,032...41,926,806
|
|
G |
TNFRSF9 |
TNF receptor superfamily member 9 |
increases expression |
ISO |
Benzalkonium Compounds results in increased expression of TNFRSF9 mRNA |
CTD |
PMID:30171875 |
|
NCBI chr 1:7,915,871...7,940,839
Ensembl chr 1:7,915,871...7,943,165
|
|
G |
TNFSF8 |
TNF superfamily member 8 |
multiple interactions |
ISO |
[IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of TNFSF8 mRNA |
CTD |
PMID:30171875 |
|
NCBI chr 9:114,893,343...114,930,595
Ensembl chr 9:114,893,343...114,930,595
|
|
G |
TP53 |
tumor protein p53 |
decreases expression |
EXP |
Benzalkonium Compounds results in decreased expression of TP53 mRNA |
CTD |
PMID:28236482 |
|
NCBI chr17:7,668,421...7,687,490
Ensembl chr17:7,661,779...7,687,546
|
|
G |
TPI1 |
triosephosphate isomerase 1 |
decreases expression |
ISO |
Benzalkonium Compounds results in decreased expression of TPI1 mRNA |
CTD |
PMID:31199489 |
|
NCBI chr12:6,867,420...6,870,948
Ensembl chr12:6,867,119...6,870,948
|
|
G |
TRDC |
T cell receptor delta constant |
decreases expression |
ISO |
Benzalkonium Compounds results in decreased expression of TRDC mRNA |
CTD |
PMID:30171875 |
|
NCBI chr14:22,462,932...22,466,577
Ensembl chr14:22,462,932...22,465,787
|
|
G |
TRDV2 |
T cell receptor delta variable 2 |
decreases expression |
ISO |
Benzalkonium Compounds results in decreased expression of TRDV4 mRNA |
CTD |
PMID:30171875 |
|
NCBI chr14:22,422,546...22,423,042
Ensembl chr14:22,422,371...22,423,042
|
|
G |
TREM2 |
triggering receptor expressed on myeloid cells 2 |
increases expression |
ISO |
Benzalkonium Compounds results in increased expression of TREM2 mRNA |
CTD |
PMID:30171875 |
|
NCBI chr 6:41,158,508...41,163,116
Ensembl chr 6:41,158,506...41,163,186
|
|
G |
TRIB3 |
tribbles pseudokinase 3 |
increases expression |
EXP |
Benzalkonium Compounds results in increased expression of TRIB3 mRNA |
CTD |
PMID:37149095 |
|
NCBI chr20:380,760...397,559
Ensembl chr20:362,835...397,559
|
|
G |
TSLP |
thymic stromal lymphopoietin |
multiple interactions |
ISO |
[IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of TSLP mRNA |
CTD |
PMID:30171875 |
|
NCBI chr 5:111,070,062...111,078,026
Ensembl chr 5:111,070,062...111,078,026
|
|
G |
ULBP1 |
UL16 binding protein 1 |
increases expression |
EXP |
Benzalkonium Compounds results in increased expression of ULBP1 mRNA |
CTD |
PMID:37149095 |
|
NCBI chr 6:149,963,943...149,973,715
Ensembl chr 6:149,963,943...149,973,715
|
|
G |
UPK3B |
uroplakin 3B |
decreases expression |
ISO |
Benzalkonium Compounds results in decreased expression of UPK3B mRNA |
CTD |
PMID:30171875 |
|
NCBI chr 7:76,510,552...76,516,522
Ensembl chr 7:76,510,525...76,516,522
|
|
G |
UQCRQ |
ubiquinol-cytochrome c reductase complex III subunit VII |
decreases expression |
ISO |
Benzalkonium Compounds results in decreased expression of UQCRQ mRNA |
CTD |
PMID:31199489 |
|
NCBI chr 5:132,866,642...132,868,847
Ensembl chr 5:132,866,630...132,868,847
|
|
G |
VEGFD |
vascular endothelial growth factor D |
increases expression |
EXP |
Benzalkonium Compounds results in increased expression of VEGFD mRNA |
CTD |
PMID:20146380 |
|
NCBI chr X:15,345,596...15,384,413
Ensembl chr X:15,345,596...15,384,413
|
|
G |
VTCN1 |
V-set domain containing T cell activation inhibitor 1 |
multiple interactions |
ISO |
[IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of VTCN1 mRNA |
CTD |
PMID:30171875 |
|
NCBI chr 1:117,143,587...117,210,927
Ensembl chr 1:117,143,587...117,210,960
|
|
G |
WDR46 |
WD repeat domain 46 |
affects response to substance |
EXP |
WDR46 SNP affects the susceptibility to Benzalkonium Compounds |
CTD |
PMID:27258892 |
|
NCBI chr 6:33,279,108...33,289,239
Ensembl chr 6:33,279,108...33,289,247
|
|
G |
XBP1 |
X-box binding protein 1 |
decreases expression |
EXP |
Benzalkonium Compounds results in decreased expression of XBP1 mRNA alternative form |
CTD |
PMID:28236482 |
|
NCBI chr22:28,794,560...28,800,569
Ensembl chr22:28,794,555...28,800,597
|
|
G |
XCL1 |
X-C motif chemokine ligand 1 |
decreases expression |
ISO |
Benzalkonium Compounds results in decreased expression of XCL1 mRNA |
CTD |
PMID:30171875 |
|
NCBI chr 1:168,576,605...168,582,069
Ensembl chr 1:168,576,605...168,582,069
|
|
|
G |
SLC22A2 |
solute carrier family 22 member 2 |
multiple interactions |
EXP |
Butylscopolammonium Bromide inhibits the reaction [SLC22A2 protein results in increased uptake of 4-(4-dimethylaminostyryl)-1-methylpyridinium] |
CTD |
PMID:21599003 |
|
NCBI chr 6:160,216,755...160,258,821
Ensembl chr 6:160,171,061...160,277,638
|
|
|
G |
ABCD1 |
ATP binding cassette subfamily D member 1 |
increases expression |
ISO |
Chlormequat results in increased expression of ABCD1 protein |
CTD |
PMID:34958886 |
|
NCBI chr X:153,724,856...153,744,755
Ensembl chr X:153,724,856...153,744,755
|
|
G |
ADARB1 |
adenosine deaminase RNA specific B1 |
decreases expression |
ISO |
Chlormequat results in decreased expression of ADARB1 protein |
CTD |
PMID:34958886 |
|
NCBI chr21:45,074,578...45,226,563
Ensembl chr21:45,073,853...45,226,560
|
|
G |
AGTRAP |
angiotensin II receptor associated protein |
increases expression |
ISO |
Chlormequat results in increased expression of AGTRAP protein |
CTD |
PMID:34958886 |
|
NCBI chr 1:11,736,136...11,750,769
Ensembl chr 1:11,736,084...11,754,802
|
|
G |
AHR |
aryl hydrocarbon receptor |
multiple interactions |
EXP |
Chlormequat promotes the reaction [Tetrachlorodibenzodioxin results in increased activity of AHR protein] |
CTD |
PMID:25684042 |
|
NCBI chr 7:17,298,652...17,346,147
Ensembl chr 7:16,916,359...17,346,152
|
|
G |
ALG12 |
ALG12 alpha-1,6-mannosyltransferase |
decreases expression |
ISO |
Chlormequat results in decreased expression of ALG12 protein |
CTD |
PMID:34958886 |
|
NCBI chr22:49,859,311...49,918,438
Ensembl chr22:49,900,229...49,918,438
|
|
G |
ALG14 |
ALG14 UDP-N-acetylglucosaminyltransferase subunit |
decreases expression |
ISO |
Chlormequat results in decreased expression of ALG14 protein |
CTD |
PMID:34958886 |
|
NCBI chr 1:94,974,405...95,072,951
Ensembl chr 1:94,974,405...95,072,951
|
|
G |
APOL4 |
apolipoprotein L4 |
increases expression |
ISO |
Chlormequat results in increased expression of APOL9A protein |
CTD |
PMID:34958886 |
|
NCBI chr22:36,189,128...36,204,833
Ensembl chr22:36,189,124...36,204,840
|
|
G |
ARHGAP20 |
Rho GTPase activating protein 20 |
increases expression |
ISO |
Chlormequat results in increased expression of ARHGAP20 protein |
CTD |
PMID:34958886 |
|
NCBI chr11:110,577,043...110,713,189
Ensembl chr11:110,577,042...110,713,189
|
|
G |
ATL1 |
atlastin GTPase 1 |
increases expression |
ISO |
Chlormequat results in increased expression of ATL1 protein |
CTD |
PMID:34958886 |
|
NCBI chr14:50,533,082...50,633,068
Ensembl chr14:50,532,509...50,634,017
|
|
G |
ATP10B |
ATPase phospholipid transporting 10B (putative) |
increases expression |
ISO |
Chlormequat results in increased expression of ATP10B protein |
CTD |
PMID:34958886 |
|
NCBI chr 5:160,563,120...160,929,360
Ensembl chr 5:160,563,120...160,852,214
|
|
G |
B9D2 |
B9 domain containing 2 |
increases expression |
ISO |
Chlormequat results in increased expression of B9D2 protein |
CTD |
PMID:34958886 |
|
NCBI chr19:41,354,417...41,364,149
Ensembl chr19:41,354,417...41,364,165
|
|
G |
BET1L |
Bet1 golgi vesicular membrane trafficking protein like |
increases expression |
ISO |
Chlormequat results in increased expression of BET1L protein |
CTD |
PMID:34958886 |
|
NCBI chr11:202,924...207,399
Ensembl chr11:167,784...207,399
|
|
G |
BGLAP |
bone gamma-carboxyglutamate protein |
decreases expression |
ISO |
Chlormequat results in decreased expression of BGLAP protein |
CTD |
PMID:28214531 |
|
NCBI chr 1:156,242,184...156,243,317
Ensembl chr 1:156,242,184...156,243,317
|
|
G |
C1QC |
complement C1q C chain |
increases expression |
ISO |
Chlormequat results in increased expression of C1QC protein |
CTD |
PMID:34958886 |
|
NCBI chr 1:22,643,633...22,648,108
Ensembl chr 1:22,643,014...22,648,110
|
|
G |
CAAP1 |
caspase activity and apoptosis inhibitor 1 |
decreases expression |
ISO |
Chlormequat results in decreased expression of CAAP1 protein |
CTD |
PMID:34958886 |
|
NCBI chr 9:26,840,685...26,892,802
Ensembl chr 9:26,840,685...26,892,803
|
|
G |
CBX1 |
chromobox 1 |
increases expression |
ISO |
Chlormequat results in increased expression of CBX1 protein |
CTD |
PMID:34958886 |
|
NCBI chr17:48,070,059...48,101,478
Ensembl chr17:48,070,052...48,101,478
|
|
G |
CCDC32 |
coiled-coil domain containing 32 |
increases expression |
ISO |
Chlormequat results in increased expression of CCDC32 protein |
CTD |
PMID:34958886 |
|
NCBI chr15:40,520,993...40,565,042
Ensembl chr15:40,528,683...40,565,054
|
|
G |
CCNYL1 |
cyclin Y like 1 |
increases expression |
ISO |
Chlormequat results in increased expression of CCNYL1 protein |
CTD |
PMID:34958886 |
|
NCBI chr 2:207,711,640...207,756,174
Ensembl chr 2:207,711,540...207,761,839
|
|
G |
CCS |
copper chaperone for superoxide dismutase |
increases expression |
ISO |
Chlormequat results in increased expression of CCS protein |
CTD |
PMID:34958886 |
|
NCBI chr11:66,593,185...66,606,019
Ensembl chr11:66,593,153...66,606,019
|
|
G |
CD151 |
CD151 molecule (Raph blood group) |
decreases expression |
ISO |
Chlormequat results in decreased expression of CD151 protein |
CTD |
PMID:34958886 |
|
NCBI chr11:832,952...838,831
Ensembl chr11:832,887...839,831
|
|
G |
CD55 |
CD55 molecule (Cromer blood group) |
increases expression |
ISO |
Chlormequat results in increased expression of CD55 protein |
CTD |
PMID:34958886 |
|
NCBI chr 1:207,321,678...207,360,966
Ensembl chr 1:207,321,519...207,386,804
|
|
G |
CFAP298 |
cilia and flagella associated protein 298 |
increases expression |
ISO |
Chlormequat results in increased expression of CFAP298 protein |
CTD |
PMID:34958886 |
|
NCBI chr21:32,599,354...32,612,377
Ensembl chr21:32,592,079...32,612,603
|
|
G |
CHMP7 |
charged multivesicular body protein 7 |
increases expression |
ISO |
Chlormequat results in increased expression of CHMP7 protein |
CTD |
PMID:34958886 |
|
NCBI chr 8:23,243,637...23,261,999
Ensembl chr 8:23,243,637...23,262,000
|
|
G |
COPRS |
coordinator of PRMT5 and differentiation stimulator |
increases expression |
ISO |
Chlormequat results in increased expression of COPRS protein |
CTD |
PMID:34958886 |
|
NCBI chr17:31,851,871...31,859,244
Ensembl chr17:31,851,871...31,859,291
|
|
G |
COQ4 |
coenzyme Q4 |
increases expression |
ISO |
Chlormequat results in increased expression of COQ4 protein |
CTD |
PMID:34958886 |
|
NCBI chr 9:128,322,839...128,334,072
Ensembl chr 9:128,322,544...128,334,072
|
|
G |
CREB1 |
cAMP responsive element binding protein 1 |
increases phosphorylation |
ISO |
Chlormequat results in increased phosphorylation of CREB1 protein |
CTD |
PMID:38552810 |
|
NCBI chr 2:207,529,962...207,605,988
Ensembl chr 2:207,529,737...207,605,988
|
|
G |
CSNK1A1 |
casein kinase 1 alpha 1 |
increases expression |
ISO |
Chlormequat results in increased expression of CSNK1A1 protein |
CTD |
PMID:34958886 |
|
NCBI chr 5:149,492,982...149,551,439
Ensembl chr 5:149,492,982...149,551,471
|
|
G |
CTSS |
cathepsin S |
decreases expression |
ISO |
Chlormequat results in decreased expression of CTSS protein |
CTD |
PMID:34958886 |
|
NCBI chr 1:150,730,188...150,765,778
Ensembl chr 1:150,730,079...150,765,957
|
|
G |
CYP11A1 |
cytochrome P450 family 11 subfamily A member 1 |
decreases expression |
ISO |
Chlormequat results in decreased expression of CYP11A1 protein |
CTD |
PMID:29447956 |
|
NCBI chr15:74,337,762...74,367,646
Ensembl chr15:74,337,759...74,367,646
|
|
G |
CYP7A1 |
cytochrome P450 family 7 subfamily A member 1 |
increases expression |
EXP |
Chlormequat results in increased expression of CYP7A1 protein |
CTD |
PMID:32194361 |
|
NCBI chr 8:58,490,178...58,500,163
Ensembl chr 8:58,490,178...58,500,163
|
|
G |
DAP |
death associated protein |
decreases expression |
ISO |
Chlormequat results in decreased expression of DAP protein |
CTD |
PMID:34958886 |
|
NCBI chr 5:10,679,230...10,761,234
Ensembl chr 5:10,679,230...10,761,234
|
|
G |
DCAF13 |
DDB1 and CUL4 associated factor 13 |
increases expression |
ISO |
Chlormequat results in increased expression of DCAF13 protein |
CTD |
PMID:34958886 |
|
NCBI chr 8:103,415,386...103,443,453
Ensembl chr 8:103,414,714...103,443,453
|
|
G |
DCTN6 |
dynactin subunit 6 |
increases expression |
ISO |
Chlormequat results in increased expression of DCTN6 protein |
CTD |
PMID:34958886 |
|
NCBI chr 8:30,156,369...30,183,639
Ensembl chr 8:30,156,319...30,183,639
|
|
G |
DDIT3 |
DNA damage inducible transcript 3 |
multiple interactions increases expression |
ISO |
4-phenylbutyric acid inhibits the reaction [Chlormequat results in increased expression of DDIT3 protein] |
CTD |
PMID:34958886 |
|
NCBI chr12:57,516,588...57,520,517
Ensembl chr12:57,516,588...57,521,737
|
|
G |
DEGS1 |
delta 4-desaturase, sphingolipid 1 |
increases expression |
ISO |
Chlormequat results in increased expression of DEGS1 protein |
CTD |
PMID:34958886 |
|
NCBI chr 1:224,183,240...224,193,441
Ensembl chr 1:224,175,756...224,193,441
|
|
G |
DNAJC14 |
DnaJ heat shock protein family (Hsp40) member C14 |
increases expression |
ISO |
Chlormequat results in increased expression of DNAJC14 protein |
CTD |
PMID:34958886 |
|
NCBI chr12:55,820,985...55,830,775
Ensembl chr12:55,820,960...55,830,824
|
|
G |
DNMBP |
dynamin binding protein |
increases expression |
ISO |
Chlormequat results in increased expression of DNMBP protein |
CTD |
PMID:34958886 |
|
NCBI chr10:99,875,571...100,009,947
Ensembl chr10:99,875,577...100,009,947
|
|
G |
DYNLT3 |
dynein light chain Tctex-type 3 |
increases expression |
ISO |
Chlormequat results in increased expression of DYNLT3 protein |
CTD |
PMID:34958886 |
|
NCBI chr X:37,838,836...37,847,571
Ensembl chr X:37,836,757...37,847,571
|
|
G |
EARS2 |
glutamyl-tRNA synthetase 2, mitochondrial |
increases expression |
ISO |
Chlormequat results in increased expression of EARS2 protein |
CTD |
PMID:34958886 |
|
NCBI chr16:23,520,754...23,557,375
Ensembl chr16:23,520,754...23,557,731
|
|
G |
EEF1A2 |
eukaryotic translation elongation factor 1 alpha 2 |
decreases expression |
ISO |
Chlormequat results in decreased expression of EEF1A2 protein |
CTD |
PMID:34958886 |
|
NCBI chr20:63,488,014...63,499,083
Ensembl chr20:63,488,013...63,499,239
|
|
G |
ELOVL1 |
ELOVL fatty acid elongase 1 |
increases expression |
ISO |
Chlormequat results in increased expression of ELOVL1 protein |
CTD |
PMID:34958886 |
|
NCBI chr 1:43,363,401...43,368,011
Ensembl chr 1:43,363,398...43,368,074
|
|
G |
ELOVL5 |
ELOVL fatty acid elongase 5 |
increases expression |
ISO |
Chlormequat results in increased expression of ELOVL5 protein |
CTD |
PMID:34958886 |
|
NCBI chr 6:53,267,404...53,348,950
Ensembl chr 6:53,267,398...53,349,179
|
|
G |
ENO3 |
enolase 3 |
decreases expression |
ISO |
Chlormequat results in decreased expression of ENO3 protein |
CTD |
PMID:34958886 |
|
NCBI chr17:4,948,710...4,957,129
Ensembl chr17:4,948,092...4,957,131
|
|
G |
EVC |
EvC ciliary complex subunit 1 |
increases expression |
ISO |
Chlormequat results in increased expression of EVC protein |
CTD |
PMID:34958886 |
|
NCBI chr 4:5,711,201...5,829,057
Ensembl chr 4:5,711,201...5,814,305
|
|
G |
FABP4 |
fatty acid binding protein 4 |
decreases expression |
ISO |
Chlormequat results in decreased expression of FABP4 protein |
CTD |
PMID:34958886 |
|
NCBI chr 8:81,478,419...81,483,233
Ensembl chr 8:81,478,419...81,483,236
|
|
G |
FANCD2 |
FA complementation group D2 |
decreases expression |
ISO |
Chlormequat results in decreased expression of FANCD2 protein |
CTD |
PMID:34958886 |
|
NCBI chr 3:10,026,437...10,101,932
Ensembl chr 3:10,026,370...10,101,932
|
|
G |
FBLN1 |
fibulin 1 |
increases expression |
ISO |
Chlormequat results in increased expression of FBLN1 protein |
CTD |
PMID:34958886 |
|
NCBI chr22:45,502,883...45,601,135
Ensembl chr22:45,502,238...45,601,135
|
|
G |
FOS |
Fos proto-oncogene, AP-1 transcription factor subunit |
decreases expression |
ISO |
Chlormequat results in decreased expression of FOS protein |
CTD |
PMID:34958886 |
|
NCBI chr14:75,278,828...75,282,230
Ensembl chr14:75,278,826...75,283,190
|
|
G |
FOXK2 |
forkhead box K2 |
decreases expression |
ISO |
Chlormequat results in decreased expression of FOXK2 protein |
CTD |
PMID:34958886 |
|
NCBI chr17:82,519,732...82,604,602
Ensembl chr17:82,519,713...82,644,662
|
|
G |
GABARAP |
GABA type A receptor-associated protein |
increases expression |
ISO |
Chlormequat results in increased expression of GABARAP protein |
CTD |
PMID:34958886 |
|
NCBI chr17:7,240,008...7,242,449
Ensembl chr17:7,240,008...7,242,449
|
|
G |
GH1 |
growth hormone 1 |
increases expression |
ISO |
Chlormequat results in increased expression of GH1 protein |
CTD |
PMID:31704167 PMID:32622971 PMID:38552810 |
|
NCBI chr17:63,917,203...63,918,839
Ensembl chr17:63,917,200...63,918,839
|
|
G |
GHR |
growth hormone receptor |
decreases expression |
ISO |
Chlormequat results in decreased expression of GHR mRNA |
CTD |
PMID:28214531 |
|
NCBI chr 5:42,423,439...42,721,878
Ensembl chr 5:42,423,439...42,721,878
|
|
G |
GHRH |
growth hormone releasing hormone |
increases expression |
ISO |
Chlormequat results in increased expression of GHRH protein |
CTD |
PMID:32622971 PMID:38552810 |
|
NCBI chr20:37,251,086...37,261,814
Ensembl chr20:37,251,086...37,261,819
|
|
G |
GNAI1 |
G protein subunit alpha i1 |
increases expression |
ISO |
Chlormequat results in increased expression of GNAI1 protein |
CTD |
PMID:34958886 |
|
NCBI chr 7:80,134,831...80,226,181
Ensembl chr 7:79,768,028...80,226,181
|
|
G |
GNG5 |
G protein subunit gamma 5 |
decreases expression |
ISO |
Chlormequat results in decreased expression of GNG5 protein |
CTD |
PMID:34958886 |
|
NCBI chr 1:84,498,325...84,506,581
Ensembl chr 1:84,498,323...84,506,581
|
|
G |
GNRH1 |
gonadotropin releasing hormone 1 |
increases expression |
ISO |
Chlormequat results in increased expression of GNRH1 protein |
CTD |
PMID:29447956 |
|
NCBI chr 8:25,419,258...25,425,040
Ensembl chr 8:25,419,258...25,424,654
|
|
G |
GSTA2 |
glutathione S-transferase alpha 2 |
increases expression |
ISO |
Chlormequat results in increased expression of GSTA2 protein |
CTD |
PMID:34958886 |
|
NCBI chr 6:52,750,087...52,763,475
Ensembl chr 6:52,750,087...52,763,475
|
|
G |
GTF2H5 |
general transcription factor IIH subunit 5 |
increases expression |
ISO |
Chlormequat results in increased expression of GTF2H5 protein |
CTD |
PMID:34958886 |
|
NCBI chr 6:158,168,350...158,199,344
Ensembl chr 6:158,168,350...158,199,344
|
|
G |
H1-0 |
H1.0 linker histone |
increases expression |
ISO |
Chlormequat results in increased expression of H1-0 protein |
CTD |
PMID:34958886 |
|
NCBI chr22:37,805,229...37,807,432
Ensembl chr22:37,805,229...37,807,432
|
|
G |
H1-5 |
H1.5 linker histone, cluster member |
increases expression |
ISO |
Chlormequat results in increased expression of H1-5 protein |
CTD |
PMID:34958886 |
|
NCBI chr 6:27,866,792...27,867,588
Ensembl chr 6:27,866,792...27,867,588
|
|
G |
HEBP2 |
heme binding protein 2 |
increases expression |
ISO |
Chlormequat results in increased expression of HEBP2 protein |
CTD |
PMID:34958886 |
|
NCBI chr 6:138,403,531...138,422,197
Ensembl chr 6:138,403,531...138,422,197
|
|
G |
HERPUD2 |
HERPUD family member 2 |
increases expression |
ISO |
Chlormequat results in increased expression of HERPUD2 protein |
CTD |
PMID:34958886 |
|
NCBI chr 7:35,632,659...35,695,135
Ensembl chr 7:35,632,659...35,697,459
|
|
G |
HNRNPC |
heterogeneous nuclear ribonucleoprotein C |
increases expression |
ISO |
Chlormequat results in increased expression of HNRNPC protein |
CTD |
PMID:34958886 |
|
NCBI chr14:21,209,147...21,269,442
Ensembl chr14:21,209,136...21,269,494
|
|
G |
HSD3B1 |
hydroxy-delta-5-steroid dehydrogenase, 3 beta- and steroid delta-isomerase 1 |
decreases expression |
ISO |
Chlormequat results in decreased expression of HSD3B1 protein |
CTD |
PMID:29447956 |
|
NCBI chr 1:119,507,203...119,515,058
Ensembl chr 1:119,507,198...119,515,054
|
|
G |
HSPA5 |
heat shock protein family A (Hsp70) member 5 |
multiple interactions increases expression |
ISO |
4-phenylbutyric acid inhibits the reaction [Chlormequat results in increased expression of HSPA5 protein] |
CTD |
PMID:34958886 |
|
NCBI chr 9:125,234,853...125,241,343
Ensembl chr 9:125,234,853...125,241,382
|
|
G |
IGF1 |
insulin like growth factor 1 |
affects expression increases expression |
ISO |
Chlormequat affects the expression of IGF1 protein Chlormequat results in increased expression of IGF1 protein |
CTD |
PMID:28214531 PMID:31704167 |
|
NCBI chr12:102,395,874...102,481,839
Ensembl chr12:102,395,874...102,481,744
|
|
G |
INA |
internexin neuronal intermediate filament protein alpha |
decreases expression |
ISO |
Chlormequat results in decreased expression of INA protein |
CTD |
PMID:34958886 |
|
NCBI chr10:103,277,138...103,290,346
Ensembl chr10:103,277,138...103,290,346
|
|
G |
ISOC2 |
isochorismatase domain containing 2 |
increases expression |
ISO |
Chlormequat results in increased expression of ISOC2 protein |
CTD |
PMID:34958886 |
|
NCBI chr19:55,452,985...55,461,642
Ensembl chr19:55,452,985...55,462,343
|
|
G |
ITGB1BP1 |
integrin subunit beta 1 binding protein 1 |
increases expression |
ISO |
Chlormequat results in increased expression of ITGB1BP1 protein |
CTD |
PMID:34958886 |
|
NCBI chr 2:9,403,475...9,423,569
Ensembl chr 2:9,403,475...9,423,528
|
|
G |
KAZN |
kazrin, periplakin interacting protein |
increases expression |
ISO |
Chlormequat results in increased expression of KAZN protein |
CTD |
PMID:34958886 |
|
NCBI chr 1:13,892,824...15,118,043
Ensembl chr 1:13,892,792...15,118,043
|
|
G |
KLHL26 |
kelch like family member 26 |
decreases expression |
ISO |
Chlormequat results in decreased expression of KLHL26 protein |
CTD |
PMID:34958886 |
|
NCBI chr19:18,637,028...18,671,721
Ensembl chr19:18,637,025...18,671,721
|
|
G |
KLHL7 |
kelch like family member 7 |
decreases expression |
ISO |
Chlormequat results in decreased expression of KLHL7 protein |
CTD |
PMID:34958886 |
|
NCBI chr 7:23,105,785...23,177,914
Ensembl chr 7:23,105,758...23,177,914
|
|
G |
LDB1 |
LIM domain binding 1 |
increases expression |
ISO |
Chlormequat results in increased expression of LDB1 protein |
CTD |
PMID:34958886 |
|
NCBI chr10:102,102,088...102,121,442
Ensembl chr10:102,106,489...102,120,368
|
|
G |
LHB |
luteinizing hormone subunit beta |
increases expression |
ISO |
Chlormequat results in increased expression of LHB protein |
CTD |
PMID:29447956 |
|
NCBI chr19:49,015,980...49,019,498
Ensembl chr19:49,015,980...49,017,091
|
|
G |
LRRC7 |
leucine rich repeat containing 7 |
increases expression |
ISO |
Chlormequat results in increased expression of LRRC7 protein |
CTD |
PMID:34958886 |
|
NCBI chr 1:69,567,922...70,144,364
Ensembl chr 1:69,567,922...70,151,945
|
|
G |
MACROH2A1 |
macroH2A.1 histone |
increases expression |
ISO |
Chlormequat results in increased expression of MACROH2A1 protein |
CTD |
PMID:34958886 |
|
NCBI chr 5:135,334,381...135,399,887
Ensembl chr 5:135,334,381...135,399,914
|
|
G |
MACROH2A2 |
macroH2A.2 histone |
increases expression |
ISO |
Chlormequat results in increased expression of MACROH2A2 protein |
CTD |
PMID:34958886 |
|
NCBI chr10:70,052,846...70,112,282
Ensembl chr10:70,052,544...70,112,282
|
|
G |
MAP4 |
microtubule associated protein 4 |
decreases expression |
ISO |
Chlormequat results in decreased expression of MAP4 protein |
CTD |
PMID:34958886 |
|
NCBI chr 3:47,850,695...48,088,848
Ensembl chr 3:47,850,690...48,089,272
|
|
G |
MGAT4B |
alpha-1,3-mannosyl-glycoprotein 4-beta-N-acetylglucosaminyltransferase B |
increases expression |
ISO |
Chlormequat results in increased expression of MGAT4B protein |
CTD |
PMID:34958886 |
|
NCBI chr 5:179,797,597...179,806,866
Ensembl chr 5:179,797,597...179,806,952
|
|
G |
MOSPD3 |
motile sperm domain containing 3 |
decreases expression |
ISO |
Chlormequat results in decreased expression of MOSPD3 protein |
CTD |
PMID:34958886 |
|
NCBI chr 7:100,612,162...100,615,377
Ensembl chr 7:100,612,102...100,615,384
|
|
G |
MOV10 |
Mov10 RNA helicase |
increases expression |
ISO |
Chlormequat results in increased expression of MOV10 protein |
CTD |
PMID:34958886 |
|
NCBI chr 1:112,674,439...112,700,739
Ensembl chr 1:112,673,141...112,700,756
|
|
G |
MPP2 |
MAGUK p55 scaffold protein 2 |
decreases expression |
ISO |
Chlormequat results in decreased expression of MPP2 protein |
CTD |
PMID:34958886 |
|
NCBI chr17:43,875,360...43,909,711
Ensembl chr17:43,875,357...43,909,711
|
|
G |
MPV17L2 |
MPV17 mitochondrial inner membrane protein like 2 |
increases expression |
ISO |
Chlormequat results in increased expression of MPV17L2 protein |
CTD |
PMID:34958886 |
|
NCBI chr19:18,193,218...18,196,948
Ensembl chr19:18,193,218...18,196,948
|
|
G |
MRPL51 |
mitochondrial ribosomal protein L51 |
increases expression |
ISO |
Chlormequat results in increased expression of MRPL51 protein |
CTD |
PMID:34958886 |
|
NCBI chr12:6,491,886...6,493,262
Ensembl chr12:6,491,886...6,493,841
|
|
G |
MRPL54 |
mitochondrial ribosomal protein L54 |
increases expression |
ISO |
Chlormequat results in increased expression of MRPL54 protein |
CTD |
PMID:34958886 |
|
NCBI chr19:3,762,682...3,767,565
Ensembl chr19:3,762,682...3,768,575
|
|
G |
MRPS14 |
mitochondrial ribosomal protein S14 |
increases expression |
ISO |
Chlormequat results in increased expression of MRPS14 protein |
CTD |
PMID:34958886 |
|
NCBI chr 1:175,012,958...175,023,425
Ensembl chr 1:175,010,789...175,023,425
|
|
G |
MTRFR |
mitochondrial translation release factor in rescue |
increases expression |
ISO |
Chlormequat results in increased expression of MTRFR protein |
CTD |
PMID:34958886 |
|
NCBI chr12:123,232,914...123,257,960
Ensembl chr12:123,233,385...123,258,079
|
|
G |
NCL |
nucleolin |
increases expression |
ISO |
Chlormequat results in increased expression of NCL protein |
CTD |
PMID:34958886 |
|
NCBI chr 2:231,453,531...231,464,484
Ensembl chr 2:231,453,531...231,483,641
|
|
G |
NHP2 |
NHP2 ribonucleoprotein |
increases expression |
ISO |
Chlormequat results in increased expression of NHP2 protein |
CTD |
PMID:34958886 |
|
NCBI chr 5:178,149,463...178,153,885
Ensembl chr 5:178,149,463...178,153,894
|
|
G |
NIPA1 |
NIPA magnesium transporter 1 |
decreases expression |
ISO |
Chlormequat results in decreased expression of NIPA1 protein |
CTD |
PMID:34958886 |
|
NCBI chr15:22,786,225...22,829,789
Ensembl chr15:22,773,063...22,829,789
|
|
G |
NPR3 |
natriuretic peptide receptor 3 |
decreases expression |
ISO |
Chlormequat results in decreased expression of NPR3 protein |
CTD |
PMID:34958886 |
|
NCBI chr 5:32,690,872...32,791,720
Ensembl chr 5:32,689,070...32,791,724
|
|
G |
NR3C2 |
nuclear receptor subfamily 3 group C member 2 |
increases expression |
ISO |
Chlormequat results in increased expression of NR3C2 protein |
CTD |
PMID:34958886 |
|
NCBI chr 4:148,078,764...148,445,508
Ensembl chr 4:148,078,762...148,444,698
|
|
G |
ORAI1 |
ORAI calcium release-activated calcium modulator 1 |
increases expression |
ISO |
Chlormequat results in increased expression of ORAI1 protein |
CTD |
PMID:34958886 |
|
NCBI chr12:121,626,530...121,643,109
Ensembl chr12:121,626,509...121,643,218
|
|
G |
PABPC1 |
poly(A) binding protein cytoplasmic 1 |
increases expression |
ISO |
Chlormequat results in increased expression of PABPC1 protein |
CTD |
PMID:34958886 |
|
NCBI chr 8:100,702,916...100,722,088
Ensembl chr 8:100,685,816...100,722,809
|
|
G |
PABPC4 |
poly(A) binding protein cytoplasmic 4 |
increases expression |
ISO |
Chlormequat results in increased expression of PABPC4 protein |
CTD |
PMID:34958886 |
|
NCBI chr 1:39,560,816...39,576,790
Ensembl chr 1:39,560,709...39,576,790
|
|
G |
PCCB |
propionyl-CoA carboxylase subunit beta |
increases expression |
ISO |
Chlormequat results in increased expression of PCCB protein |
CTD |
PMID:34958886 |
|
NCBI chr 3:136,250,340...136,330,169
Ensembl chr 3:136,250,340...136,337,896
|
|
G |
PEX26 |
peroxisomal biogenesis factor 26 |
increases expression |
ISO |
Chlormequat results in increased expression of PEX26 protein |
CTD |
PMID:34958886 |
|
NCBI chr22:18,077,990...18,105,396
Ensembl chr22:18,077,923...18,105,396
|
|
G |
PGPEP1 |
pyroglutamyl-peptidase I |
increases expression |
ISO |
Chlormequat results in increased expression of PGPEP1 protein |
CTD |
PMID:34958886 |
|
NCBI chr19:18,340,598...18,369,950
Ensembl chr19:18,340,598...18,369,950
|
|
G |
PHLDB1 |
pleckstrin homology like domain family B member 1 |
increases expression |
ISO |
Chlormequat results in increased expression of PHLDB1 protein |
CTD |
PMID:34958886 |
|
NCBI chr11:118,606,436...118,658,028
Ensembl chr11:118,606,440...118,658,031
|
|
G |
PIAS3 |
protein inhibitor of activated STAT 3 |
decreases expression |
ISO |
Chlormequat results in decreased expression of PIAS3 protein |
CTD |
PMID:34958886 |
|
NCBI chr 1:145,848,522...145,859,081
Ensembl chr 1:145,848,522...145,859,836
|
|
G |
PIK3CD |
phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta |
increases expression |
ISO |
Chlormequat results in increased expression of PIK3CD protein |
CTD |
PMID:34958886 |
|
NCBI chr 1:9,627,258...9,729,114
Ensembl chr 1:9,629,889...9,729,114
|
|
G |
PITPNM2 |
phosphatidylinositol transfer protein membrane associated 2 |
increases expression |
ISO |
Chlormequat results in increased expression of PITPNM2 protein |
CTD |
PMID:34958886 |
|
NCBI chr12:122,983,480...123,151,848
Ensembl chr12:122,983,480...123,151,090
|
|
G |
POLE4 |
DNA polymerase epsilon 4, accessory subunit |
increases expression |
ISO |
Chlormequat results in increased expression of POLE4 protein |
CTD |
PMID:34958886 |
|
NCBI chr 2:74,958,643...74,970,128
Ensembl chr 2:74,958,643...74,970,128
|
|
G |
POU1F1 |
POU class 1 homeobox 1 |
increases expression |
ISO |
Chlormequat results in increased expression of POU1F1 protein |
CTD |
PMID:38552810 |
|
NCBI chr 3:87,259,404...87,276,584
Ensembl chr 3:87,259,404...87,276,584
|
|
G |
PPHLN1 |
periphilin 1 |
increases expression |
ISO |
Chlormequat results in increased expression of PPHLN1 protein |
CTD |
PMID:34958886 |
|
NCBI chr12:42,326,167...42,448,621
Ensembl chr12:42,238,447...42,459,715
|
|
G |
PRKACA |
protein kinase cAMP-activated catalytic subunit alpha |
affects expression |
ISO |
Chlormequat affects the expression of PRKACA protein |
CTD |
PMID:38552810 |
|
NCBI chr19:14,091,688...14,117,762
Ensembl chr19:14,091,688...14,118,084
|
|
G |
PRKAR1B |
protein kinase cAMP-dependent type I regulatory subunit beta |
increases expression |
ISO |
Chlormequat results in increased expression of PRKAR1B protein |
CTD |
PMID:34958886 |
|
NCBI chr 7:549,197...728,934
Ensembl chr 7:549,197...727,650
|
|
G |
PSMB7 |
proteasome 20S subunit beta 7 |
increases expression |
ISO |
Chlormequat results in increased expression of PSMB7 protein |
CTD |
PMID:34958886 |
|
NCBI chr 9:124,353,465...124,415,442
Ensembl chr 9:124,353,465...124,415,444
|
|
G |
RAB6A |
RAB6A, member RAS oncogene family |
increases expression |
ISO |
Chlormequat results in increased expression of RAB6A protein |
CTD |
PMID:34958886 |
|
NCBI chr11:73,675,638...73,761,074
Ensembl chr11:73,675,638...73,761,137
|
|
G |
RAD17 |
RAD17 checkpoint clamp loader component |
increases expression |
ISO |
Chlormequat results in increased expression of RAD17 protein |
CTD |
PMID:34958886 |
|
NCBI chr 5:69,369,293...69,414,801
Ensembl chr 5:69,369,293...69,414,801
|
|
G |
RHOQ |
ras homolog family member Q |
increases expression |
ISO |
Chlormequat results in increased expression of RHOQ protein |
CTD |
PMID:34958886 |
|
NCBI chr 2:46,542,490...46,584,688
Ensembl chr 2:46,541,806...46,584,688
|
|
G |
RNF113A |
ring finger protein 113A |
decreases expression |
ISO |
Chlormequat results in decreased expression of RNF113A1 protein |
CTD |
PMID:34958886 |
|
NCBI chr X:119,870,475...119,871,733
Ensembl chr X:119,870,475...119,871,733
|
|
G |
RNF185 |
ring finger protein 185 |
increases expression multiple interactions |
ISO |
Chlormequat results in increased expression of RNF185 protein 4-phenylbutyric acid inhibits the reaction [Chlormequat results in increased expression of RNF185 protein] |
CTD |
PMID:34958886 |
|
NCBI chr22:31,160,182...31,207,019
Ensembl chr22:31,160,182...31,207,019
|
|
G |
RSPRY1 |
ring finger and SPRY domain containing 1 |
increases expression |
ISO |
Chlormequat results in increased expression of RSPRY1 protein |
CTD |
PMID:34958886 |
|
NCBI chr16:57,186,152...57,240,469
Ensembl chr16:57,186,137...57,240,469
|
|
G |
RTN1 |
reticulon 1 |
decreases expression |
ISO |
Chlormequat results in decreased expression of RTN1 protein |
CTD |
PMID:34958886 |
|
NCBI chr14:59,595,976...59,870,776
Ensembl chr14:59,595,976...59,870,776
|
|
G |
S100A1 |
S100 calcium binding protein A1 |
increases expression |
ISO |
Chlormequat results in increased expression of S100A1 protein |
CTD |
PMID:34958886 |
|
NCBI chr 1:153,628,434...153,632,039
Ensembl chr 1:153,627,926...153,632,039
|
|
G |
SAMD8 |
sterile alpha motif domain containing 8 |
increases expression |
ISO |
Chlormequat results in increased expression of SAMD8 protein |
CTD |
PMID:34958886 |
|
NCBI chr10:75,099,593...75,182,123
Ensembl chr10:75,099,586...75,182,123
|
|
G |
SAR1A |
secretion associated Ras related GTPase 1A |
increases expression |
ISO |
Chlormequat results in increased expression of SAR1A protein |
CTD |
PMID:34958886 |
|
NCBI chr10:70,147,289...70,170,514
Ensembl chr10:70,147,289...70,170,523
|
|
G |
SHROOM1 |
shroom family member 1 |
decreases expression |
ISO |
Chlormequat results in decreased expression of SHROOM1 protein |
CTD |
PMID:34958886 |
|
NCBI chr 5:132,822,141...132,830,647
Ensembl chr 5:132,822,141...132,830,659
|
|
G |
SKI |
SKI proto-oncogene |
increases expression |
ISO |
Chlormequat results in increased expression of SKI protein |
CTD |
PMID:34958886 |
|
NCBI chr 1:2,228,319...2,310,213
Ensembl chr 1:2,227,388...2,310,213
|
|
G |
SLC48A1 |
solute carrier family 48 member 1 |
decreases expression |
ISO |
Chlormequat results in decreased expression of SLC48A1 protein |
CTD |
PMID:34958886 |
|
NCBI chr12:47,753,934...47,782,751
Ensembl chr12:47,753,916...47,782,751
|
|
G |
SLIT3 |
slit guidance ligand 3 |
increases expression |
ISO |
Chlormequat results in increased expression of SLIT3 protein |
CTD |
PMID:34958886 |
|
NCBI chr 5:168,661,740...169,301,139
Ensembl chr 5:168,661,740...169,301,139
|
|
G |
SLU7 |
SLU7 homolog, splicing factor |
increases expression |
ISO |
Chlormequat results in increased expression of SLU7 protein |
CTD |
PMID:34958886 |
|
NCBI chr 5:160,401,641...160,419,081
Ensembl chr 5:160,401,641...160,421,711
|
|
G |
SMIM26 |
small integral membrane protein 26 |
decreases expression |
ISO |
Chlormequat results in decreased expression of SMIM26 protein |
CTD |
PMID:34958886 |
|
NCBI chr20:18,567,432...18,569,611
Ensembl chr20:18,567,347...18,569,563
|
|
G |
SPNS1 |
SPNS lysolipid transporter 1, lysophospholipid |
increases expression |
ISO |
Chlormequat results in increased expression of SPNS1 protein |
CTD |
PMID:34958886 |
|
NCBI chr16:28,974,778...28,984,765
Ensembl chr16:28,974,221...28,984,548
|
|
G |
SPPL2B |
signal peptide peptidase like 2B |
increases expression |
ISO |
Chlormequat results in increased expression of SPPL2B protein |
CTD |
PMID:34958886 |
|
NCBI chr19:2,328,684...2,355,095
Ensembl chr19:2,328,615...2,355,095
|
|
G |
SST |
somatostatin |
affects expression |
ISO |
Chlormequat affects the expression of SST protein |
CTD |
PMID:38552810 |
|
NCBI chr 3:187,668,912...187,670,394
Ensembl chr 3:187,668,912...187,670,394
|
|
G |
ST3GAL1 |
ST3 beta-galactoside alpha-2,3-sialyltransferase 1 |
increases expression |
ISO |
Chlormequat results in increased expression of ST3GAL1 protein |
CTD |
PMID:34958886 |
|
NCBI chr 8:133,454,848...133,571,887
Ensembl chr 8:133,454,848...133,571,926
|
|
G |
ST7L |
suppression of tumorigenicity 7 like |
decreases expression |
ISO |
Chlormequat results in decreased expression of ST7L protein |
CTD |
PMID:34958886 |
|
NCBI chr 1:112,517,803...112,619,684
Ensembl chr 1:112,523,514...112,620,825
|
|
G |
STAR |
steroidogenic acute regulatory protein |
decreases expression |
ISO |
Chlormequat results in decreased expression of STAR protein |
CTD |
PMID:29447956 |
|
NCBI chr 8:38,142,700...38,150,952
Ensembl chr 8:38,142,700...38,150,992
|
|
G |
STK26 |
serine/threonine kinase 26 |
increases expression |
ISO |
Chlormequat results in increased expression of STK26 protein |
CTD |
PMID:34958886 |
|
NCBI chr X:132,023,302...132,075,943
Ensembl chr X:132,023,302...132,075,943
|
|
G |
SUSD2 |
sushi domain containing 2 |
increases expression |
ISO |
Chlormequat results in increased expression of SUSD2 protein |
CTD |
PMID:34958886 |
|
NCBI chr22:24,181,487...24,189,106
Ensembl chr22:24,181,487...24,189,106
|
|
G |
TAF7 |
TATA-box binding protein associated factor 7 |
increases expression |
ISO |
Chlormequat results in increased expression of TAF7 protein |
CTD |
PMID:34958886 |
|
NCBI chr 5:141,318,490...141,320,784
Ensembl chr 5:141,259,884...141,320,784
|
|
G |
TCAF1 |
TRPM8 channel associated factor 1 |
increases expression |
ISO |
Chlormequat results in increased expression of TCAF1 protein |
CTD |
PMID:34958886 |
|
NCBI chr 7:143,851,375...143,902,176
Ensembl chr 7:143,851,375...143,902,198
|
|
G |
TCEANC |
transcription elongation factor A N-terminal and central domain containing |
decreases expression |
ISO |
Chlormequat results in decreased expression of TCEANC protein |
CTD |
PMID:34958886 |
|
NCBI chr X:13,653,141...13,665,409
Ensembl chr X:13,653,112...13,681,964
|
|
G |
TENT2 |
terminal nucleotidyltransferase 2 |
increases expression |
ISO |
Chlormequat results in increased expression of TENT2 protein |
CTD |
PMID:34958886 |
|
NCBI chr 5:79,612,441...79,688,246
Ensembl chr 5:79,612,120...79,688,246
|
|
G |
THEM4 |
thioesterase superfamily member 4 |
decreases expression |
ISO |
Chlormequat results in decreased expression of THEM4 protein |
CTD |
PMID:34958886 |
|
NCBI chr 1:151,870,866...151,909,511
Ensembl chr 1:151,870,866...151,909,637
|
|
G |
THOC6 |
THO complex subunit 6 |
increases expression |
ISO |
Chlormequat results in increased expression of THOC6 protein |
CTD |
PMID:34958886 |
|
NCBI chr16:3,024,035...3,027,750
Ensembl chr16:3,024,027...3,027,755
|
|
G |
TIRAP |
TIR domain containing adaptor protein |
increases expression |
ISO |
Chlormequat results in increased expression of TIRAP protein |
CTD |
PMID:34958886 |
|
NCBI chr11:126,283,093...126,294,933
Ensembl chr11:126,282,497...126,298,845
|
|
G |
TKT |
transketolase |
increases expression |
ISO |
Chlormequat results in increased expression of TKT protein |
CTD |
PMID:34958886 |
|
NCBI chr 3:53,224,712...53,256,022
Ensembl chr 3:53,224,712...53,256,052
|
|
G |
TMEM106C |
transmembrane protein 106C |
increases expression |
ISO |
Chlormequat results in increased expression of TMEM106C protein |
CTD |
PMID:34958886 |
|
NCBI chr12:47,963,596...47,968,878
Ensembl chr12:47,963,569...47,968,878
|
|
G |
TMEM184C |
transmembrane protein 184C |
decreases expression |
ISO |
Chlormequat results in decreased expression of TMEM184C protein |
CTD |
PMID:34958886 |
|
NCBI chr 4:147,617,397...147,636,721
Ensembl chr 4:147,617,386...147,672,044
|
|
G |
TMEM208 |
transmembrane protein 208 |
increases expression |
ISO |
Chlormequat results in increased expression of TMEM208 protein |
CTD |
PMID:34958886 |
|
NCBI chr16:67,227,130...67,229,278
Ensembl chr16:67,227,103...67,229,278
|
|
G |
TMEM222 |
transmembrane protein 222 |
increases expression |
ISO |
Chlormequat results in increased expression of TMEM222 protein |
CTD |
PMID:34958886 |
|
NCBI chr 1:27,322,163...27,336,400
Ensembl chr 1:27,322,145...27,336,400
|
|
G |
TNFSF11 |
TNF superfamily member 11 |
affects expression |
ISO |
Chlormequat affects the expression of TNFSF11 mRNA |
CTD |
PMID:28214531 |
|
NCBI chr13:42,562,736...42,608,013
Ensembl chr13:42,562,736...42,608,013
|
|
G |
TP53I11 |
tumor protein p53 inducible protein 11 |
increases expression |
ISO |
Chlormequat results in increased expression of TP53I11 protein |
CTD |
PMID:34958886 |
|
NCBI chr11:44,932,348...44,951,306
Ensembl chr11:44,885,903...44,951,306
|
|
G |
TRA2A |
transformer 2 alpha homolog |
increases expression |
ISO |
Chlormequat results in increased expression of TRA2A protein |
CTD |
PMID:34958886 |
|
NCBI chr 7:23,504,780...23,531,981
Ensembl chr 7:23,504,780...23,532,041
|
|
G |
TRAM2 |
translocation associated membrane protein 2 |
decreases expression |
ISO |
Chlormequat results in decreased expression of TRAM2 protein |
CTD |
PMID:34958886 |
|
NCBI chr 6:52,497,408...52,577,060
Ensembl chr 6:52,497,408...52,577,060
|
|
G |
TTC12 |
tetratricopeptide repeat domain 12 |
increases expression |
ISO |
Chlormequat results in increased expression of TTC12 protein |
CTD |
PMID:34958886 |
|
NCBI chr11:113,314,583...113,373,297
Ensembl chr11:113,314,579...113,383,544
|
|
G |
UBE2D1 |
ubiquitin conjugating enzyme E2 D1 |
multiple interactions increases expression |
ISO |
4-phenylbutyric acid inhibits the reaction [Chlormequat results in increased expression of UBE2D1 protein] |
CTD |
PMID:34958886 |
|
NCBI chr10:58,335,006...58,370,748
Ensembl chr10:58,334,979...58,370,751
|
|
G |
UCP2 |
uncoupling protein 2 |
decreases expression |
ISO |
Chlormequat results in decreased expression of UCP2 protein |
CTD |
PMID:34958886 |
|
NCBI chr11:73,974,672...73,983,202
Ensembl chr11:73,974,061...73,982,843
|
|
G |
WDR74 |
WD repeat domain 74 |
increases expression |
ISO |
Chlormequat results in increased expression of WDR74 protein |
CTD |
PMID:34958886 |
|
NCBI chr11:62,832,905...62,841,809
Ensembl chr11:62,832,342...62,841,809
|
|
G |
WSB2 |
WD repeat and SOCS box containing 2 |
decreases expression |
ISO |
Chlormequat results in decreased expression of WSB2 protein |
CTD |
PMID:34958886 |
|
NCBI chr12:118,032,687...118,062,174
Ensembl chr12:118,032,687...118,062,430
|
|
G |
ZEB1 |
zinc finger E-box binding homeobox 1 |
increases expression |
ISO |
Chlormequat results in increased expression of ZEB1 protein |
CTD |
PMID:34958886 |
|
NCBI chr10:31,318,417...31,529,804
Ensembl chr10:31,318,495...31,529,814
|
|
|
G |
BMAL1 |
basic helix-loop-helix ARNT like 1 |
decreases expression |
ISO |
cocaine hydrochloride decreases expression of Bmal1 mRNA in caudate-putamen |
RGD |
PMID:15994025 |
RGD:405866348 |
NCBI chr11:13,276,652...13,387,266
Ensembl chr11:13,276,652...13,387,266
|
|
G |
CLOCK |
clock circadian regulator |
increases expression |
ISO |
cocaine hydrochloride increases expression of Clock mRNA in caudate-putamen |
RGD |
PMID:15994025 |
RGD:405866348 |
NCBI chr 4:55,427,903...55,546,909
Ensembl chr 4:55,427,903...55,546,909
|
|
G |
CRY1 |
cryptochrome circadian regulator 1 |
decreases expression increases expression |
ISO |
cocaine hydrochloride decreases expression of Cry1 mRNA in caudate-putamen cocaine hydrochloride increases expression of Cry1 mRNA in hippocampal formation |
RGD |
PMID:15994025 PMID:15994025 |
RGD:405866347, RGD:405866347 |
NCBI chr12:106,991,364...107,093,549
Ensembl chr12:106,991,364...107,093,549
|
|
G |
CRY2 |
cryptochrome circadian regulator 2 |
decreases expression |
ISO |
cocaine hydrochloride decreases expression of Cry2 mRNA in caudate-putamen |
RGD |
PMID:15994025 |
RGD:405866347 |
NCBI chr11:45,847,118...45,883,244
Ensembl chr11:45,847,118...45,883,248
|
|
G |
NPAS2 |
neuronal PAS domain protein 2 |
decreases expression |
ISO |
cocaine hydrochloride decreases expression of hippocampal formation and caudate-putamen |
RGD |
PMID:15994025 |
RGD:405866347 |
NCBI chr 2:100,818,723...100,996,829
Ensembl chr 2:100,820,139...100,996,829
|
|
G |
PER1 |
period circadian regulator 1 |
increases expression |
ISO |
cocaine hydrochloride increases expression of Per1 mRNA in hippocampal formation and caudate-putamen |
RGD |
PMID:15994025 |
RGD:405866348 |
NCBI chr17:8,140,472...8,152,404
Ensembl chr17:8,140,467...8,156,506
|
|
G |
PER2 |
period circadian regulator 2 |
increases expression decreases expression |
ISO |
ocaine hydrochloride increases expression of Per2 mRNA in hippocampal formation cocaine hydrochloride decreases expression of Per2 mRNA in caudate-putamen |
RGD |
PMID:15994025 PMID:15994025 |
RGD:405866348, RGD:405866348 |
NCBI chr 2:238,244,044...238,300,065
Ensembl chr 2:238,244,044...238,290,102
|
|
G |
PER3 |
period circadian regulator 3 |
increases expression |
ISO |
cocaine hydrochloride increases expression of Per3 mRNA in hippocampal formation and caudate-putamen |
RGD |
PMID:15994025 |
RGD:405866348 |
NCBI chr 1:7,784,291...7,845,177
Ensembl chr 1:7,784,291...7,845,177
|
|
|
G |
CRP |
C-reactive protein |
decreases expression |
EXP |
Colesevelam Hydrochloride results in decreased expression of CRP protein |
CTD |
PMID:16616026 |
|
NCBI chr 1:159,712,289...159,714,589
Ensembl chr 1:159,712,289...159,714,589
|
|
G |
HMGCR |
3-hydroxy-3-methylglutaryl-CoA reductase |
multiple interactions increases expression |
ISO |
Colesevelam Hydrochloride promotes the reaction [Simvastatin results in increased expression of HMGCR mRNA] Colesevelam Hydrochloride results in increased expression of HMGCR mRNA |
CTD |
PMID:22120639 |
|
NCBI chr 5:75,336,529...75,362,116
Ensembl chr 5:75,336,329...75,364,001
|
|
G |
LDLR |
low density lipoprotein receptor |
increases expression |
ISO |
Colesevelam Hydrochloride results in increased expression of LDLR mRNA |
CTD |
PMID:22120639 |
|
NCBI chr19:11,089,463...11,133,820
Ensembl chr19:11,089,418...11,133,820
|
|
|
G |
ABCA1 |
ATP binding cassette subfamily A member 1 |
multiple interactions |
EXP |
Colforsin promotes the reaction [Diethylhexyl Phthalate results in decreased expression of ABCA1 mRNA] |
CTD |
PMID:37536456 |
|
NCBI chr 9:104,781,006...104,928,155
Ensembl chr 9:104,781,006...104,928,155
|
|
G |
ABCB1 |
ATP binding cassette subfamily B member 1 |
increases expression multiple interactions |
EXP |
Colforsin results in increased expression of ABCB1 mRNA N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Colforsin results in increased expression of ABCB1 mRNA] |
CTD |
PMID:12926078 |
|
NCBI chr 7:87,503,017...87,713,295
Ensembl chr 7:87,503,017...87,713,323
|
|
G |
ABCB4 |
ATP binding cassette subfamily B member 4 |
multiple interactions decreases expression |
EXP |
Colforsin inhibits the reaction [Doxorubicin results in increased expression of ABCB4 mRNA]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Colforsin results in decreased expression of ABCB4 mRNA] |
CTD |
PMID:12926078 |
|
NCBI chr 7:87,365,896...87,476,027
Ensembl chr 7:87,401,696...87,480,435
|
|
G |
ABCC2 |
ATP binding cassette subfamily C member 2 |
increases expression |
EXP |
Colforsin results in increased expression of ABCC2 mRNA; Colforsin results in increased expression of ABCC2 protein |
CTD |
PMID:19580841 PMID:26049102 |
|
NCBI chr10:99,782,640...99,852,594
Ensembl chr10:99,782,640...99,852,594
|
|
G |
ABCC4 |
ATP binding cassette subfamily C member 4 (PEL blood group) |
decreases expression multiple interactions |
EXP |
Colforsin results in decreased expression of ABCC4 mRNA Valproic Acid inhibits the reaction [Colforsin results in decreased expression of ABCC4 mRNA] |
CTD |
PMID:37385477 |
|
NCBI chr13:95,019,835...95,301,451
Ensembl chr13:95,019,835...95,301,475
|
|
G |
ABCG2 |
ATP binding cassette subfamily G member 2 (JR blood group) |
increases expression multiple interactions |
EXP |
Colforsin results in increased expression of ABCG2 mRNA Colforsin inhibits the reaction [anandamide inhibits the reaction [CREB1 protein modified form binds to ABCG2 promoter]] |
CTD |
PMID:19580841 PMID:30610963 |
|
NCBI chr 4:88,090,264...88,231,626
Ensembl chr 4:88,090,150...88,231,628
|
|
G |
ACACA |
acetyl-CoA carboxylase alpha |
increases phosphorylation |
ISO |
Colforsin results in increased phosphorylation of ACACA protein |
CTD |
PMID:18390901 |
|
NCBI chr17:37,084,992...37,406,836
Ensembl chr17:37,084,992...37,406,836
|
|
G |
ACHE |
acetylcholinesterase (Yt blood group) |
increases activity increases expression |
ISO |
Colforsin results in increased activity of ACHE protein; Colforsin results in increased activity of ACHE protein alternative form Colforsin results in increased expression of ACHE mRNA |
CTD |
PMID:18514641 |
|
NCBI chr 7:100,889,994...100,896,994
Ensembl chr 7:100,889,994...100,896,974
|
|
G |
ACSL3 |
acyl-CoA synthetase long chain family member 3 |
increases expression |
EXP |
Colforsin results in increased expression of ACSL3 mRNA |
CTD |
PMID:16751804 |
|
NCBI chr 2:222,861,036...222,944,639
Ensembl chr 2:222,860,942...222,944,639
|
|
G |
ACTA2 |
actin alpha 2, smooth muscle |
decreases expression multiple interactions |
EXP ISO |
Colforsin results in decreased expression of ACTA2 protein Colforsin inhibits the reaction [Carbon Tetrachloride results in increased expression of ACTA2 protein] |
CTD |
PMID:21603974 PMID:27590029 |
|
NCBI chr10:88,935,074...88,991,337
Ensembl chr10:88,934,822...88,991,339
|
|
G |
ADAM12 |
ADAM metallopeptidase domain 12 |
decreases expression |
EXP |
Colforsin results in decreased expression of ADAM12 mRNA |
CTD |
PMID:15313392 PMID:15967414 |
|
NCBI chr10:126,012,391...126,388,477
Ensembl chr10:126,012,381...126,388,477
|
|
G |
ADAMTS1 |
ADAM metallopeptidase with thrombospondin type 1 motif 1 |
decreases expression |
EXP |
Colforsin results in decreased expression of ADAMTS1 mRNA |
CTD |
PMID:15313392 PMID:15967414 |
|
NCBI chr21:26,835,755...26,845,409
Ensembl chr21:26,835,755...26,845,409
|
|
G |
ADCY5 |
adenylate cyclase 5 |
multiple interactions |
ISO |
ADCY5 protein results in increased susceptibility to [Colforsin co-treated with Quinpirole] |
CTD |
PMID:12223546 |
|
NCBI chr 3:123,282,296...123,449,090
Ensembl chr 3:123,282,296...123,449,090
|
|
G |
ADCY6 |
adenylate cyclase 6 |
affects response to substance |
ISO |
ADCY6 protein affects the susceptibility to Colforsin |
CTD |
PMID:12393090 |
|
NCBI chr12:48,766,194...48,789,974
Ensembl chr12:48,766,194...48,789,089
|
|
G |
ADCY9 |
adenylate cyclase 9 |
multiple interactions increases activity |
ISO |
[Colforsin co-treated with Miconazole] results in increased activity of ADCY9 protein Colforsin results in increased activity of ADCY9 protein |
CTD |
PMID:30607468 |
|
NCBI chr16:3,953,387...4,116,442
Ensembl chr16:3,953,387...4,116,442
|
|
G |
ADM |
adrenomedullin |
multiple interactions increases expression |
EXP |
cobaltous chloride inhibits the reaction [Valproic Acid inhibits the reaction [Colforsin results in increased expression of ADM mRNA]]; Valproic Acid inhibits the reaction [Colforsin results in increased expression of ADM mRNA] |
CTD |
PMID:38296531 |
|
NCBI chr11:10,305,073...10,307,397
Ensembl chr11:10,305,073...10,307,397
|
|
G |
ADRA1A |
adrenoceptor alpha 1A |
multiple interactions |
EXP |
[Colforsin co-treated with 1-Methyl-3-isobutylxanthine] affects the reaction [[Phenylephrine binds to and results in increased activity of ADRA1A protein] which affects the transport of Potassium] |
CTD |
PMID:19419905 |
|
NCBI chr 8:26,748,150...26,867,379
Ensembl chr 8:26,748,150...26,867,278
|
|
G |
ADRA2C |
adrenoceptor alpha 2C |
multiple interactions affects localization increases expression |
EXP |
AKAP13 protein modified form affects the reaction [Colforsin affects the localization of ADRA2C protein]; AKAP13 protein modified form affects the reaction [Colforsin results in increased expression of ADRA2C mRNA] |
CTD |
PMID:24701590 |
|
NCBI chr 4:3,766,385...3,768,526
Ensembl chr 4:3,766,348...3,768,526
|
|
G |
ADRB1 |
adrenoceptor beta 1 |
affects response to substance multiple interactions |
EXP |
ADRB1 protein polymorphism affects the susceptibility to Colforsin [[Colforsin co-treated with 1-Methyl-3-isobutylxanthine] results in increased activity of [ADRB1 protein binds to ADRB2 protein]] affects the reaction [KCNH2 protein results in increased transport of Potassium]; [Colforsin co-treated with 1-Methyl-3-isobutylxanthine] promotes the reaction [[ADRB1 protein binds to ADRB2 protein] which results in increased abundance of Cyclic AMP]; [Colforsin co-treated with 1-Methyl-3-isobutylxanthine] results in increased activity of [ADRB1 protein binds to ADRB2 protein] |
CTD |
PMID:14502278 PMID:19419905 |
|
NCBI chr10:114,043,866...114,046,904
Ensembl chr10:114,043,866...114,046,904
|
|
G |
ADRB2 |
adrenoceptor beta 2 |
multiple interactions increases expression increases phosphorylation |
EXP |
[[Colforsin co-treated with 1-Methyl-3-isobutylxanthine] results in increased activity of [ADRB1 protein binds to ADRB2 protein]] affects the reaction [KCNH2 protein results in increased transport of Potassium]; [Colforsin co-treated with 1-Methyl-3-isobutylxanthine] promotes the reaction [[ADRB1 protein binds to ADRB2 protein] which results in increased abundance of Cyclic AMP]; [Colforsin co-treated with 1-Methyl-3-isobutylxanthine] results in increased activity of [ADRB1 protein binds to ADRB2 protein] Colforsin results in increased expression of ADRB2 mRNA Colforsin results in increased phosphorylation of ADRB2 protein |
CTD |
PMID:14722251 PMID:19419905 PMID:24705868 |
|
NCBI chr 5:148,826,611...148,828,623
Ensembl chr 5:148,826,611...148,828,623
|
|
G |
ADRB3 |
adrenoceptor beta 3 |
decreases expression |
ISO |
Colforsin results in decreased expression of ADRB3 mRNA |
CTD |
PMID:10725275 |
|
NCBI chr 8:37,962,990...37,966,599
Ensembl chr 8:37,962,990...37,966,599
|
|
G |
AHR |
aryl hydrocarbon receptor |
multiple interactions affects localization |
EXP ISO |
[Colforsin results in increased activity of AHR protein] which results in increased expression of CXCL8 mRNA; [Colforsin results in increased activity of AHR protein] which results in increased expression of CXCL8 protein; [Colforsin results in increased activity of AHR protein] which results in increased secretion of CXCL8 protein; Colforsin promotes the reaction [[AHR protein binds to RELB protein] which binds to CXCL8 promoter]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Colforsin promotes the reaction [[AHR protein binds to RELB protein] which binds to CXCL8 promoter]]; PDE2A protein inhibits the reaction [Colforsin affects the localization of AHR protein] AHR protein inhibits the reaction [[Colforsin co-treated with Tetradecanoylphorbol Acetate] results in increased expression of PER1 mRNA] |
CTD |
PMID:15972329 PMID:17329248 PMID:17823304 PMID:23291558 |
|
NCBI chr 7:17,298,652...17,346,147
Ensembl chr 7:16,916,359...17,346,152
|
|
G |
AKAP13 |
A-kinase anchoring protein 13 |
multiple interactions |
EXP |
AKAP13 protein modified form affects the reaction [Colforsin affects the localization of ADRA2C protein]; AKAP13 protein modified form affects the reaction [Colforsin results in increased expression of ADRA2C mRNA]; AKAP13 protein modified form inhibits the reaction [Colforsin results in increased phosphorylation of CREB1 protein] |
CTD |
PMID:24701590 |
|
NCBI chr15:85,380,603...85,749,358
Ensembl chr15:85,380,571...85,749,358
|
|
G |
AKR1C3 |
aldo-keto reductase family 1 member C3 |
decreases expression |
EXP |
Colforsin results in decreased expression of AKR1C3 mRNA |
CTD |
PMID:28235592 |
|
NCBI chr10:5,048,781...5,107,686
Ensembl chr10:5,035,354...5,107,686
|
|
G |
AKT1 |
AKT serine/threonine kinase 1 |
multiple interactions |
ISO |
Colforsin inhibits the reaction [Oxidopamine results in decreased phosphorylation of AKT1 protein] |
CTD |
PMID:16339297 |
|
NCBI chr14:104,769,349...104,795,748
Ensembl chr14:104,769,349...104,795,759
|
|
G |
AKT2 |
AKT serine/threonine kinase 2 |
multiple interactions |
ISO |
Colforsin inhibits the reaction [Oxidopamine results in decreased phosphorylation of AKT2 protein] |
CTD |
PMID:16339297 |
|
NCBI chr19:40,230,317...40,285,345
Ensembl chr19:40,230,317...40,285,536
|
|
G |
AKT3 |
AKT serine/threonine kinase 3 |
multiple interactions |
ISO |
Colforsin inhibits the reaction [Oxidopamine results in decreased phosphorylation of AKT3 protein] |
CTD |
PMID:16339297 |
|
NCBI chr 1:243,488,233...243,851,079
Ensembl chr 1:243,488,233...243,851,079
|
|
G |
ALB |
albumin |
multiple interactions |
ISO |
Colforsin inhibits the reaction [Carbon Tetrachloride results in decreased expression of ALB protein] |
CTD |
PMID:27590029 |
|
NCBI chr 4:73,404,287...73,421,482
Ensembl chr 4:73,397,114...73,421,482
|
|
G |
ALPI |
alkaline phosphatase, intestinal |
multiple interactions |
EXP |
Colforsin inhibits the reaction [Methotrexate results in increased activity of ALPI protein] |
CTD |
PMID:16598758 |
|
NCBI chr 2:232,456,153...232,460,753
Ensembl chr 2:232,456,125...232,460,753
|
|
G |
ALPP |
alkaline phosphatase, placental |
multiple interactions increases expression |
EXP |
[Colforsin results in increased abundance of Cyclic AMP] which results in increased expression of ALPP mRNA; Chlorpromazine inhibits the reaction [Colforsin results in increased expression of ALPP mRNA]; Clozapine inhibits the reaction [Colforsin results in increased expression of ALPP mRNA]; Desipramine inhibits the reaction [Colforsin results in increased expression of ALPP mRNA] |
CTD |
PMID:16036225 |
|
NCBI chr 2:232,378,751...232,382,889
Ensembl chr 2:232,378,724...232,382,889
|
|
G |
AOC1 |
amine oxidase copper containing 1 |
increases activity |
ISO |
Colforsin results in increased activity of AOC1 protein |
CTD |
PMID:2860926 |
|
NCBI chr 7:150,852,120...150,861,504
Ensembl chr 7:150,824,627...150,861,504
|
|
G |
APPBP2 |
amyloid beta precursor protein binding protein 2 |
decreases expression |
EXP |
Colforsin results in decreased expression of APPBP2 mRNA |
CTD |
PMID:16751804 |
|
NCBI chr17:60,443,158...60,526,242
Ensembl chr17:60,443,158...60,526,242
|
|
G |
AR |
androgen receptor |
multiple interactions increases expression |
EXP |
AR protein affects the reaction [Colforsin results in decreased expression of SESN1 protein]; AR protein promotes the reaction [Colforsin results in increased expression of HMGCR protein]; AR protein promotes the reaction [Colforsin results in increased expression of INSIG1 protein]; AR protein promotes the reaction [Colforsin results in increased expression of KLK2 protein]; AR protein promotes the reaction [Colforsin results in increased expression of KLK3 protein]; Colforsin promotes the reaction [Metribolone results in increased activity of AR protein] Colforsin results in increased expression of AR protein |
CTD |
PMID:16751804 PMID:17219378 |
|
NCBI chr X:67,544,021...67,730,619
Ensembl chr X:67,544,021...67,730,619
|
|
G |
AREG |
amphiregulin |
increases expression multiple interactions |
EXP ISO |
Colforsin results in increased expression of AREG mRNA N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Colforsin results in increased expression of AREG mRNA]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Colforsin results in increased expression of AREG protein] |
CTD |
PMID:15284208 PMID:15313392 PMID:15474502 PMID:15967414 PMID:20378682 |
|
NCBI chr 4:74,445,136...74,455,005
Ensembl chr 4:74,445,136...74,455,005
|
|
G |
ARRB1 |
arrestin beta 1 |
multiple interactions |
EXP |
Colforsin inhibits the reaction [[carvedilol co-treated with ARRB1 protein] results in increased expression of MIR190A mRNA] |
CTD |
PMID:24334028 |
|
NCBI chr11:75,260,122...75,351,661
Ensembl chr11:75,260,122...75,351,705
|
|
G |
ATP5MF-PTCD1 |
ATP5MF-PTCD1 readthrough |
multiple interactions |
EXP |
[Colforsin co-treated with Diethylhexyl Phthalate] affects the expression of ATP5MF-PTCD1 mRNA |
CTD |
PMID:35892601 |
|
NCBI chr 7:99,416,739...99,466,167
Ensembl chr 7:99,419,749...99,466,197
|
|
G |
ATXN3 |
ataxin 3 |
decreases expression |
EXP |
Colforsin results in decreased expression of ATXN3 mRNA |
CTD |
PMID:16751804 |
|
NCBI chr14:92,044,775...92,106,582
Ensembl chr14:92,044,496...92,106,621
|
|
G |
BCL2 |
BCL2 apoptosis regulator |
multiple interactions |
EXP |
[S-(1,2-dichlorovinyl)cysteine co-treated with Colforsin] results in decreased expression of BCL2 mRNA; S-(1,2-dichlorovinyl)cysteine inhibits the reaction [Colforsin results in increased expression of BCL2 mRNA] |
CTD |
PMID:36336211 PMID:37544576 |
|
NCBI chr18:63,123,346...63,320,090
Ensembl chr18:63,123,346...63,320,128
|
|
G |
BDNF |
brain derived neurotrophic factor |
multiple interactions increases expression |
EXP ISO |
1-bromopropane inhibits the reaction [Colforsin results in increased expression of BDNF mRNA]; 1-bromopropane inhibits the reaction [Colforsin results in increased expression of BDNF protein] Colforsin inhibits the reaction [Caffeine results in decreased expression of BDNF mRNA]; Colforsin inhibits the reaction [Caffeine results in decreased expression of BDNF protein] Colforsin results in increased expression of BDNF mRNA; Colforsin results in increased expression of BDNF protein |
CTD |
PMID:19189864 PMID:35917217 |
|
NCBI chr11:27,654,893...27,722,030
Ensembl chr11:27,654,893...27,722,058
|
|
G |
BMAL1 |
basic helix-loop-helix ARNT like 1 |
increases expression |
ISO |
Colforsin results in increased expression of BMAL1 mRNA |
CTD |
PMID:30524225 |
|
NCBI chr11:13,276,652...13,387,266
Ensembl chr11:13,276,652...13,387,266
|
|
G |
BMP6 |
bone morphogenetic protein 6 |
multiple interactions |
EXP |
BMP6 protein inhibits the reaction [Colforsin results in increased expression of CYP11A1 mRNA]; BMP6 protein inhibits the reaction [Colforsin results in increased expression of CYP19A1 mRNA]; BMP6 protein inhibits the reaction [Colforsin results in increased expression of HSD3B1 mRNA]; BMP6 protein inhibits the reaction [Colforsin results in increased expression of OXT mRNA]; BMP6 protein inhibits the reaction [Colforsin results in increased expression of STAR mRNA]; BMP6 protein inhibits the reaction [Colforsin results in increased secretion of Progesterone]; FST protein inhibits the reaction [BMP6 protein inhibits the reaction [Colforsin results in increased secretion of Progesterone]] |
CTD |
PMID:18936084 |
|
NCBI chr 6:7,726,099...7,881,728
Ensembl chr 6:7,726,099...7,881,728
|
|
G |
C4A |
complement C4A (Chido/Rodgers blood group) |
multiple interactions |
EXP |
[Colforsin co-treated with Diethylhexyl Phthalate] affects the expression of C4A mRNA |
CTD |
PMID:35892601 |
|
NCBI chr 6:31,982,057...32,002,681
Ensembl chr 6:31,982,057...32,002,681
|
|
G |
C4B_2 |
complement component 4B (Chido/Rodgers blood group), copy 2 |
multiple interactions |
EXP |
[Colforsin co-treated with Diethylhexyl Phthalate] affects the expression of C4B_2 mRNA |
CTD |
PMID:35892601 |
|
|
|
G |
CACNA1G |
calcium voltage-gated channel subunit alpha1 G |
multiple interactions |
ISO |
Mibefradil inhibits the reaction [[Colforsin co-treated with 1-Methyl-3-isobutylxanthine] results in increased activity of CACNA1G protein]; Nickel inhibits the reaction [[Colforsin co-treated with 1-Methyl-3-isobutylxanthine] results in increased activity of CACNA1G protein] |
CTD |
PMID:17110049 |
|
NCBI chr17:50,560,715...50,627,474
Ensembl chr17:50,560,715...50,627,474
|
|
G |
CACNA1H |
calcium voltage-gated channel subunit alpha1 H |
multiple interactions |
ISO |
Mibefradil inhibits the reaction [[Colforsin co-treated with 1-Methyl-3-isobutylxanthine] results in increased activity of CACNA1H protein]; Nickel inhibits the reaction [[Colforsin co-treated with 1-Methyl-3-isobutylxanthine] results in increased activity of CACNA1H protein] |
CTD |
PMID:17110049 |
|
NCBI chr16:1,153,106...1,221,768
Ensembl chr16:1,153,103...1,224,169
|
|
G |
CACNA1I |
calcium voltage-gated channel subunit alpha1 I |
multiple interactions |
ISO |
Mibefradil inhibits the reaction [[Colforsin co-treated with 1-Methyl-3-isobutylxanthine] results in increased activity of CACNA1I protein]; Nickel inhibits the reaction [[Colforsin co-treated with 1-Methyl-3-isobutylxanthine] results in increased activity of CACNA1I protein] |
CTD |
PMID:17110049 |
|
NCBI chr22:39,570,753...39,689,735
Ensembl chr22:39,570,753...39,689,735
|
|
G |
CALCRL |
calcitonin receptor like receptor |
multiple interactions |
EXP |
Colforsin inhibits the reaction [EDN1 protein results in increased expression of CALCRL mRNA] |
CTD |
PMID:25194819 |
|
NCBI chr 2:187,341,964...187,448,252
Ensembl chr 2:187,341,964...187,448,460
|
|
G |
CAMKK2 |
calcium/calmodulin dependent protein kinase kinase 2 |
increases expression |
EXP |
Colforsin results in increased expression of CAMKK2 mRNA |
CTD |
PMID:16751804 |
|
NCBI chr12:121,237,692...121,297,819
Ensembl chr12:121,237,675...121,298,308
|
|
G |
CASK |
calcium/calmodulin dependent serine protein kinase |
increases phosphorylation multiple interactions |
ISO |
Colforsin results in increased phosphorylation of CASK protein Colforsin promotes the reaction [CASK protein modified form binds to TBR1 protein]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Colforsin results in increased phosphorylation of CASK protein] |
CTD |
PMID:20067577 |
|
NCBI chr X:41,514,934...41,923,554
Ensembl chr X:41,514,934...41,923,554
|
|
G |
CASP1 |
caspase 1 |
increases activity |
ISO |
Colforsin results in increased activity of CASP1 mRNA; Colforsin results in increased activity of CASP1 protein |
CTD |
PMID:21832250 |
|
NCBI chr11:105,025,443...105,036,686
Ensembl chr11:105,025,397...105,035,250
|
|
G |
CASP3 |
caspase 3 |
increases activity multiple interactions |
EXP ISO |
Colforsin results in increased activity of CASP3 protein Colforsin inhibits the reaction [Puromycin Aminonucleoside results in increased activity of CASP3 protein] KT 5720 inhibits the reaction [Colforsin results in increased activity of CASP3 protein] Colforsin inhibits the reaction [Cisplatin results in increased cleavage of and results in increased activity of CASP3 protein] |
CTD |
PMID:16396944 PMID:20131233 PMID:21745194 PMID:31278978 |
|
NCBI chr 4:184,627,696...184,649,447
Ensembl chr 4:184,627,696...184,650,062
|
|
G |
CAT |
catalase |
multiple interactions |
ISO |
Colforsin inhibits the reaction [mancozeb results in decreased activity of CAT protein] |
CTD |
PMID:29283200 |
|
NCBI chr11:34,438,934...34,472,060
Ensembl chr11:34,438,934...34,472,060
|
|
G |
CCL5 |
C-C motif chemokine ligand 5 |
multiple interactions |
ISO |
Colforsin inhibits the reaction [Reactive Oxygen Species results in increased expression of CCL5 mRNA]; Colforsin inhibits the reaction [TNF protein results in increased expression of CCL5 mRNA] |
CTD |
PMID:10495789 |
|
NCBI chr17:35,871,491...35,880,360
Ensembl chr17:35,871,491...35,880,793
|
|
G |
CD55 |
CD55 molecule (Cromer blood group) |
multiple interactions increases expression |
EXP |
3',4'-dimethoxy-alpha-naphthoflavone inhibits the reaction [Colforsin results in increased expression of CD55 mRNA] |
CTD |
PMID:22553215 |
|
NCBI chr 1:207,321,678...207,360,966
Ensembl chr 1:207,321,519...207,386,804
|
|
G |
CDC6 |
cell division cycle 6 |
increases expression |
EXP |
Colforsin results in increased expression of CDC6 mRNA |
CTD |
PMID:16751804 |
|
NCBI chr17:40,287,879...40,304,657
Ensembl chr17:40,287,879...40,304,657
|
|
G |
CDH1 |
cadherin 1 |
affects activity decreases expression increases expression |
EXP |
Colforsin affects the activity of CDH1 protein Colforsin results in decreased expression of CDH1 protein Colforsin results in increased expression of CDH1 protein |
CTD |
PMID:10413674 PMID:30983542 PMID:38301883 |
|
NCBI chr16:68,737,292...68,835,537
Ensembl chr16:68,737,292...68,835,537
|
|
G |
CDRT4 |
CMT1A duplicated region transcript 4 |
multiple interactions |
EXP |
[Colforsin co-treated with Diethylhexyl Phthalate] affects the expression of CDRT4 mRNA |
CTD |
PMID:35892601 |
|
NCBI chr17:15,436,015...15,467,621
Ensembl chr17:15,436,015...15,475,728
|
|
G |
CEBPA |
CCAAT enhancer binding protein alpha |
multiple interactions increases expression |
ISO |
Colforsin inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of CEBPA mRNA] Colforsin inhibits the reaction [mono-(2-ethylhexyl)phthalate results in decreased expression of CEBPA protein] Colforsin results in increased expression of CEBPA protein |
CTD |
PMID:17407152 PMID:21832167 |
|
NCBI chr19:33,299,934...33,302,534
Ensembl chr19:33,299,934...33,302,534
|
|
G |
CEBPB |
CCAAT enhancer binding protein beta |
increases expression multiple interactions |
ISO |
Colforsin results in increased expression of CEBPB mRNA [Atrazine co-treated with Colforsin] results in increased expression of CEBPB protein |
CTD |
PMID:14684744 PMID:25253736 |
|
NCBI chr20:50,190,583...50,192,690
Ensembl chr20:50,190,734...50,192,690
|
|
G |
CFTR |
CF transmembrane conductance regulator |
affects localization multiple interactions increases activity |
EXP ISO |
Colforsin affects the localization of CFTR protein [Colforsin co-treated with Genistein] results in increased activity of CFTR protein; AICA ribonucleotide inhibits the reaction [Colforsin results in increased activity of CFTR protein] [1-Methyl-3-isobutylxanthine co-treated with Colforsin] results in increased activity of CFTR protein; Colforsin promotes the reaction [Nimodipine results in increased activity of CFTR protein] 3-((3-trifluoromethyl)phenyl)-5-((3-carboxyphenyl)methylene)-2-thioxo-4-thiazolidinone inhibits the reaction [[[Colforsin co-treated with Genistein] results in increased activity of CFTR protein] which results in increased transport of Iodides]; 4,4'-Diisothiocyanostilbene-2,2'-Disulfonic Acid inhibits the reaction [Colforsin results in increased activity of CFTR protein]; 5-butyl-6-hydroxy-10-chlorobenzo(c)quinolizinium chloride inhibits the reaction [CFTR protein mutant form inhibits the reaction [[Colforsin co-treated with Genistein] results in increased transport of Iodides]]; 5-butyl-7-chloro-6-hydroxybenzo(c)quinolizinium inhibits the reaction [CFTR protein mutant form inhibits the reaction [[Colforsin co-treated with Genistein] results in increased transport of Iodides]]; 6-hydroxy-10-chlorobenzo(c)quinolizinium inhibits the reaction [CFTR protein mutant form inhibits the reaction [[Colforsin co-treated with Genistein] results in increased transport of Iodides]]; [1-Methyl-3-isobutylxanthine co-treated with Colforsin] results in increased activity of CFTR protein; [1-Methyl-3-isobutylxanthine co-treated with Colforsin] results in increased activity of CFTR protein mutant form; [5-butyl-6-hydroxy-10-chlorobenzo(c)quinolizinium chloride co-treated with Colforsin] results in increased activity of CFTR protein mutant form; [[Colforsin co-treated with Genistein] results in increased activity of CFTR protein] which results in increased transport of Iodides; [Colforsin co-treated with 1-Methyl-3-isobutylxanthine] results in increased activity of CFTR protein; [Colforsin co-treated with Genistein] results in increased activity of CFTR protein; [Colforsin co-treated with lumacaftor] results in increased activity of CFTR protein mutant form; [Colforsin co-treated with NS 004] results in increased activity of CFTR protein mutant form; [ivacaftor co-treated with Colforsin co-treated with lumacaftor] results in increased activity of CFTR protein mutant form; [ivacaftor co-treated with Colforsin] results in increased activity of CFTR protein; benzyloxycarbonylleucyl-leucyl-leucine aldehyde promotes the reaction [5-butyl-7-chloro-6-hydroxybenzo(c)quinolizinium inhibits the reaction [CFTR protein mutant form inhibits the reaction [[Colforsin co-treated with Genistein] results in increased transport of Iodides]]]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde promotes the reaction [miglustat inhibits the reaction [CFTR protein mutant form inhibits the reaction [[Colforsin co-treated with Genistein] results in increased transport of Iodides]]]; Brefeldin A inhibits the reaction [5-butyl-7-chloro-6-hydroxybenzo(c)quinolizinium inhibits the reaction [CFTR protein mutant form inhibits the reaction [[Colforsin co-treated with Genistein] results in increased transport of Iodides]]]; Brefeldin A inhibits the reaction [miglustat inhibits the reaction [CFTR protein mutant form inhibits the reaction [[Colforsin co-treated with Genistein] results in increased transport of Iodides]]]; CFTR protein mutant form inhibits the reaction [[Colforsin co-treated with Genistein] results in increased transport of Iodides]; Colforsin binds to and results in decreased activity of CFTR protein; Colforsin promotes the reaction [CFTR protein affects the export of Chlorides]; Colforsin promotes the reaction [Nimodipine results in increased activity of CFTR protein]; Colforsin results in increased phosphorylation of and results in increased activity of CFTR protein; fenamic acid inhibits the reaction [[[Colforsin co-treated with Genistein] results in increased activity of CFTR protein] which results in increased transport of Iodides]; fenamic acid inhibits the reaction [Colforsin results in increased activity of CFTR protein]; geldanamycin promotes the reaction [5-butyl-7-chloro-6-hydroxybenzo(c)quinolizinium inhibits the reaction [CFTR protein mutant form inhibits the reaction [[Colforsin co-treated with Genistein] results in increased transport of Iodides]]]; geldanamycin promotes the reaction [miglustat inhibits the reaction [CFTR protein mutant form inhibits the reaction [[Colforsin co-treated with Genistein] results in increased transport of Iodides]]]; Glyburide inhibits the reaction [[[Colforsin co-treated with Genistein] results in increased activity of CFTR protein] which results in increased transport of Iodides]; Glyburide inhibits the reaction [Colforsin results in increased activity of CFTR protein]; miglustat inhibits the reaction [CFTR protein mutant form inhibits the reaction [[Colforsin co-treated with Genistein] results in increased transport of Iodides]]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Colforsin results in increased activity of CFTR protein]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Colforsin results in increased phosphorylation of CFTR protein]; Ozone inhibits the reaction [Colforsin results in increased activity of CFTR protein]; Thapsigargin promotes the reaction [5-butyl-7-chloro-6-hydroxybenzo(c)quinolizinium inhibits the reaction [CFTR protein mutant form inhibits the reaction [[Colforsin co-treated with Genistein] results in increased transport of Iodides]]]; Thapsigargin promotes the reaction [miglustat inhibits the reaction [CFTR protein mutant form inhibits the reaction [[Colforsin co-treated with Genistein] results in increased transport of Iodides]]]; VRT 532 analog promotes the reaction [Colforsin results in increased activity of CFTR protein mutant form]; VRT 532 promotes the reaction [Colforsin results in increased activity of CFTR protein mutant form] Colforsin analog results in increased activity of CFTR protein mutant form; Colforsin results in increased activity of CFTR protein; Colforsin results in increased activity of CFTR protein mutant form |
CTD |
PMID:12519745 PMID:12914781 PMID:14502435 PMID:14967738 PMID:15163550 PMID:15194485 PMID:15246976 PMID:15389550 PMID:15517342 PMID:15763242 PMID:15790911 PMID:15986093 PMID:15994425 PMID:16027156 PMID:16038730 PMID:17596272 PMID:18230692 PMID:19061877 PMID:21724857 PMID:22074181 PMID:32374624 PMID:33872679 More...
|
|
NCBI chr 7:117,480,025...117,668,665
Ensembl chr 7:117,287,120...117,715,971
|
|
G |
CGA |
glycoprotein hormones, alpha polypeptide |
increases secretion increases expression multiple interactions |
EXP ISO |
Colforsin results in increased secretion of CGA protein Colforsin results in increased expression of CGA protein Colforsin results in increased expression of CGA mRNA Colforsin promotes the reaction [CGA protein results in increased abundance of Cyclic AMP]; perfluorobutanesulfonic acid inhibits the reaction [Colforsin results in increased expression of CGA protein]; perfluorooctane sulfonic acid inhibits the reaction [Colforsin results in increased expression of CGA protein] Colforsin inhibits the reaction [ESR2 gene mutant form inhibits the reaction [CGA protein results in increased abundance of Cyclic AMP]] |
CTD |
PMID:8404651 PMID:16503475 PMID:20378682 PMID:33144174 |
|
NCBI chr 6:87,085,498...87,095,106
Ensembl chr 6:87,085,498...87,095,106
|
|
G |
CGB1 |
chorionic gonadotropin subunit beta 1 |
increases expression multiple interactions increases secretion |
EXP |
Colforsin results in increased expression of CGB1 mRNA Valproic Acid inhibits the reaction [Colforsin results in increased expression of CGB1 mRNA]; Valproic Acid inhibits the reaction [Colforsin results in increased secretion of CGB1 protein] |
CTD |
PMID:37385477 |
|
NCBI chr19:49,035,569...49,036,895
Ensembl chr19:49,035,569...49,036,895
|
|
G |
CGB2 |
chorionic gonadotropin subunit beta 2 |
increases expression |
EXP |
Colforsin results in increased expression of CGB2 mRNA |
CTD |
PMID:29679653 |
|
NCBI chr19:49,031,890...49,033,238
Ensembl chr19:49,031,890...49,033,238
|
|
G |
CGB3 |
chorionic gonadotropin subunit beta 3 |
multiple interactions increases expression increases secretion |
EXP |
[Cadmium Chloride results in increased abundance of Cadmium] inhibits the reaction [Colforsin results in increased expression of CGB3 mRNA]; cobaltous chloride inhibits the reaction [Valproic Acid promotes the reaction [Colforsin results in increased expression of CGB3 mRNA]]; Colforsin promotes the reaction [Benzo(a)pyrene results in increased expression of CGB3 mRNA]; Colforsin promotes the reaction [CGB3 protein results in increased abundance of Cyclic AMP]; Flame Retardants inhibits the reaction [[CGB3 protein co-treated with Colforsin] results in increased abundance of Cyclic AMP]; Flame Retardants inhibits the reaction [Colforsin promotes the reaction [CGB3 protein results in increased abundance of Cyclic AMP]]; hexabromocyclododecane inhibits the reaction [Colforsin promotes the reaction [CGB3 protein results in increased abundance of Cyclic AMP]]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide affects the reaction [Colforsin results in increased expression of CGB3 mRNA]; Valproic Acid promotes the reaction [Colforsin results in increased expression of CGB3 mRNA]; Valproic Acid promotes the reaction [Colforsin results in increased expression of CGB3 protein] Colforsin results in increased expression of CGB3 mRNA; Colforsin results in increased expression of CGB3 protein Colforsin results in increased secretion of CGB3 protein |
CTD |
PMID:23347875 PMID:24361490 PMID:35908931 PMID:38296531 |
|
NCBI chr19:49,022,869...49,024,333
Ensembl chr19:49,022,869...49,024,333
|
|
G |
CGB7 |
chorionic gonadotropin subunit beta 7 |
multiple interactions increases expression |
EXP |
perfluorobutanesulfonic acid inhibits the reaction [Colforsin results in increased expression of CGB7 mRNA]; perfluorooctane sulfonic acid inhibits the reaction [Colforsin results in increased expression of CGB7 mRNA] |
CTD |
PMID:33144174 |
|
NCBI chr19:49,054,274...49,057,749
Ensembl chr19:49,054,274...49,058,860
|
|
G |
CIDEC |
cell death inducing DFFA like effector c |
increases expression |
ISO |
Colforsin results in increased expression of CIDEC protein |
CTD |
PMID:21097823 |
|
NCBI chr 3:9,866,710...9,880,253
Ensembl chr 3:9,866,711...9,880,255
|
|
G |
CKMT1A |
creatine kinase, mitochondrial 1A |
multiple interactions |
EXP |
[Colforsin co-treated with Diethylhexyl Phthalate] affects the expression of CKMT1A mRNA |
CTD |
PMID:35892601 |
|
NCBI chr15:43,692,786...43,699,222
Ensembl chr15:43,692,886...43,699,222 Ensembl chr15:43,692,886...43,699,222
|
|
G |
CNR1 |
cannabinoid receptor 1 |
multiple interactions affects response to substance increases activity |
EXP |
(1-(2-morpholin-4-yl-ethyl)-1H-indol-3-yl)-(2,2,3,3-tetramethylcyclopropyl)methanone inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR1 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; (1-pentyl-1H-indol-3-yl)(2,2,3,3-tetramethylcyclopropyl)methanone inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR1 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; (4-ethyl-1-naphthalenyl)(1-(5-fluoropentyl)-1H-indol-3-yl)methanone inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR1 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; 1-(2-cyclohexylethyl)-3-(2-methoxyphenylacetyl)indole inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR1 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; 1-(5-fluoropentyl)-3-(4-methyl-1-naphthoyl)indole analog inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR1 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; 1-(5-fluoropentyl)-3-(4-methyl-1-naphthoyl)indole inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR1 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; 1-(cyclohexylmethyl)-1H-indole-3-carboxylic acid 8-quinolinyl ester inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR1 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; 1-pentyfluoro-1H-indole-3-carboxylic acid 8-quinolinyl ester inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR1 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; 1-pentyl-1H-indole-3-carboxylic acid 8-quinolinyl ester inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR1 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; 1-pentyl-3-(1-naphthoyl)indole analog inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR1 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; 2-(4-methoxyphenyl)-1-(1-pentyl-indol-3-yl)methanone inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR1 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; 3-((adamantan-1-yl)carbonyl)-1-pentylindole analog inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR1 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; 3-((adamantan-1-yl)carbonyl)-1-pentylindole inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR1 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; 3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol inhibits the reaction [Colforsin results in increased activity of CNR1 protein]; [3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR1 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]; [Dronabinol binds to and results in increased activity of CNR1 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]; [Medroxyprogesterone Acetate co-treated with Estradiol co-treated with Colforsin] results in increased expression of CNR1 mRNA; AM 6527 analog inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR1 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; AM 6527 inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR1 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; CNR1 protein inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]; delta(9)-tetrahydrocannabinolic acid inhibits the reaction [3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol inhibits the reaction [Colforsin results in increased activity of CNR1 protein]]; delta(9)-tetrahydrocannabinolic acid inhibits the reaction [Colforsin results in increased activity of CNR1 protein]; Dronabinol inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR1 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; Dronabinol inhibits the reaction [Colforsin results in increased activity of CNR1 protein]; FDU-PB-22 inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR1 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; FUB-PB-22 compound inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR1 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; Indazoles analog inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR1 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; Indoles analog inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR1 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; N-(1-adamantyl)-1-(5-fluoropentyl)-1H-indazole-3-carboxamide inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR1 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; N-(1-adamantyl)-1-pentylindazole-3-carboxamide analog inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR1 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; N-(adamantan-1-yl)-1-(5-fluoropentyl)-1H-indole-3-carboxamide inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR1 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; N-(adamtan-1-yl)-1-pentyl-1H-indole-3-carboxamide analog inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR1 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; N-(adamtan-1-yl)-1-pentyl-1H-indole-3-carboxamide inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR1 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; N-1-naphthalenyl-1-pentyl-1H-indazole-3-carboxamide analog inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR1 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; N-1-naphthalenyl-1-pentyl-1H-indazole-3-carboxamide inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR1 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; napht-1-yl 1-(5-fluoropentyl)-1H-indole-3-carboxylate inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR1 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; THJ-2201 inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR1 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; XLR-11 analog inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR1 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; XLR-11 inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR1 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]] CNR1 protein affects the susceptibility to Colforsin |
CTD |
PMID:27429655 PMID:27527584 PMID:28861508 PMID:31154070 |
|
NCBI chr 6:88,139,864...88,167,349
Ensembl chr 6:88,139,864...88,166,347
|
|
G |
CNR2 |
cannabinoid receptor 2 |
multiple interactions increases activity affects response to substance |
EXP ISO |
(1-(2-morpholin-4-yl-ethyl)-1H-indol-3-yl)-(2,2,3,3-tetramethylcyclopropyl)methanone inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR2 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; (1-pentyl-1H-indol-3-yl)(2,2,3,3-tetramethylcyclopropyl)methanone inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR2 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; (4-ethyl-1-naphthalenyl)(1-(5-fluoropentyl)-1H-indol-3-yl)methanone inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR2 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; 1-(2-cyclohexylethyl)-3-(2-methoxyphenylacetyl)indole inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR2 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; 1-(5-fluoropentyl)-3-(4-methyl-1-naphthoyl)indole analog inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR2 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; 1-(5-fluoropentyl)-3-(4-methyl-1-naphthoyl)indole inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR2 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; 1-(cyclohexylmethyl)-1H-indole-3-carboxylic acid 8-quinolinyl ester inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR2 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; 1-pentyfluoro-1H-indole-3-carboxylic acid 8-quinolinyl ester inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR2 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; 1-pentyl-1H-indole-3-carboxylic acid 8-quinolinyl ester inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR2 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; 1-pentyl-3-(1-naphthoyl)indole analog inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR2 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; 2-(4-methoxyphenyl)-1-(1-pentyl-indol-3-yl)methanone inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR2 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; 3-((adamantan-1-yl)carbonyl)-1-pentylindole analog inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR2 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; 3-((adamantan-1-yl)carbonyl)-1-pentylindole inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR2 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; 3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol inhibits the reaction [Colforsin results in increased activity of CNR2 protein]; [3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR2 protein] inhibits the reaction [Colforsin results in increased abundance of Cyclic AMP]; [3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR2 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]; [Dronabinol binds to and results in increased activity of CNR2 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]; [Medroxyprogesterone Acetate co-treated with Estradiol co-treated with Colforsin] results in increased expression of CNR2 mRNA; [virodhamine binds to and results in increased activity of CNR2 protein] inhibits the reaction [Colforsin results in increased abundance of Cyclic AMP]; AM 6527 analog inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR2 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; AM 6527 inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR2 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; CNR2 protein inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]; Dronabinol inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR2 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; Dronabinol inhibits the reaction [Colforsin results in increased activity of CNR2 protein]; FDU-PB-22 inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR2 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; FUB-PB-22 compound inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR2 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; Indazoles analog inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR2 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; Indoles analog inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR2 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; N-(1-adamantyl)-1-(5-fluoropentyl)-1H-indazole-3-carboxamide inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR2 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; N-(1-adamantyl)-1-pentylindazole-3-carboxamide analog inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR2 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; N-(adamantan-1-yl)-1-(5-fluoropentyl)-1H-indole-3-carboxamide inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR2 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; N-(adamtan-1-yl)-1-pentyl-1H-indole-3-carboxamide analog inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR2 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; N-(adamtan-1-yl)-1-pentyl-1H-indole-3-carboxamide inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR2 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; N-1-naphthalenyl-1-pentyl-1H-indazole-3-carboxamide analog inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR2 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; N-1-naphthalenyl-1-pentyl-1H-indazole-3-carboxamide inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR2 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; napht-1-yl 1-(5-fluoropentyl)-1H-indole-3-carboxylate inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR2 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; Pertussis Toxin inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR2 protein] inhibits the reaction [Colforsin results in increased abundance of Cyclic AMP]]; Pertussis Toxin inhibits the reaction [[virodhamine binds to and results in increased activity of CNR2 protein] inhibits the reaction [Colforsin results in increased abundance of Cyclic AMP]]; SR 144528 inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR2 protein] inhibits the reaction [Colforsin results in increased abundance of Cyclic AMP]]; SR 144528 inhibits the reaction [[virodhamine binds to and results in increased activity of CNR2 protein] inhibits the reaction [Colforsin results in increased abundance of Cyclic AMP]]; THJ-2201 inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR2 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; XLR-11 analog inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR2 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; XLR-11 inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR2 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]] CNR2 protein affects the susceptibility to Colforsin |
CTD |
PMID:17558435 PMID:27429655 PMID:27527584 PMID:28861508 PMID:30504240 PMID:31154070 More...
|
|
NCBI chr 1:23,870,515...23,913,362
Ensembl chr 1:23,870,515...23,913,362
|
|
G |
CREB1 |
cAMP responsive element binding protein 1 |
increases activity increases expression increases phosphorylation multiple interactions |
ISO EXP |
Colforsin results in increased activity of CREB1 protein Colforsin results in increased expression of CREB1 mRNA; Colforsin results in increased expression of CREB1 protein modified form Colforsin results in increased phosphorylation of CREB1 protein 3-(3-chloro-4-hydroxyphenylamino)-4-(4-nitrophenyl)-1H-pyrrole-2,5-dione inhibits the reaction [Resveratrol inhibits the reaction [Colforsin results in increased phosphorylation of CREB1 protein]]; Colforsin inhibits the reaction [Caffeine results in decreased expression of CREB1 mRNA]; Colforsin inhibits the reaction [Carbon Tetrachloride results in decreased expression of CREB1 protein modified form]; Colforsin promotes the reaction [CREB1 protein binds to POU1F1 promoter]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Colforsin results in increased phosphorylation of CREB1 protein]; Okadaic Acid inhibits the reaction [Resveratrol inhibits the reaction [Colforsin results in increased phosphorylation of CREB1 protein]]; Resveratrol inhibits the reaction [Colforsin promotes the reaction [CREB1 protein binds to POU1F1 promoter]]; Resveratrol inhibits the reaction [Colforsin results in increased phosphorylation of CREB1 protein]; SIRT1 mutant form inhibits the reaction [Resveratrol inhibits the reaction [Colforsin results in increased phosphorylation of CREB1 protein]]; SIRT1 protein inhibits the reaction [Colforsin results in increased phosphorylation of CREB1 protein]; SIRT1 protein mutant form inhibits the reaction [Colforsin results in increased phosphorylation of CREB1 protein] AKAP13 protein modified form inhibits the reaction [Colforsin results in increased phosphorylation of CREB1 protein]; anandamide inhibits the reaction [Colforsin results in increased phosphorylation of CREB1 protein]; Colforsin inhibits the reaction [anandamide inhibits the reaction [CREB1 protein modified form binds to ABCG2 promoter]]; Colforsin results in increased phosphorylation of and results in increased activity of CREB1 protein [Colforsin co-treated with 1-Methyl-3-isobutylxanthine] results in increased phosphorylation of CREB1 protein; alisol B inhibits the reaction [[Colforsin co-treated with 1-Methyl-3-isobutylxanthine] results in increased phosphorylation of CREB1 protein]; oxophenylarsine inhibits the reaction [Colforsin results in increased activity of CREB1 protein]; oxophenylarsine inhibits the reaction [Colforsin results in increased phosphorylation of CREB1 protein]; RTKI cpd inhibits the reaction [Colforsin results in increased phosphorylation of CREB1 protein] |
CTD |
PMID:10908723 PMID:11113530 PMID:15522277 PMID:17141199 PMID:17322281 PMID:17460731 PMID:17680988 PMID:18004999 PMID:20512473 PMID:21745194 PMID:23292070 PMID:24701590 PMID:27509375 PMID:27590029 PMID:28051915 PMID:28601556 PMID:29179997 PMID:30610963 PMID:35917217 More...
|
|
NCBI chr 2:207,529,962...207,605,988
Ensembl chr 2:207,529,737...207,605,988
|
|
G |
CREBBP |
CREB binding protein |
multiple interactions |
EXP |
Colforsin promotes the reaction [GCM1 protein binds to CREBBP protein]; CREBBP protein affects the reaction [Colforsin results in increased activity of GCM1 protein] |
CTD |
PMID:16166624 |
|
NCBI chr16:3,725,054...3,880,713
Ensembl chr16:3,725,054...3,880,713
|
|
G |
CREM |
cAMP responsive element modulator |
increases expression |
ISO |
Colforsin results in increased expression of CREM mRNA; Colforsin results in increased expression of CREM mRNA alternative form; Colforsin results in increased expression of CREM protein |
CTD |
PMID:8810303 PMID:12791704 |
|
NCBI chr10:35,126,846...35,212,958
Ensembl chr10:35,126,791...35,212,958
|
|
G |
CRH |
corticotropin releasing hormone |
multiple interactions increases secretion |
ISO EXP |
CRH protein inhibits the reaction [[Colforsin co-treated with CGB3 protein] results in increased chemical synthesis of Cyclic AMP]; CRH protein inhibits the reaction [[Colforsin co-treated with CGB3 protein] results in increased chemical synthesis of Testosterone]; CRH protein inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]; CRH protein inhibits the reaction [Colforsin results in increased chemical synthesis of Testosterone] [perfluorooctane sulfonic acid co-treated with Colforsin] results in increased expression of CRH mRNA Colforsin results in increased secretion of CRH protein |
CTD |
PMID:2153673 PMID:33144174 |
|
NCBI chr 8:66,176,376...66,178,464
Ensembl chr 8:66,176,376...66,178,464
|
|
G |
CRLS1 |
cardiolipin synthase 1 |
increases expression |
EXP |
Colforsin results in increased expression of CRLS1 mRNA |
CTD |
PMID:16751804 |
|
NCBI chr20:6,005,938...6,040,053
Ensembl chr20:6,006,093...6,040,053
|
|
G |
CRYAB |
crystallin alpha B |
multiple interactions |
ISO |
Colforsin inhibits the reaction [arsenite results in increased expression of CRYAB protein] |
CTD |
PMID:8769853 |
|
NCBI chr11:111,908,564...111,923,740
Ensembl chr11:111,908,564...111,923,722
|
|
G |
CSH1 |
chorionic somatomammotropin hormone 1 |
decreases expression multiple interactions |
EXP |
Colforsin results in decreased expression of CSH1 mRNA [Valproic Acid co-treated with Colforsin] results in decreased expression of CSH1 mRNA; [Valproic Acid co-treated with Colforsin] results in decreased expression of CSH1 protein; cobaltous chloride promotes the reaction [Valproic Acid promotes the reaction [Colforsin results in decreased expression of CSH1 mRNA]]; Valproic Acid promotes the reaction [Colforsin results in decreased expression of CSH1 mRNA] |
CTD |
PMID:29679653 PMID:38296531 |
|
NCBI chr17:63,894,918...63,896,574
Ensembl chr17:63,894,909...63,896,661
|
|
G |
CSH2 |
chorionic somatomammotropin hormone 2 |
decreases expression |
EXP |
Colforsin results in decreased expression of CSH2 mRNA |
CTD |
PMID:37385477 |
|
NCBI chr17:63,872,012...63,873,729
Ensembl chr17:63,872,012...63,873,766
|
|
G |
CXCL8 |
C-X-C motif chemokine ligand 8 |
multiple interactions |
ISO EXP |
Colforsin promotes the reaction [Tetrachlorodibenzodioxin results in increased expression of CXCL15 mRNA] [Colforsin results in increased activity of AHR protein] which results in increased expression of CXCL8 mRNA; [Colforsin results in increased activity of AHR protein] which results in increased expression of CXCL8 protein; [Colforsin results in increased activity of AHR protein] which results in increased secretion of CXCL8 protein; [nickel sulfate co-treated with Colforsin] results in increased secretion of CXCL8 protein; Colforsin promotes the reaction [[AHR protein binds to RELB protein] which binds to CXCL8 promoter]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Colforsin promotes the reaction [[AHR protein binds to RELB protein] which binds to CXCL8 promoter]] |
CTD |
PMID:17823304 PMID:19063610 PMID:23526216 |
|
NCBI chr 4:73,740,569...73,743,716
Ensembl chr 4:73,740,519...73,743,716
|
|
G |
CYP11A1 |
cytochrome P450 family 11 subfamily A member 1 |
affects expression multiple interactions increases expression |
EXP ISO |
Colforsin affects the expression of CYP11A1 mRNA [Colforsin co-treated with Zearalenone] results in increased expression of CYP11A1 mRNA Colforsin results in increased expression of CYP11A1 mRNA [Colforsin co-treated with triptolide] results in decreased expression of CYP11A1 mRNA; Aminoglutethimide inhibits the reaction [Colforsin results in increased expression of CYP11A1 mRNA]; BMP6 protein inhibits the reaction [Colforsin results in increased expression of CYP11A1 mRNA]; Hexachlorocyclohexane inhibits the reaction [Colforsin results in increased expression of CYP11A1 mRNA]; Metyrapone inhibits the reaction [Colforsin results in increased expression of CYP11A1 mRNA]; Valproic Acid affects the reaction [Colforsin affects the expression of CYP11A1 mRNA] [Atrazine co-treated with Colforsin] results in increased expression of CYP11A1 mRNA; RARRES2 protein inhibits the reaction [Colforsin results in increased expression of CYP11A1 protein] |
CTD |
PMID:14691014 PMID:16935330 PMID:17080404 PMID:18936084 PMID:20726872 PMID:22446829 PMID:22948218 PMID:25253736 PMID:25765474 PMID:25871633 PMID:26783879 PMID:28235592 PMID:31557376 More...
|
|
NCBI chr15:74,337,762...74,367,646
Ensembl chr15:74,337,759...74,367,646
|
|
G |
CYP11B1 |
cytochrome P450 family 11 subfamily B member 1 |
increases activity increases expression multiple interactions |
EXP |
Colforsin results in increased activity of CYP11B1 protein Colforsin results in increased expression of CYP11B1 mRNA [1-chloro-4-(2,2-dichloro-1-(4-chlorophenyl)ethenyl)-3-(methylsulfonyl)benzene co-treated with Colforsin] affects the expression of CYP11B1 mRNA; [Colforsin co-treated with triptolide] results in decreased expression of CYP11B1 mRNA; Hexachlorocyclohexane inhibits the reaction [Colforsin results in increased expression of CYP11B1 mRNA] |
CTD |
PMID:12525251 PMID:17080404 PMID:19164467 PMID:19900470 PMID:21256172 PMID:25765474 PMID:25871633 PMID:28235592 PMID:31557376 More...
|
|
NCBI chr 8:142,872,357...142,879,825
Ensembl chr 8:142,872,356...142,879,846
|
|
G |
CYP11B2 |
cytochrome P450 family 11 subfamily B member 2 |
increases expression multiple interactions |
EXP |
Colforsin results in increased expression of CYP11B2 mRNA [1-chloro-4-(2,2-dichloro-1-(4-chlorophenyl)ethenyl)-3-(methylsulfonyl)benzene co-treated with Colforsin] affects the expression of CYP11B2 mRNA; [Colforsin co-treated with triptolide] results in decreased expression of CYP11B2 mRNA; Hexachlorocyclohexane inhibits the reaction [Colforsin results in increased expression of CYP11B2 mRNA]; Ketoconazole promotes the reaction [Colforsin results in increased expression of CYP11B2 mRNA] |
CTD |
PMID:16935330 PMID:17080404 PMID:19164467 PMID:19900470 PMID:21256172 PMID:22446829 PMID:25765474 PMID:25871633 PMID:28235592 PMID:31557376 More...
|
|
NCBI chr 8:142,910,559...142,917,843
Ensembl chr 8:142,910,559...142,917,843
|
|
G |
CYP17A1 |
cytochrome P450 family 17 subfamily A member 1 |
increases expression multiple interactions |
ISO EXP |
Colforsin results in increased expression of CYP17A1 mRNA [Colforsin co-treated with triptolide] results in decreased expression of CYP17A1 mRNA; Apigenin inhibits the reaction [Colforsin results in increased expression of CYP17A1 mRNA]; Hexachlorocyclohexane inhibits the reaction [Colforsin results in increased expression of CYP17A1 mRNA]; Ketoconazole inhibits the reaction [Colforsin results in increased expression of CYP17A1 mRNA]; Metyrapone inhibits the reaction [Colforsin results in increased expression of CYP17A1 mRNA]; TGFB1 protein inhibits the reaction [Colforsin results in increased expression of CYP17A1 mRNA]; Valproic Acid inhibits the reaction [Colforsin results in increased expression of CYP17A1 mRNA] |
CTD |
PMID:15625562 PMID:15886251 PMID:16935330 PMID:17080404 PMID:20726872 PMID:22446829 PMID:22461451 PMID:23370353 PMID:25871633 PMID:28235592 PMID:31100596 PMID:31557376 More...
|
|
NCBI chr10:102,830,531...102,837,413
Ensembl chr10:102,830,531...102,837,472
|
|
G |
CYP19A1 |
cytochrome P450 family 19 subfamily A member 1 |
increases activity increases expression multiple interactions |
EXP ISO |
Colforsin results in increased activity of CYP19A1 protein Colforsin results in increased expression of CYP19A1 mRNA 1-(6-((3-methoxyestra-1,3,5(10)-trien-17-yl)amino)hexyl)-1H-pyrrole-2,5-dione inhibits the reaction [Colforsin results in increased expression of CYP19A1 mRNA]; [Colforsin co-treated with Tetradecanoylphorbol Acetate] results in increased expression of CYP19A1 mRNA; [Colforsin results in increased activity of CYP19A1 protein] which results in increased abundance of Estradiol; [Colforsin results in increased activity of CYP19A1 protein] which results in increased abundance of Testosterone; Alitretinoin inhibits the reaction [NR5A2 protein promotes the reaction [[Colforsin co-treated with Tetradecanoylphorbol Acetate] results in increased expression of CYP19A1 mRNA]]; Aminoglutethimide inhibits the reaction [Colforsin results in increased expression of CYP19A1 mRNA]; Atrazine inhibits the reaction [Colforsin results in increased expression of CYP19A1 mRNA]; BMP6 protein inhibits the reaction [Colforsin results in increased expression of CYP19A1 mRNA]; Hexachlorocyclohexane inhibits the reaction [Colforsin results in increased expression of CYP19A1 mRNA]; mono-(2-ethylhexyl)phthalate inhibits the reaction [Colforsin results in increased expression of CYP19A1 mRNA]; NR4A1 protein inhibits the reaction [Colforsin results in increased expression of CYP19A1 mRNA]; NR4A2 protein inhibits the reaction [Colforsin results in increased expression of CYP19A1 mRNA]; NR4A3 protein inhibits the reaction [Colforsin results in increased expression of CYP19A1 mRNA]; NR5A2 protein promotes the reaction [[Colforsin co-treated with Tetradecanoylphorbol Acetate] results in increased expression of CYP19A1 mRNA]; Valproic Acid inhibits the reaction [Colforsin results in increased activity of CYP19A1 protein]; Valproic Acid inhibits the reaction [Colforsin results in increased expression of CYP19A1 mRNA]; ZNF461 protein inhibits the reaction [Colforsin results in increased expression of CYP19A1 mRNA] RARRES2 protein inhibits the reaction [Colforsin results in increased expression of CYP19A1 protein] Colforsin results in increased expression of CYP19A1 mRNA; Colforsin results in increased expression of CYP19A1 protein |
CTD |
PMID:14691014 PMID:16357189 PMID:16935330 PMID:16996190 PMID:17080404 PMID:18936084 PMID:19822197 PMID:20087668 PMID:20723554 PMID:20726872 PMID:22446829 PMID:22461451 PMID:22948218 PMID:24361490 PMID:25765474 PMID:25871633 PMID:28235592 PMID:28859905 PMID:29701941 PMID:31100596 PMID:37551828 More...
|
|
NCBI chr15:51,208,057...51,338,596
Ensembl chr15:51,208,057...51,338,601
|
|
G |
CYP1A1 |
cytochrome P450 family 1 subfamily A member 1 |
multiple interactions affects expression |
ISO EXP |
Colforsin inhibits the reaction [Lipopolysaccharides results in decreased activity of CYP1A1 protein] Valproic Acid affects the reaction [Colforsin affects the expression of CYP1A1 mRNA] Colforsin affects the reaction [Benzo(a)pyrene results in increased expression of CYP1A1 mRNA] |
CTD |
PMID:1849469 PMID:15710352 PMID:20726872 |
|
NCBI chr15:74,719,542...74,725,528
Ensembl chr15:74,719,542...74,725,536
|
|
G |
CYP1A2 |
cytochrome P450 family 1 subfamily A member 2 |
multiple interactions |
ISO |
Colforsin affects the reaction [Benzo(a)pyrene results in increased expression of CYP1A2 mRNA] Colforsin inhibits the reaction [Lipopolysaccharides results in decreased activity of CYP1A2 protein] |
CTD |
PMID:1849469 PMID:15710352 |
|
NCBI chr15:74,748,845...74,756,607
Ensembl chr15:74,748,845...74,756,607
|
|
G |
CYP1B1 |
cytochrome P450 family 1 subfamily B member 1 |
increases expression |
ISO |
Colforsin results in increased expression of CYP1B1 mRNA; Colforsin results in increased expression of CYP1B1 protein |
CTD |
PMID:7588239 |
|
NCBI chr 2:38,067,509...38,076,151
Ensembl chr 2:38,066,973...38,109,902
|
|
G |
CYP21A2 |
cytochrome P450 family 21 subfamily A member 2 |
multiple interactions increases expression |
EXP |
[Colforsin co-treated with Ketoconazole] results in decreased expression of CYP21A2 mRNA; [Colforsin co-treated with triptolide] results in decreased expression of CYP21A2 mRNA; Apigenin inhibits the reaction [Colforsin results in increased expression of CYP21A2 mRNA]; daidzein inhibits the reaction [Colforsin results in increased expression of CYP21A2 mRNA]; Valproic Acid inhibits the reaction [Colforsin results in increased expression of CYP21A2 mRNA] |
CTD |
PMID:16935330 PMID:20726872 PMID:21256172 PMID:22446829 PMID:23370353 PMID:25871633 PMID:28235592 PMID:31557376 More...
|
|
NCBI chr 6:32,038,415...32,041,644
Ensembl chr 6:32,038,327...32,041,644
|
|
G |
CYP2A6 |
cytochrome P450 family 2 subfamily A member 6 |
increases expression |
ISO |
Colforsin results in increased expression of CYP2A5 mRNA |
CTD |
PMID:11162586 |
|
NCBI chr19:40,843,541...40,850,447
Ensembl chr19:40,843,541...40,850,447
|
|
G |
CYP2E1 |
cytochrome P450 family 2 subfamily E member 1 |
multiple interactions |
EXP |
[S-(1,2-dichlorovinyl)cysteine co-treated with Colforsin] results in decreased expression of CYP2E1 mRNA |
CTD |
PMID:37544576 |
|
NCBI chr10:133,527,363...133,539,123
Ensembl chr10:133,520,406...133,561,220
|
|
G |
CYP3A4 |
cytochrome P450 family 3 subfamily A member 4 |
multiple interactions increases expression |
EXP |
[S-(1,2-dichlorovinyl)cysteine co-treated with Colforsin] results in increased expression of CYP3A4 mRNA Colforsin results in increased expression of CYP3A4 mRNA |
CTD |
PMID:37544576 |
|
NCBI chr 7:99,756,967...99,784,184
Ensembl chr 7:99,756,960...99,784,248
|
|
G |
DBH |
dopamine beta-hydroxylase |
multiple interactions increases expression |
ISO |
Colforsin inhibits the reaction [Atrazine results in decreased expression of DBH protein]; Colforsin inhibits the reaction [Simazine results in decreased expression of DBH protein] Colforsin results in increased expression of DBH protein |
CTD |
PMID:14550852 |
|
NCBI chr 9:133,636,363...133,659,329
Ensembl chr 9:133,636,363...133,659,329
|
|
G |
DCT |
dopachrome tautomerase |
increases expression |
EXP |
Colforsin results in increased expression of DCT mRNA; Colforsin results in increased expression of DCT protein |
CTD |
PMID:17460731 PMID:28601556 |
|
NCBI chr13:94,436,811...94,549,406
Ensembl chr13:94,436,811...94,479,682
|
|
G |
DIO2 |
iodothyronine deiodinase 2 |
increases activity multiple interactions increases expression |
ISO |
Colforsin results in increased activity of DIO2 protein Buthionine Sulfoximine inhibits the reaction [Colforsin results in increased activity of DIO2 protein]; Hydrogen Peroxide inhibits the reaction [Colforsin results in increased activity of DIO2 protein]; Hydrogen Peroxide inhibits the reaction [Colforsin results in increased expression of DIO2 mRNA]; Sodium Selenite inhibits the reaction [Hydrogen Peroxide inhibits the reaction [Colforsin results in increased activity of DIO2 protein]]; U 0126 inhibits the reaction [Hydrogen Peroxide inhibits the reaction [Colforsin results in increased activity of DIO2 protein]]; U 0126 inhibits the reaction [Hydrogen Peroxide inhibits the reaction [Colforsin results in increased expression of DIO2 mRNA]] |
CTD |
PMID:18420745 PMID:19036883 |
|
NCBI chr14:80,197,526...80,231,057
Ensembl chr14:80,197,526...80,387,757
|
|
G |
DIO3 |
iodothyronine deiodinase 3 |
multiple interactions |
ISO |
Colforsin promotes the reaction [Hydrogen Peroxide results in increased expression of DIO3 mRNA] |
CTD |
PMID:18420745 |
|
NCBI chr14:101,561,495...101,563,452
Ensembl chr14:101,560,139...101,563,452
|
|
G |
DNM1L |
dynamin 1 like |
decreases expression multiple interactions |
EXP |
Colforsin results in decreased expression of DNM1L protein PINK1 protein affects the reaction [Colforsin results in decreased expression of DNM1L protein] |
CTD |
PMID:24792327 |
|
NCBI chr12:32,679,301...32,745,650
Ensembl chr12:32,679,200...32,745,650
|
|
G |
DRD2 |
dopamine receptor D2 |
multiple interactions |
EXP |
[Quinpirole binds to and results in increased activity of DRD2 protein] inhibits the reaction [Colforsin results in increased abundance of Cyclic AMP]; epigallocatechin gallate inhibits the reaction [[Quinpirole binds to and results in increased activity of DRD2 protein] inhibits the reaction [Colforsin results in increased abundance of Cyclic AMP]] |
CTD |
PMID:17958328 |
|
NCBI chr11:113,409,605...113,475,398
Ensembl chr11:113,409,605...113,475,691
|
|
G |
DYNLL2 |
dynein light chain LC8-type 2 |
increases expression |
EXP |
Colforsin results in increased expression of DYNLL2 mRNA |
CTD |
PMID:16751804 |
|
NCBI chr17:58,083,419...58,095,542
Ensembl chr17:58,083,419...58,095,542
|
|
G |
EDN1 |
endothelin 1 |
multiple interactions |
EXP |
Colforsin inhibits the reaction [EDN1 protein results in increased expression of CALCRL mRNA]; Colforsin inhibits the reaction [EDN1 protein results in increased expression of ICAM2 mRNA] |
CTD |
PMID:25194819 |
|
NCBI chr 6:12,230,516...12,297,194
Ensembl chr 6:12,290,361...12,297,194
|
|
G |
EGF |
epidermal growth factor |
multiple interactions |
EXP |
[EGF co-treated with Colforsin co-treated with Rotenone] results in increased expression of HSPD1 mRNA; [EGF co-treated with Colforsin co-treated with Rotenone] results in increased expression of SOD1 mRNA; [EGF co-treated with Colforsin co-treated with Rotenone] results in increased expression of SOD1 protein; [EGF co-treated with Colforsin co-treated with Rotenone] results in increased expression of SOD2 mRNA; [EGF co-treated with Colforsin co-treated with Rotenone] results in increased expression of SOD2 protein; Acetylcysteine inhibits the reaction [[EGF co-treated with Colforsin co-treated with Rotenone] results in increased expression of HSPD1 mRNA]; Acetylcysteine inhibits the reaction [[EGF co-treated with Colforsin co-treated with Rotenone] results in increased expression of SOD1 mRNA]; Acetylcysteine inhibits the reaction [[EGF co-treated with Colforsin co-treated with Rotenone] results in increased expression of SOD1 protein]; Acetylcysteine inhibits the reaction [[EGF co-treated with Colforsin co-treated with Rotenone] results in increased expression of SOD2 mRNA]; Acetylcysteine inhibits the reaction [[EGF co-treated with Colforsin co-treated with Rotenone] results in increased expression of SOD2 protein] |
CTD |
PMID:32092105 |
|
NCBI chr 4:109,912,883...110,013,766
Ensembl chr 4:109,912,883...110,013,766
|
|
G |
EGR1 |
early growth response 1 |
decreases expression multiple interactions |
EXP |
Colforsin results in decreased expression of EGR1 mRNA; Colforsin results in decreased expression of EGR1 protein Colforsin inhibits the reaction [Ethanol results in increased expression of EGR1 mRNA]; Colforsin inhibits the reaction [Ethanol results in increased expression of EGR1 protein]; Ethanol inhibits the reaction [Colforsin results in decreased expression of EGR1 mRNA]; Ethanol inhibits the reaction [Colforsin results in decreased expression of EGR1 protein] |
CTD |
PMID:29802914 |
|
NCBI chr 5:138,465,479...138,469,303
Ensembl chr 5:138,465,479...138,469,303
|
|
G |
EIF2B5 |
eukaryotic translation initiation factor 2B subunit epsilon |
increases expression |
EXP |
Colforsin results in increased expression of EIF2B5 mRNA |
CTD |
PMID:16751804 |
|
NCBI chr 3:184,135,358...184,145,311
Ensembl chr 3:184,135,038...184,146,127
|
|
G |
EIF3CL |
eukaryotic translation initiation factor 3 subunit C like |
multiple interactions |
EXP |
[Colforsin co-treated with Diethylhexyl Phthalate] affects the expression of EIF3CL mRNA |
CTD |
PMID:35892601 |
|
NCBI chr16:28,379,581...28,426,418
Ensembl chr16:28,379,579...28,403,841
|
|
G |
EIF5A2 |
eukaryotic translation initiation factor 5A2 |
decreases expression |
EXP |
Colforsin results in decreased expression of EIF5A2 mRNA |
CTD |
PMID:30983542 |
|
NCBI chr 3:170,888,418...170,908,637
Ensembl chr 3:170,888,418...170,908,644
|
|
G |
EPHX1 |
epoxide hydrolase 1 |
affects expression multiple interactions |
EXP |
Colforsin affects the expression of EPHX1 mRNA Valproic Acid affects the reaction [Colforsin affects the expression of EPHX1 mRNA] |
CTD |
PMID:20726872 |
|
NCBI chr 1:225,810,124...225,845,563
Ensembl chr 1:225,810,124...225,845,563
|
|
G |
EPS8 |
EGFR pathway substrate 8, signaling adaptor |
decreases expression |
EXP |
Colforsin results in decreased expression of EPS8 mRNA |
CTD |
PMID:15313392 PMID:15967414 |
|
NCBI chr12:15,620,134...15,789,388
Ensembl chr12:15,620,134...15,882,329
|
|
G |
EREG |
epiregulin |
increases expression |
EXP ISO |
Colforsin results in increased expression of EREG mRNA |
CTD |
PMID:15313392 PMID:15474502 PMID:15967414 PMID:20378682 |
|
NCBI chr 4:74,365,145...74,388,749
Ensembl chr 4:74,365,145...74,388,749
|
|
G |
ERVFRD-1 |
endogenous retrovirus group FRD member 1, envelope |
multiple interactions increases expression increases secretion |
EXP |
[Cadmium Chloride results in increased abundance of Cadmium] inhibits the reaction [Colforsin results in increased expression of ERVFRD-1 mRNA]; Colforsin promotes the reaction [Benzo(a)pyrene results in increased expression of ERVFRD-1 mRNA]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide affects the reaction [Colforsin results in increased expression of ERVFRD-1 mRNA]; Valproic Acid inhibits the reaction [Colforsin results in increased expression of ERVFRD-1 mRNA] Colforsin results in increased expression of ERVFRD-1 mRNA; Colforsin results in increased expression of ERVFRD-1 protein Colforsin results in increased secretion of ERVFRD-1 protein |
CTD |
PMID:24361490 PMID:29679653 PMID:31278978 PMID:33144174 PMID:35908931 PMID:36336211 PMID:37385477 PMID:38296531 More...
|
|
NCBI chr 6:11,102,489...11,111,725
Ensembl chr 6:11,102,324...11,111,845
|
|
G |
ERVW-1 |
endogenous retrovirus group W member 1, envelope |
multiple interactions increases expression |
EXP |
[Colforsin co-treated with Sertraline] results in increased expression of ERVW-1 mRNA; Valproic Acid inhibits the reaction [Colforsin results in increased expression of ERVW-1 mRNA] Colforsin results in increased expression of ERVW-1 mRNA; Colforsin results in increased expression of ERVW-1 protein |
CTD |
PMID:29679653 PMID:31278978 PMID:33144174 PMID:36336211 PMID:37385477 |
|
NCBI chr 7:92,468,380...92,477,946
Ensembl chr 7:92,468,380...92,477,986
|
|
G |
ESR1 |
estrogen receptor 1 |
decreases expression |
EXP |
Colforsin results in decreased expression of ESR1 mRNA |
CTD |
PMID:31278978 |
|
NCBI chr 6:151,656,672...152,129,619
Ensembl chr 6:151,656,691...152,129,619
|
|
G |
ESR2 |
estrogen receptor 2 |
multiple interactions decreases expression |
ISO EXP |
Colforsin inhibits the reaction [ESR2 gene mutant form inhibits the reaction [CGA protein results in increased abundance of Cyclic AMP]] Colforsin results in decreased expression of ESR2 mRNA |
CTD |
PMID:20378682 PMID:31278978 |
|
NCBI chr14:64,226,707...64,338,613
Ensembl chr14:64,084,232...64,338,112
|
|
G |
ESRRA |
estrogen related receptor alpha |
increases expression |
EXP |
Colforsin results in increased expression of ESRRA mRNA; Colforsin results in increased expression of ESRRA protein |
CTD |
PMID:20351196 |
|
NCBI chr11:64,305,524...64,316,743
Ensembl chr11:64,305,497...64,316,743
|
|
G |
EVI5 |
ecotropic viral integration site 5 |
increases expression |
EXP |
Colforsin results in increased expression of EVI5 mRNA |
CTD |
PMID:16751804 |
|
NCBI chr 1:92,508,696...92,792,410
Ensembl chr 1:92,508,696...92,792,404
|
|
G |
F2 |
coagulation factor II, thrombin |
multiple interactions |
EXP |
Colforsin inhibits the reaction [F2 protein results in increased uptake of Manganese] |
CTD |
PMID:2125206 |
|
NCBI chr11:46,719,213...46,739,506
Ensembl chr11:46,719,196...46,739,506
|
|
G |
F2R |
coagulation factor II thrombin receptor |
multiple interactions |
ISO |
[C186 65 binds to and results in increased activity of F2R protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP] |
CTD |
PMID:22207716 |
|
NCBI chr 5:76,716,126...76,735,770
Ensembl chr 5:76,716,126...76,735,770
|
|
G |
F2RL3 |
F2R like thrombin or trypsin receptor 3 |
multiple interactions |
ISO |
[GYPGKF-NH(2) binds to and results in increased activity of F2RL3 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP] |
CTD |
PMID:22207716 |
|
NCBI chr19:16,888,999...16,892,606
Ensembl chr19:16,888,999...16,892,606
|
|
G |
FADS1 |
fatty acid desaturase 1 |
increases expression |
EXP |
Colforsin results in increased expression of FADS1 mRNA |
CTD |
PMID:16751804 |
|
NCBI chr11:61,799,627...61,817,003
Ensembl chr11:61,799,627...61,829,318
|
|
G |
FASN |
fatty acid synthase |
multiple interactions |
EXP |
[Colforsin co-treated with 6-(4-chlorophenyl)imidazo(2,1-b)(1,3)thiazole-5-carbaldehyde O-(3,4-dichlorobenzyl)oxime] results in increased expression of FASN mRNA; [Colforsin co-treated with Leflunomide] results in increased expression of FASN mRNA; [Colforsin co-treated with teriflunomide] results in increased expression of FASN mRNA |
CTD |
PMID:30364229 |
|
NCBI chr17:82,078,338...82,098,236
Ensembl chr17:82,078,338...82,098,294
| |